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ABSTRACT
The School of Graduate Studies
The University of Alabama in Huntsville

Degree Doctor of Philosophy

College/Program Science/Biotechnology Science
and Engineering

Name of Candidate
Title

Unnatiben Shaileshkumar Patel

Nanomaterials in Theranostics – Therapeutics and Diagnosis
Against Infectious Diseases

Nanomaterials-based hybrid nano therapy is gaining attraction as a promising way
to treat intracellular bacterial infections. Gold-based nanomaterials have been widely used
for biomedical applications such as photothermal therapy (PTT). This thesis discusses the
development of a combination therapeutic approach that kills intracellular bacteria in
conjunction with photothermal and antibiotic therapy using gold nanorod (GNR) based
nano-assembly. This NIR laser-activated nano-assembly delivers antibiotics to the site of
infection and offers PTT. The synergistic application of both therapies increases the
efficacy of treatment. The protected delivery of antibiotics and their release in the
proximity of the bacterial surface decreases off-target toxicity and drug dosage. The core
of the nano-assembly is composed of GNRs coated with a mesoporous silica shell (MS).
The MS shell serves as a carrier for the anti-tuberculosis drug bedaquiline. The core-shell
nanoparticle is encapsulated within a thermo-sensitive liposome (TSL). The TSL layer is
further conjugated to the mycobacteria-targeting peptide NZX. NZX mediates the adhesion
of the final nano-assembly onto the mycobacterial surface. Upon NIR laser irradiation
iv

GNRs convert the photon energy of the laser to localized heat, which melts the TSL,
triggering the release of bedaquiline. The antibacterial activity of the final nano-assembly
against Mycobacterium smegmatis (Msmeg) was 20 folds more efficacious than the free
drug equivalent. Mtb can alter immune defense mechanisms exerted by the host
macrophage. Hence, host-targeted nano-assemblies (HTNs) were fabricated by
-Glucan) onto the nano-assembly.

-

Glucan conjugated HTNs to the dectin-1 receptor present on macrophages increases the
free radical production and cellular uptake of HTNs. An NIR laser triggers the
photothermally induced structural disruption of the nano-assembly, releasing the drug at
the targeted sites. The released bedaquiline within the macrophage promotes phagosome
acidification and phagolysosome formation, effectively killing 99% of intracellular
bacteria. Similar nano-assemblies were developed for dual-targeted drug delivery against
lung carcinoma and proved to be 20 fold more effective than the anticancer drug alone.
Finally, a simple and rapid diagnostic test was developed for detecting mycobacteria within
a minute using lectin conjugated multi-core silica-coated magnetic nanoparticles.
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CHAPTER 1. BIBLIOGRAPHIC STUDY OF NANOMATERIALS IN
THERANOSTICS

1.1

Introduction
Theranostics is the combination of therapy and diagnosis. Diagnosis is the ability

to detect disease state, and therapy is defined as treating the diagnosed disease.
Nanotheranostics is applied when nanomaterials are used for theranostics. Nanomaterials
can be well-defined as a material with sizes ranging between 1 and 1000 nm, which
employs as curative agents or carriers at the nanoscale level to develop nanomedicines.
The field of biomedicine is an interdisciplinary area comprising nanobiotechnology, drug
delivery, biosensors, and tissue engineering, which has been powered by nanomaterials. In
recent years, the use of nanomaterials in medicine and, more specifically, in drug delivery
has expanded into a broad range of clinical applications. Nanomaterials offer many
benefits, such as improving the stability and solubility of encapsulated cargos, promoting
transport across membranes, site-specificity, and targeted delivery of precise medicine.1
Nanoscale-sized particle have unique structural,2 chemical,3 physical,4 optical,5 magnetic,6
electrical,7 and biological properties.8, 9 Based on their physical and chemical properties, a
variety of nanomaterials have been developed up to date, such as inorganic nanoparticles
(NPs) including metal NPs,10- gold-based,11 magnetic,12 mesoporous silica NPs,13 and
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quantum dots,14 lipids nano-system,15 - liposomes, micelles, dendrimer, and polymeric NPs
are increasingly being utilized as vehicles for antibiotics delivery.16, 17 Selected organic
nanomaterials such as liposomes, polymer NPs/micelles, and metallic NPs such as gold
NPs have been approved by Food and Drug Administration (FDA) for theranostics
purposes.18 Liposomes, polymeric NPs, micelles, hydrogels are considered “soft matter.”
In recent years hybrid nano-systems, a co-formulation of metallic NPs with the soft matter
have been synthesized. These hybrid nano-systems harvest the properties of both metallic
and soft matter counterparts. The incorporation of metallic NPs into soft-matter systems
offers unique advantages in that it combines the highly desirable drug-delivery properties
of traditional drug-delivery vehicles such as excellent colloidal stability, ease of
fabrication, biocompatibility, and high drug-loading capacities with novel stimuliresponsive antibiotics release mechanisms imparted by the inorganic NPs.
1.2

Gold-based nanomaterials
Based on the morphology and properties of gold nanoparticles (AuNPs), they can be

classified into two main categories: isotropic (spherical) and anisotropic (non-spherical).
The synthesis of isotropic AuNPs is performed in several ways, and the most common
route is the reduction of Hydrogen tetrachloroaurate(III) (HAuCl 4) to gold ions. In the early
1950s, Turkevitch produced AuNPs using sodium citrate as a reducing agent, and
numerous researchers have adapted this method to synthesize AuNPs of various sizes. 19, 20
It was first utilized to make isotropic NPs with a diameter of 15 nm. 19, 20 The reduction of
gold salt be utilized to synthesize AuNPs from 10-150 nm.

19, 21

AuNPs exhibit unique

optical properties, and the main properties that govern their theragnostic applications are
surface plasmon resonance (SPR). When AuNPs are exposed to light, the light's oscillating
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electromagnetic field causes the gold's free electrons (conduction band electrons, 6s) to
oscillate collectively. This electron oscillation across the particle surface induces charge
separation in the ionic lattice, resulting in a dipole oscillation in the direction of the light's
electric field. The oscillation amplitude reaches its maximum at a specific frequency,
known as a localized surface plasmon resonance (LSPR).
Because the SPR causes strong absorption of the incident light, it can be measured
with a UV–Vis absorption spectrometer. The intensity and wavelength of the LSPR band
are affected by parameters such as the metal type, particle size, shape, structure, and
composition. In gold nanospheres (isotropic or spherical), this electron oscillation induces
strong light absorption and an LSPR peak around 520 nm. In contrast, anisotropic (nonspherical) nanoparticles can exhibit electron oscillation along multiple axes. Anisotropic
or non-spherical AuNPs include gold nano - rods, 22 prisms,23 stars,24 triangles,25 cubes,26
pyramids,27 cages,28 wires.29 These varied shapes can be synthesized by varying the
concentration of reducing agents surfactants and controlling reaction conditions. 30-32
According to perspective application, it becomes important to control the physical
parameters of the AuNPs, such as size and shape. Shape variation of anisotropic NPs
provides surface plasmon absorbance over wider wavelengths in the electromagnetic
spectrum than isotropic NPs. Anisotropic AuNPs can absorb in the near-infrared (NIR)
range, making them useful as photothermal agents in biological applications where tissue
absorption in this region is minimal, thanks to gold's recognized biocompatibility. 33 In this
thesis, we focus mainly on gold nanorods (GNRs).
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1.2.1

Gold nanorods (GNRs) synthesis

Figure 1.1. The absorption spectrum of an aqueous solution of GNRs.

GNRs are one type of anisotropic gold nanostructures that have received much
attention for their optical properties in theranostics applications. Mie's theory cannot
explain the optical behavior of nanorods because Mie’s theory only applies to isotropic
particles.34 Gustav Mie discovered that the optical properties of AuNPs are affected by
several factors, including nanoparticle size, medium refractive index, and gold dielectric
constant.34 The extinction maximum redshifted slightly as the particle size of AuNPs
increased from 20 to 100 nm.34 Later on, Richard Gans refined Mie's boundary conditions
for spheroids to predict the existence of two absorption bands: a transverse surface plasmon
resonance peak (TSPR) linked to the rod's width and a longitudinal surface plasmon
4

resonance peak (LSPR) band related to the rod's length. 19, 34, 35 In Figure 1.1, the transverse
band can be seen at 520 nm, and the longitudinal band is seen around 790 nm. The
absorbance wavelength of the LSPR band can be changed to the NIR region by changing
the aspect ratio of the nanorod. The aspect ratio of nanorods is defined as the ratio of the
length of the major axis to the width of the minor axis. Researchers have developed several
synthesis protocols for GNRs, including a seed-mediated method, 36 seedless methods,37
photochemical methods,38 and electrochemical methods.39 Out of all listed methods, the
seed-mediated method by Murphy et al. has been widely accepted to generate a high aspect
ratio of nanorods.40 In Murphy et al. used sodium citrate to reduce gold salt to prepare
aqueous solutions monodispersed spherical gold seeds (2 – 3 nm). The citrate stabilized
gold

seeds

were

then

added

to

the

growth

solution,

which

contained

cetyltrimethylammonium bromide (CTAB), ascorbic acid, gold salt, and silver nitrate
(AgNO3). CTAB is used to stabilize GNRs, ascorbic acid act as a mild reducing agent, and
AgNO3 controls the aspect ratio of nanorods.

Three different mechanisms for the

longitudinal growth of GNRs have been proposed: (1) silver underpotential deposition, in
which a monolayer quantity of Ag(0) is proposed to preferentially deposit onto the growing
longitudinal facets to favor anisotropic growth,41 (2) surfactant templating, in which
elongated CTAB micelles form a soft template for the growth of GNRs, potentially with
the synergistic involvement of silver in the micelles,42, 43 (3) facet-specific capping, where

growth.44, 45 The experimental data support all three hypotheses to some extent, but none
of them can entirely explain all experimental findings, and there is still a lot of speculations
in the literature about the complete mechanism. 46, 47
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Scheme 1.1. Fabrication of GNRs. Gold seed are prepared in an aqueous solution of CTAB
and HAuCl4 via reduction of Au3+ to Au0 by NaBH4. The gold seeds are added to the growth
solution containing CTAB, HAuCl4, and AgNO3, which has been reduced from Au3+ to
Au+ by ascorbic acid.

However, the GNRs synthesized with this approach contained many spherical
AuNPs. El-Sayed et al. improved this technique by replacing citrate with CTAB during Au
seed formation.48 They also showed that the nanorod aspect ratio could be controlled by
varying the concentration of Ag+ ions in the growth solution. In this thesis, the seedmediated method was employed to synthesize GNRs. In a typical seed-mediated method,
as shown in Scheme 1.1, the gold seed solution (~ 2 nm) is prepared by reduction of
HAuCl4 in the presence of CTAB and cold sodium borohydride (NaBH 4), reducing Au3+ to
Au0 and forming CTAB capped gold seeds. When sodium borohydride is added to the
solution, the color changes from pale yellow to pale brown, indicating complete reduction.
These as-prepared gold seeds were subsequently added to the growth solution consisting
of 0.1 M CTAB, 0.50 mM HAuCl4, 10 mM AgNO3, and 0.1 M ascorbic acid to form
CTAB-stabilized GNR. The exact mechanism is still debated; however, the well-known
hypothesis is that the surfactant CTAB is employed as a stabilizer and a capping agent to
adhere to attach to the {100} facets of the seeds. 49 This slows growth in that direction while
allowing elongation on the {111} facets at the ends of the nanorods. 50,
6

51

The

Scheme 1.2. Crystallography of GNRs with ends dominantly {111} crystallographic
planes and the side facets dominantly {110}. These GNRs are synthesized using seedmediated approaches.

crystallography of GNRs has been studied very well, previously published. 50, 52 The typical
crystallography of GNRs showed in Scheme 1.2. The longitudinal axis is {110} which is
the preferential binding site for the CTAB bilayer, forcing anisotropic growth on the {111}
ends while the end facets are {111}.48, 53 Ascorbic acid acts as a mild reducing agent added
to the growth solution to reduce Au3+ to Au+, and the solution turns light yellow to
colorless, followed by the gold seeds added to the growth solution. Because ascorbic acid
is a weaker reducing agent, growth is slower, allowing for the formation of CTAB-capped
GNRs with length 42 ± 3.8 nm and width from 11.2 ± 1.1 nm, and the calculated average
aspect ratio is 3.8:1. AgNO3 controls the aspect ratio of nanorods. As the amount of silver
increases, different colors (red wine color - aspect ratio 3.8 by adding 4.8 mL of 10 mM
AgNO3 ) of GNRs solutions can be produced with red-shifted LSPR maxima. GNRs are
purified by centrifugation, then the pellets are resuspended in deionized water, and can be
stored at room temperature for several months.
GNRs synthesis must be carried out carefully, as each reagent plays a significant
role in the growth of GNRs. The function of the surfactant in GNRs synthesis has been
well studied, and the surfactant's purity is also essential in the application. During GNRs
synthesis, we observed that using CTAB from different commercial vendors and different
7

lot numbers gave inconsistent GNRs aspect ratios. Smith et al. documented the variability
in the aspect ratio of GNRs using CTAB from 10 different vendors. 54 They suspected the
variability was due to differences in iodide concentration in CTAB between suppliers. They
found that adding potassium iodide at 50 ppm completely prevented rod growth due to
iodide adsorption on the Au (111) face.54 Rayavarapu et al. also examined different lot
numbers of CTAB from some of these sources, and they observed that iodide impurities
varied lot-to-lot and not just by a supplier.55 Hence, researchers should test the CTAB
reagent for contaminant iodine concentration to ensure successful GNRs synthesis.
1.2.2

Photothermal activity of GNRs
As previously stated, AuNPs absorb light very strongly due to SPR, and SPR

absorption is affected by the shape and size of the AuNPs. 34 When the shape of AuNPs
changes from sphere to the rod, the SPR absorption splits into two bands: LSPR, a stronger
long-wavelength band in the NIR region due to longitudinal electron oscillation, and TSPR,
a weak short wavelength band in the visible region due to transverse electronic
oscillation.56 The LSPR peak is extremely sensitive to the aspect ratio (length/width) of
GNRs, whereas the TSPR peak is not.57 This strong SPR absorption, followed by rapid
energy conversion and dissipation, can be easily used to heat the local environment using
NIR light radiation with a frequency that strongly overlaps with the SPR absorption band
of GNRs.57 Anisotropic geometries are thought to aid GNRs in exhibiting intense LSPR
bands, resulting in highly efficient and localized light-to-heat conversion after suitable NIR
irradiation making them very useful for photothermal therapy (PTT) of cancers and other
diseases. GNRs are a promising candidate for use as a photothermal agent because of (1)
their ability to convert light energy to thermal energy and (2) their tunable absorption in
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the NIR region of the biological window (700–1000 nm), where biological tissue has a
high transmissivity.58 Huang et al. were among the first to use GNRs to demonstrate
photothermal killing of cancer cells.59 GNRs were coupled with anti-epidermal growth
factor receptor monoclonal antibodies, which are overexpressed in cancer cells. Upon
illumination of laser irradiation on GNRs resulted in more effective destruction of
malignant oral epithelial cancer cells than nonmalignant cells. 59 To target the surface of the
Pseudomonas aeruginosa, Norman et al. employed antibody-functionalized GNRs.60 Laser
irradiation of bacteria cultured with functionalized GNRs resulted in 75% cell death and
irreversible cell wall damage.60 Using targeted GNRs, photothermal death can be highly
successful, as seen in these two examples. Another study by Ocsoy et al. prepared two
types of gold NPs, spherical gold nanoparticles (AuNPs) and gold nanorods (GNRs). 61
These nanomaterials were further modified with DNA aptamers that can specifically bind
with MRSA. Based on their results, both the Apt@AuNPs and the Apt@GNRs
successfully bound with MRSA. However, only the Apt@GNRs effectively inactivated the
bacteria through hyperthermia. According to the authors, one possible explanation is their
longitudinal absorption of NIR radiation and photothermal conversion. This could confirm
that the shapes of AuNPs have a large influence on their photothermal effects. There are
several reports where GNRs used as a photothermal agent in antibacterial mechanism. 62, 63
1.2.3

Encapsulation strategies of GNRs
Despite the benefits of CTAB in GNR synthesis, CTAB's high cytotoxicity is a

significant concern that threatens to undermine any potential use of GNRs in a biological
setting. The CTAB layer must be replaced or completely encapsulated by a more
biocompatible coating for biological application. The interactions of CTAB with the cell's
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phospholipid bilayer and the inhibition of the enzyme adenosine triphosphate (ATP)
synthase by the cetrimonium cation are the causes of cell toxicity, both of which result in
cell death.64 However, several methods are reported to tailor the surface chemistry of GNRs
to avoid these issues, which could prevent GNR’s bio applications. 65 Here, we focus on a
few standard techniques which are utilized in this thesis that includes the methods of
inorganic mesoporous silica coating and liposome encapsulation as shown in Scheme 1.3.

Scheme 1.3. Encapsulation strategies of CTAB-coated GNR.

1.2.3.1 Mesoporous silica coating of GNRs
Silica coating has been shown to improve GNRs colloidal stability in organic
solvents while also improving thermal stability by preserving the optical characteristics of
GNRs. Silica coating is a helpful technique for GNRs surface modification. Silica can
increase the colloidal stability of GNRs in organic solvents while enhancing the thermal
stability to preserve GNRs’ optical properties.66 On the silica surface, the reactive silanol
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(-Si-OH) groups are present, which can be modified with other silane-functionalized
ligands such as polyethylene glycol (PEG) or targeting ligands peptide, antibodies,
aptamers, and small molecules.67 Furthermore, silica nanoparticles with a porous structure
known as mesoporous silica nanoparticles (MSNs) have grown in popularity in recent
years.68

Its

uniform and controllable pore size, straightforward

independent

functionalization of the surface, internal and exterior pores, and pore opening gating
mechanism distinguish it as a unique and potential drug carrier.68 MSNs are those with
pore sizes ranging from 2 to 50 nm with an ordered arrangement of pores, resulting in a
porous ordered structure.69 The pore size of MSNs can be adjusted and fine-tuned using
different surfactants and reaction conditions.69 In terms of synthesis, Stöber was the pioneer
in synthesizing silica nanoparticles and MSNs.70 Since then, several changes have been
made to Stöber synthesis to produce monodisperse, ordered, nanosized MSNs. Grun et. al.,
were the first to modify the Stöber synthesis method by using a cationic surfactant as a
template to produce a spherical structure.71 To be an excellent carrier for drug delivery,
MSNs must have homogeneous particle size and a large pore volume to increase loading
capacity.72 These parameters can be fine-tuned by variations in the pH of the reaction
mixture, surfactant concentration, silica source, and temperature of the reaction. 73
In this thesis, we have coated GNRs with mesoporous silica shells where we have
loaded both hydrophilic and hydrophobic drugs as cargo in different experiments. We have
synthesized MSNs by the surfactant-template method developed by the Matsuura group. 74
Tetraethyl orthosilicate (TEOS) was used as a hydrolytic inorganic silica precursor and 3aminopropyltriethoxysilane (APTES) co-condenses with TEOS to form the silica shell
layer in addition to acting as a morphological stabilizer. The surfactant CTAB acts both as
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a stabilizer and mesostructure-directing agent. CTAB forms micelles, which act as a
framework for the growth of the TEOS/APTES based silica shell. Base catalyst NaOH
hydrolyzes TEOS/APTES to silicate. The electrostatic interactions between negatively
charged silicate oligomers hydrolyzed from TEOS/APTES and positively charged CTABstabilized gold nanorods lead to the formation of core-shell structured GNRs coated
mesoporous silica shell. Gorelikov et. al., have developed surfactant-based templet method
in which they have directly coated mesoporous silica onto CTAB gold nanorods. 74 NaOH
is added to GNRs to adjust the pH to 11 and is followed by injections of TEOS which
polymerizes to form silica in a base-catalyzed reaction.74 Other researchers have modified
reaction parameters such as temperature, TEOS, APTES, and CTAB concentration to
control mesoporous silica shell thickness on GNRs.75, 76
Researchers have successfully used MSN carriers to transport a wide range of
cargo, including drugs and macromolecules such as proteins, DNA, and RNA. 77 Numerous
studies have reported various loading mechanisms of MSNs such as pore filling, 78
adsorptions,79, and grafting.72 The loading strategies of MSNs are highly dependent on the
carried biomolecules. For example, small drug molecules or short peptides can be easily
loaded within pores or grafted onto surfaces, whereas larger and more charged molecules
may be rejected if the mesopores are not properly conditioned.80 Both hydrophilic and
hydrophobic drugs can be incorporated into the pores of MSNs by adsorption mechanism,
which is a straightforward method.72 In the adsorption method, the mesoporous silica is
immersed in the concentrated drug solution, and drug molecules are then adsorbed on the
MSNs’ pores. Centrifugation is then used to separate the drug-loaded MSNs from the
solution. After that, the particles are dried to remove any remaining solvent. MSNs have a
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higher loading capacity than other carriers because of their large pore volume. In terms of
the release profile of drugs from MSNs, the profile is primarily determined by the drug
diffusion from pores. This can be tailored by modifying the surface of the MSNs to meet
biological requirements.81 Recently, there has been much interest in studying the drug
release from MSN or hybrid nano-assembly in response to external specific stimuli such
as magnetic, ultrasound, and NIR light.82 The mechanism is based on the nanocarriers'
conformational changes or destruction of MSNs in response to light. Li et al. reported a
NIR laser-responsive MSNs nanocarriers composed of GNRs capped with reversible
single-strand DNA.83 This DNA strand was controlled by a laser switcher, which controlled
the drug release from the nanocarrier. These nanocarriers were able to deliver drugs
precisely at a specific time and to a specified location.83
1.2.3.2 Liposome encapsulation
Liposomes are the most widely researched nanoscale drug delivery platform.
Liposomes were discovered in the 1960s by Bangham and colleagues at the Babraham
Institute, University of Cambridge, and were published in 1964.84 Liposomes are colloidal
spherical structures formed by the self-assembly of amphiphilic lipids (lipids having polar
end and non-polar end) molecules such as phospholipids and cholesterol. One or more lipid
bilayers arranged around an internal aqueous core, with the polar head groups orientated
to the inner and non-polar head groups towards the outer, make up a liposome membrane. 85
Liposomes have the unique capacity to load and deliver molecules of variable solubility
thanks to their well-organized structure.86 Hydrophilic molecules can be loaded into the
aqueous core, hydrophobic molecules into the lipid bilayer, and amphiphilic molecules into
the water/lipid bilayer interface.86 A suitable liposomal formulation can be achieved
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according to the application by selecting an appropriate liposome composition,
functionalization, and even a targeting method. The choice of phospholipids, head group
and chain length, and the ratio of liposome components are all critical factors in
determining liposome safety, stability, and efficiency.86 Liposomes are mostly made up of
phospholipids and are classified into two types: natural and synthetic. Phosphatidylcholine
(PC), and phosphatidylethanolamine (PE), which are abundant phosphatides in plants and
animals, are the most natural phospholipids used to make liposomes. 87 Natural
phospholipids are primarily found in egg yolk and soya beans.
Natural lipids are used to make synthetic phospholipids. Natural phospholipids are
modified in the head groups, aliphatic chains, and alcohols to produce a variety of synthetic
phospholipids that have proven to be more stable.87 The synthetic lipids includes 1,2Distearoyl-sn-glycero-3-phosphocholine

(DSPC),

1,2-Dipalmitoyl-sn-glycero-3-

phosphocholine (DPPC), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, (DOPE), 1,2Distearoyl-sn-glycero-3-phosphoethanolamine

(DSPE)

and

monopalmitoyl

phosphocholine (MPPC).88 Because of their amphipathic nature, phospholipids have a
strong ability to form stable bilayers in aqueous environments.88 Liposomes are formed
due to hydrophilic interactions between polar head groups, van der waals forces between
hydrocarbon chains (which hold the long hydrocarbon tails together), and hydrogen bonds
with water molecules.88,

89

Water molecules repel hydrophobic chains, resulting in

spontaneous liposome self-assembly in a closed bilayer. Liposomes can acquire positive,
negative, or neutral charges depending on the head group of the phospholipids.
Incorporation of cholesterol into the lipid bilayer of liposomes can affect bilayer fluidity
and rigidity, reducing permeability and increasing in vitro and in vivo stability. 90
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Cholesterol, as a hydrophobic molecule, inhibits lipid chain interactions by intercalating
between them, enhancing liposome membrane stabilization.90 Using various PEGs in the
liposome composition or on the surface of liposomes can be an excellent way to extend the
half-life of blood circulation from a few minutes (standard liposomes) to many hours. 91 It
was reported that longer-chain PEGs improved blood circulation time than short chains. 91
To prepare liposome, there are various techniques have been reported such as thin-film
hydration,92 reverse-phase evaporation,93 solvent injection techniques,94 size reduction
methods including probe sonication and extrusion.93
Liposomes have a distinct phase transition temperature (T c) at which they transition
('melt') from a gel to a liquid phase. The phase transition temperature of phospholipids is a
crucial parameter that can alter the fluidity of the lipids within the bilayer. 95 At a
temperature below Tc, the phospholipids are in the gel phase, and present low fluidity and
low permeability as individual molecules within the bilayer move gently. 96 In the gel phase,
lipid molecules are organized and condensed with fully extended hydrocarbon chains,
which are restricted to the membrane's two-dimensional plane.96 At temperatures greater
than the Tc, the phospholipids bilayer exists entirely in the liquid phase. Individual lipid
molecules are still limited to the two-dimensional plane of the membrane, but they can
move freely and quickly (millions of exchanges per second) within it. 97 As a result, the
membrane becomes fully fluidized and permeable throughout.97 Taking advantage of this
liposome property, temperature-sensitive (thermo-sensitive) liposomes have recently
emerged as an appealing option for treating cancer and infectious disease in a controlled
and predictable manner using external energy sources.98 When thermosensitive liposomes
are exposed to heating, the lipid bilayer undergoes a melting phase transition from a gel to
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a liquid-crystalline phase, allowing a rapid increase in bilayer permeability and thus the
rapid release of small molecules or drugs.98, 99 The exact temperature and broadness of the
phase transition depend on the lipid composition and can be adjusted to clinically relevant
mild-hyperthermia temperatures (39–43 °C).99 DPPC and MPPC are widely used to
prepare thermo-sensitive liposomes as their Tc values are around 43 °C.99
In this thesis, we have prepared a thermo-sensitive liposome, as the amount of DPPC
used in liposome preparation was the highest (85%) in molar ratio compared to cholesterol
(10%) and DSPE-PEG(2000) amine (5%). As previously studied in our recent paper, these
liposomes become permeable at temperature ~ 50 °C. 100 Thermo-sensitive liposomes are
the widely researched nanoscale anti-cancer and antimicrobial delivery system primarily
due to their ability to provide thermal stability, colloidal stability, controlled drug release,
which also act as a biocompatible carrier and provide a surface for attaching targeting
biomolecules such as antibodies, peptides, aptamer and small molecules. 101, 102 Regarding
GNRs, Hua et al. reported that docetaxel drug encapsulated multifunctional GNRs in
liposomes for cancer treatment.103 Cui et. al. reported lipid bilayer modified GNRs coated
MSNs for NIR controlled drug delivery for cancer treatment.104 Thermo-responsiveinspired drug-delivery nano-transporter (TRIDENT) nano-system was developed by Quing
et al. in which nano-system formulated from natural fatty acids with a tunable melting point
around 43 °C was chosen as the hydrophobic vehicle for encapsulation of antibiotic
imipenem and photosensitizer IR780 dye.105 The drug-loaded nano-system was wrapped
with lecithin and DSPE-PEG2000 to increase the biocompatibility of the resulting
TRIDENT. TRIDENT's 100% bactericidal capacity against antibiotic-resistant and clinical
MDR bacteria using chemo-photothermal therapy was demonstrated in vitro and in vivo.
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1.2.4

Nanoparticles (NPs)-mediated targeted drug delivery
Targeted drug delivery can be accomplished either passively or actively. Passive

targeting is achieved by incorporating the therapeutic agent into a macromolecule or NPs
that passively reaches the target organ. Active targeting necessitates the conjugation of
targeting ligands such as peptides, antibodies, proteins, aptamers, carbohydrates, and small
molecules onto the NPs’ surface.106 These targeting ligand conjugated NPs selectively bind
to specific cell surface receptors, resulting in cell internalization via receptor-mediated
endocytosis and increasing host immune response in some applications. 107
The properties of nanomaterials make them attractive candidates for targeted drug
delivery platforms. Due to the nanoscale size, they can easily penetrate the tissue system,
allowing for easy drug uptake by cells and efficient drug delivery at the desired location. 108
Surface area of NPs is larger, providing more space to accommodate bulky targeting ligand
on its surface, which helps design a targeted drug delivery platform. 109 Furthermore,
surface functionality is the principal parameter dominating NPs interactions with cells and
subsequent cell uptake.110 When using NPs for targeted delivery with any of the ligands, it
is necessary to chemically modify the surface of the NPs with appropriate chemistry to
introduce reactive moieties, providing functional groups that can be conjugated to a
targeting ligand of choice. The selective ligand must contain a functional group that can
also be used for conjugation. The majority of the conjugation chemistries used to modify
NPs are covalent. Some of the most common covalent reactions used in conjugating NPs
to targeting ligands include chemical reactions that use reactive carbonyl groups (carbonyl
reacts with hydrazide or alkyoxyamine to form hydrazone or oxime bond), amine-reactive
groups (amine reacts with activated carboxylate or imidoester to form amide or amidine
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bond), and reactive sulfhydryl groups (thiol reacts with maleimide, gold surface, to form
thioester, and gold-thiol bond, respectively).106 These NPs conjugated targeting ligands
could guide the NPs to the intended target and specifically recognize the target site. Xiao
et al. reported conjugation of targeting peptide on GNRs via a two-step process; thiolated
linkers was anchored onto the GNRs through the thiol moiety. Other end of thiol linkers
were used to conjugate the heterobifunctional PEG derivative of NHS ester, which is then
used for the targeting ligand conjugation.111 Doxorubicin (Dox) was also covalently
conjugated on GNR via PEGylation. They have developed this nano system for combined
anticancer targeted drug delivery and PET imaging.111
Multivalency is yet another important factor in designing a ligand-receptor-mediated
targeted drug delivery platform.112 Multivalent interactions defined as multiple ligands
with proper ligand presentation binds to specific receptors having two or more binding
sites. In this regard, NPs can be used as a scaffold to present multiple copies of ligands on
the NPs. Depending on the size of the NPs and the size of ligands, hundreds and thousands
of ligands can be presented on the NPs.113 Once targeting ligands are conjugated to NP
surface, they can bind to cell surface receptors in a multivalent manner. While free ligands
only bind to receptors in a monovalent fashion, conjugating them to NP surface increases
valency to be multivalent. Multivalent binding increases the strength of binding. For
example, free carbohydrates interact weakly with cell surface lectins with a dissociation
constant (KD) in the millimolar range.113 But functionalizing carbohydrates on NPs (to
create glyconanoparticles), binding interactions can be increased to nanomolar range. 113
Cells also utilize multivalency to increase binding affinity towards weak ligands. Wang et
al. studied the binding affinity of glyconanoparticle (GNP)-protein multivalent interactions
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based on a fluorescent competition binding assay.114 Wang et. al., synthesized carbohydrate
conjugated AuNPs, to create GNPs. They measured the binding affinities of these GNPs
with lectins and found a 1000-fold enhancement in K D in the nanomolar range compared
to the micromolar range for free carbohydrate-lectin interaction. 114
When we discuss active targeting between ligand conjugated nanomaterials and cell
surface receptors, it is essential to study the ligand-receptor binding interaction. Targeting
ligand conjugated nanomaterials interact with receptors present on the cell surface or
bacterial cell wall, and the strength of interaction directly impacts the outcome, such as the
uptake, toxicity, and clearance of the nanomaterials.115 The strength of such interactions
can be quantified by measuring the binding affinity (KD). There are several techniques by
which binding affinity between targeting ligand conjugated nanomaterials and receptors
can be measured, such as fluorescence/absorption-based assay,116 Surface Plasmon
Resonance Spectroscopy (SPR),117 Isothermal Titration Calorimetry (ITC),118 and enzymelinked assay.119, 120 Out of all, fluorescence-based techniques have been widely used to
determine binding affinities between ligands and receptors. In this assay, either the
nanomaterial or the receptor needs to be inherently fluorescent or is conjugated with a
fluorophore. The fluorescence-based techniques have been used widely to determine
binding affinities of surface-bound ligands on nanomaterials, including microarrays,
fluorescence quenching, and fluorescence anisotropy. Yan group has developed the
fluorescence competition assay to determine the K D between concanavalin A (Con A) and
carbohydrate-functionalized AuNPs.114 They have used varying concentrations of ligand
conjugated fluorescent NPs, together with a fixed concentration of free carbohydrate
(mannose) ligands incubated and the fluorescence of the supernatant was measured. Then
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from the dose-response curve, IC50 values were obtained.114 Then, after using the ChengPrusoff equation, the KD was calculated. Using a similar method, they studied how the
ligand presentation impacted the binding affinity of ligand conjugated fluorescent NPs
including the ligand density, linker length, and size.114 Their results showed that the more
ligands present on the NPs, the longer the dwelling time of the lectin on the ligands and the
slower the lectin would dissociate.114 Hence, binding affinity increased with the ligand
density. Regarding the spacer, their results clearly demonstrate that longer spacers led to
the enhanced binding affinity of GNPs with lectins.114 This is due to curved surfaces of
NPs, reducing the steric hindrance when the lectin approaches the ligands, making the
ligands more accessible for interacting with the lectin.114 Smaller NPs yielded the highest
affinity enhancement, likely due to their large surface-to-volume ratio and higher mobility
in solution.114
In this thesis, we have conjugated various targeting ligands (peptides, small
molecules) on a liposomal surface via an amide linkage. These functionalized nanoassemblies were used for treating intracellular mycobacterial infections. We have also
systematically studied binding interaction between ligand conjugated nano-assemblies and
cell surface receptors. Also, the impact of ligand presentation in terms of size of nanoassembly and ligand density on binding affinity was studied. In the cancer project, we have
conjugated peptide GE-11 and folic acid on nano-assemblies and investigated targeted
therapy for lung cancer treatment.
1.3

Drug delivery platforms for infectious disease
Globally, infectious diseases are a significant cause of morbidity and mortality. 121

Infectious diseases mainly caused by pathogenic organisms such as bacteria, viruses, fungi,
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and parasites continue to be the leading cause of hospitalization and death worldwide. 122,
123

Infectious diseases are complicated to treat, as their continued transmission and high

fatality rates are seen.124 Although significant progress has been made using smallmolecule antibiotics, peptides, and nucleic acids, there are still significant challenges in
the effective treatment of infectious diseases.125 Overuse of antibiotics leads to antibiotic
resistance, which is a concerning situation that can weaken an individual's immune system.
The rapid emergence of drug resistance is now a serious global health issue. 126 Bacteria
resist antibiotics through two main mechanisms: (1) preventing antibiotics from reaching
their target at high concentrations and (2) modifying or bypassing the target that antibiotics
act on.127 Bacteria eliminate antibiotics by using efflux pumps in their cell walls that
remove antibiotic drugs that enter the cell.128 These efflux pumps are ubiquitous in bacteria
and can transport signal molecules and nutrients. Some of these pumps can also transport
antibiotics out of the bacterium, lowering antibiotic concentrations within the bacterial
cell.128 In some cases, mutations in the bacterial DNA can cause the bacteria to produce
more of a specific pump, increasing resistance.128 For example, Pseudomonas aeruginosa
bacteria can produce pumps to eliminate several antibiotic drugs, including
fluoroquinolones, beta-lactams, chloramphenicol, and trimethoprim. 129 Bacteria restrict
access by modifying or restricting the number of entryways available. 130 The gramnegative bacteria have a protective outer coat (membrane) that keeps them safe from the
environment.131 These bacteria use this membrane to prevent antibiotics from entering
selectively.131 Bacteria can modify or destroy the antibiotics with their enzymes, proteins
which break down the drug.132 For example, Carbapenemases are enzymes produced by
Klebsiella pneumoniae bacteria that break down carbapenem drugs and most other beta-
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lactam antibiotics.132 Antibiotics are often designed to target and kill specific bacteria
components (or targets). However, bacteria alter the antibiotic's target, causing the drug to
no longer fit and function properly.133 For example, the mcr-1 gene in Escherichia coli
bacteria can add a chemical to the exterior of the cell wall that prevents the antibiotic
colistin from latching onto it.134 By all of these mechanisms, bacteria develop antibiotic
resistance. Hence, innovative strategies for maximizing the efficacy of currently available
drugs must be developed.
In this regard, nanotechnology is emerging as a potential strategy for overcoming
antibiotics' many drawbacks while also enhancing their therapeutic benefits. NPs could be
a promising solution because they can fight against bacteria and act as carriers for
antibiotics and natural antimicrobial compounds. The use of NPs as a carrier in antibiotic
delivery suggests a promising way to design effective therapeutics against many
pathogenic bacteria.135 Nanocarriers have the potential to overcome drug solubility and
stability issues and reduce drug-induced side effects. 136 It is possible to achieve co-delivery
of two or more drugs or therapeutic modalities for combination therapy using
nanocarriers.137 The administration of antimicrobial agents via nanocarriers can advance
therapeutic index, extend drug circulation, reduce drug dosage and achieve controlled drug
release, thereby improving overall pharmacokinetics.138 NPs’ surface characteristics can
be altered for targeted drug delivery by targeting ligands such as small molecules, proteins,
peptides, and nucleic acids. The immune system is unaware of the loaded NPs that are
efficiently targeted to specific sites.139 A drug-loaded nanocarriers can be used for various
administration routes, including oral, nasal, parenteral, intra-ocular, and so on. 18 Hence,
NPs-based drug delivery offers tremendous benefits over free antibiotics. Various
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nanocarriers have been studied extensively, including polymeric NPs, hydrogels, micelles,
liposomes, solid lipid NPs, quantum dots, silica NPs, and inorganic metal NPs, including
gold and silver, and magnetic NPs.140 This thesis focused on drug delivery platforms for
intracellular bacterial infections such as TB.
1.3.1

Tuberculosis (TB)
Globally, an estimated 10 million people had TB in 2020.141 Mycobacterium

tuberculosis (Mtb) is the primary cause of tuberculosis, a chronic communicable disease
that primarily affects the lungs (pulmonary tuberculosis) but can also affect other organs
(extrapulmonary tuberculosis). Mtb is a gram-positive aerobic, rod-shaped acid-fast
bacillus that is highly contagious.142 The primary host for Mtb is humans.143 It is primarily
an intracellular pathogen and survives mainly in the host macrophage. Tubercle bacilli can
survive in host macrophages because the bacterium possesses an innate ability to suppress
the antimicrobial response of the macrophage.144 TB infection is spread by infected patients
with aerosolized sputum. These aerosols contain viable tubercle bacilli that can infect an
uninfected person. An aerosol droplet carrying viable tubercle bacilli is inhaled and travels
to the alveoli in the lungs. Tubercle bacilli are phagocytosed and multiply within alveolar
macrophages. The immune cell (macrophage) evading mechanism by Mtb is shown in
Scheme 1.4., where Mtb manipulates host immune response in two ways; (1) inhibition of
phagosome maturation (2) phagolysosome inhibition.
The interaction between Mtb and macrophage occurs by recognizing pathogenassociated molecular patterns (PAMPs) present on Mtb. Some of the pattern recognition
receptors present on the surface of macrophages include C-type lectin receptors, toll-like
receptors, folate receptors, and CD44 receptors. After entering the macrophage, Mtb is
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Scheme 1.4. Survival mechanism of mycobacteria inside host macrophage cells.

taken up by the phagosome.145 Under normal conditions, the V-ATPase pump present on
the cell membrane of the phagosome pumps protons into the phagosome. 146 This increases
the acidity of the phagosome and is called the maturation of phagosome or acidification of
phagosome.146 In the case of Mtb infection, Mtb releases the protein tyrosine phosphatase
(PTPA) protein.147 Thus, inhibition of phagosome acidification is one of the survival
strategies of Mtb inside the macrophage. In a common bacterial infection, phagosome
fusion with lysosome leads to phagolysosome formation.143 Upon initiation of this process
– free radicals such as reactive oxygen species (ROS) and reactive nitrogen species (RNS)
production increases. This also increases the formation of bactericidal enzymes such as
peptidase. All these processes together act conjunctly to kill intracellular bacteria. 143
However, in Mtb infection, phagolysosome formation is inhibited by Mtb. Also,
intracellular Mtb can inhibit ROS/RNS generation and prevent the decrease in intracellular
pH. 143 Finally, these Mtb infected macrophages form a hard shell called a granuloma. The
bacilli replicate within the granuloma and then burst out and infect other healthy cells and
24

tissue to develop active TB.148 Therefore, it is paramount to kill intracellular Mtb to prevent
the formation of active TB.
Antibiotics have significantly reduced the prevalence of TB. The treatment of TB
is intensive and requires daily intake of ‘first-line’ antibiotics isoniazid (INH) and
rifampicin (RIF) for at least 6 months to achieve sufficient suppression of Mtb.149 If Mtb
becomes resistant to first-line antibiotics, the Mtb is then identified as multi-drug resistant
(MDR). If infected with MDR-TB, second-line drugs such as levofloxacin, moxifloxacin,
and linezolid, which are more cytotoxic, are given for 18 months. 150 Long treatment (6-24
months) periods of antibiotic treatment raise extremely drug-resistant TB (XDR-TB). Due
to the rising global incidence of MDR-TB, more emphasis is being placed on developing
new drugs with novel antibacterial mechanisms. 151 In 2012, FDA approved two drugs
against MDR-TB: bedaquiline (BQ) and delamanid.152 According to Giraud-Gatineau et
al. BQ inhibits the mycobacterial adenosine triphosphate (ATP) synthesis and has been
shown to alter the human immune response to bacterial infection independently of its direct
antimicrobial actions153 Anti-tuberculosis drugs face a significant hurdle to eradicate
intracellular Mtb that resides in lung macrophages.154 Even upon entering macrophages,
antibiotics are quickly cleared from the cell before its action on intracellular Mtb. 154 As a
result of these factors, there is an increasing need for more effective therapies that offer
higher efficiency in killing intracellular Mtb in a shorter treatment time frame. Based on
all the benefits that nanotechnology offer, it has gained attention as a tool for improving
current treatment methods, especially as drug delivery platforms for delivering drugs with
high cytotoxicity and low solubility.
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1.3.2

Drug delivery platform for TB
Drug delivery using nanocarriers is an emerging strategy to fight against various

diseases. Nanoscale size of nanomaterials offers several benefits to overcome the
challenges of current TB treatment. Due to their size and surface chemistry, antibioticsloaded NPs (nanocarriers) are avidly taken up by macrophages. The key advantages of
nanocarrier systems over free drugs include increased bioavailability, prevention of
premature drug release, protection from inactivation of the entrapped drug, sustained and
controlled drug release, and the potential to reduce antibiotic doses, and hence adverse
effects and administration frequency.155 The variety of nanocarriers have been developed,
including inorganic nanocarriers, liposomes, lipid NPs, polymeric NPs, nano micelles,
dendrimers, nanogels, etc.155 There are various methods by which antibiotics can be loaded
into nanocarriers such as chemical conjugation, physical encapsulation, and physical
adsorption.18 Overall, nanocarriers can target host cells in two ways: passive targeting and
active targeting, as shown in Scheme 1.5. Passive targeting refers to the drug delivery of
nanocarriers without requiring a specific targeting ligand. In the case of tuberculosis, we
can use the fact that immune cells like macrophages, monocytes, and dendritic cells
phagocytose and endocytose nanoparticles readily.156 Immune cells are constantly being
recruited to infection sites, notably granulomas.
Furthermore, nanocarriers can be customized to improve macrophage uptakes by
altering their properties (size, charge, rigidness, shape). Soria-Carrera et al. developed
polypeptide micelles coated with alginates where they encapsulated BQ drug and showed
enhanced antimicrobial activity by 3x fold (with MIC 0.01-0.03

g/mL) against Mtb

H37Rv compared to free drug BQ and enhanced stability in gastric and intestinal simulated
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Scheme 1.5. Drug delivery strategies for TB infection.
media.157 Another study by El-Ridy et al. fabricated niosomes (Niosomes are delivery
vesicles made up of surfactants with or without cholesterol and can transport the drug.) and
loaded drug ethambutol and showed enhanced antimicrobial activity in vivo. 158
Antimycobacterial peptides such as NZX also gained interest in TB therapeutics. Tenhald
et al. reported delivery of NZX antimycobacterial peptide using mesoporous silica
nanoparticles and showed inhibition of intracellular mycobacteria in macrophage. 159
Several studies reported using liposomes, polymers, micelles, inorganic NPs, and NPs as a
drug delivery vehicle for TB treatments.160 In contrast, active targeting involves the
delivery of a drug to targeted sites based on recognizing specific ligands conjugated to the
NPs, which bind on specific receptors expressed by cells at the targeted site. Active
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targeting offers many benefits compared to passive targeting, such as enabling the
administration of drugs at a lower effective dose, reducing off-site toxicity of drug,
receptor-mediated endocytosis enhances intracellular drug concentration at target sites,
specifically targeting infectious sites without affecting healthy cells. 161 For TB, to enhance
the specificity of drug-loaded nanocarriers, we can take advantage of pattern recognition
receptors of macrophage cells. Shrivastava et al. reported mannosylated liposomes loaded
with dual anti-TB drugs RIF and INH to treat pulmonary TB. 162 Many studies have reported
using mannose as a targeting ligand conjugated on nanocarriers to target intracellular Mtb.
For example, mannose conjugated on solid lipid NPs, 163 polymeric NPs,164 gelatin NPs,165,
and liposomes.166 Hydrophilic or hydrophobic drug-loaded mannose conjugated NPs have
been used for antibiotic delivery with some success.167 Targeting folate receptors that are
overexpressed on macrophages has been used as a strategy to target Mtb infected
macrophages.161 Recently, Shah et al. developed nanocapsules, in which RIF was loaded
into folic acid conjugated chitosan NPs.168 Shan and co., demonstrated promising results
for targeted delivery of drug; enhanced uptake of chitosan NPs, and higher lung drug
concentration.168
1.3.3

Gold NPs-based drug delivery platform for TB
In recent years, the development of stimuli-responsive hybrid nano-systems co-

formulated with inorganic (magnetic, silver, gold NPs) and organic liposomes, polymers,
and micelles have become a fast-emerging field. Stimuli-responsive release of antibiotics
in response to a magnetic field, ultrasounds, and light has been developed. Light or
electromagnetic radiation has been widely used as a trigger to design responsive drug
delivery systems. Electromagnetic radiation employing ultraviolet (<400 nm), visible, or
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near-infrared – I (NIR- I) regions (700 – 1000 nm) frequencies have been used as stimuli. 169
Among them, the NIR region of the electromagnetic spectrum has received much attention.
169-176

NIR responsive materials are usually called photothermal agents. 177 Photothermal

heating occurs due to the absorption of light by an ensemble of electrons on the surface of
conductive materials (e.g., gold) and the subsequent dissipation of that energy as heat.
Plasmonically active metal NPs (The plasmonically active metal NPs have free electrons
in metal NPs and when they interact with light, it is called plasmonic effect), such as gold
nanorods (GNRs) are particularly effective photothermal agents because of their large
absorbance cross-sections, tunable optical properties, and highly efficient conversion of
light into heat.178 These properties make them an appealing PT agent in biomedical
applications.
Photothermal heating can either be used to deliver thermal energy to a localized
area as reported by the Liu group in their research work,179, 180 or throughout the drug
carrier, thereby causing the destruction of the encapsulating material and triggering the
release of the loaded therapeutics. Some early demonstrations of photothermal effects to
release antibacterial agents from drug carriers have been reported in several research
studies.181-183 Specifically for TB treatment, so far in the literature, none of the studies has
reported the use of GNRs as the photothermal agent, which is then coated with mesoporous
structure, into which hydrophilic and hydrophobic drugs can be loaded, followed by
thermo-sensitive

liposome

encapsulation,

and

finally

conjugating

targeting

antimycobacterial peptide or host-targeting carbohydrate ligand. Hybrid nano-assemblies
that was developed for this thesis offer (a) colloidal stability, (b) prevent premature drug
release, (c) increased internalization into infected host cells, (d) control release of drug
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through melting of thermo-sensitive liposome (e) photothermal activity (f) enhanced
intracellular drug concentration due to targeting efficiency (g) modify host immune
responses (h) low toxicity.
1.4

Drug delivery platforms for cancer
Globally, cancer is one of the leading causes of death, and based on Global Cancer

Observatory (GCO), by 2030, approximately 30 million cancer patients will die from
cancer each year.184 Cancer pathology is distinguished by inherent genetic alterations and
cellular disorders, indicating abnormal and uncontrollable cellular growth that eventually
leads to the patient's death.185, 186 Chemotherapy is the most commonly used systemic
treatment for cancer cell proliferation, disease progression, and metastasis. On the other
hand, chemotherapeutic drugs kill cancer cells and inevitably attack healthy cells, causing
side effects.187 Drug carriers that preserve or improve chemotherapeutic efficacy while
decreasing the severity of side effects are therefore critically required.
In the past decades, nanoparticles-mediated drug delivery platforms have been
extensively studied by researchers. Nanoparticle-based drug delivery has systems area
already being used in cancer treatments. For example, the FDA approved a liposomal
version of doxorubicin (Doxil) in 1995 to treat AIDS-related Kaposi sarcoma.188 The FDA
approved protein-bound paclitaxel (Abraxane), an albumin-based nanoparticle, for clinical
use in the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer in
2005.189 Nanomaterials offers many benefits when designing a drug delivery system, for
example (1) they can improve the pharmacokinetic and pharmacological properties of
drugs by increasing their water solubility and protecting them from being dissolved in the
bloodstream, (2) offer targeted drug delivery to specific tissues or cells (3) limiting drug
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accumulation in non-targeted organs such the kidneys, liver, and spleen, and improving
therapeutic efficacy, (4) offer real-time monitoring of treatment efficacy with a
combination of imaging and therapeutic agents. In this thesis we focus mainly on drug
delivery towards lung cancer.
1.4.1

Drug delivery platforms for lung cancer
In developed countries, lung cancer is the most common cancer in men and

women.190 It is also the most significant cause of cancer death globally, accounting for
18.4% of all cancer deaths.190 The top three cancer types in terms of mortality are lung,
breast, and colorectum cancer.191 Due to treatment difficulties and late prognosis on a
global scale, lung cancer is responsible for the most significant number of deaths among
all cancer types, and it is also the leading cause of cancer death in men. Currently, the
World Health Organization (WHO) differentiates several types of lung cancer, mainly
classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)
based on the cell morphology. NSCLC is considered an aggressive type of cancer; it affects
a much broader population and accounts for 80% of all lung cancer cases. 192 Current cancer
treatment approaches include surgery, chemotherapy, radiotherapy, and immunotherapy,
which can be used alone or in combination, and the decision will be based primarily on the
stage of cancer and the patient's overall health. All of these techniques have their
limitations. For example, surgery does not always result in complete tumor removal,
whereas radiation therapy may reduce tumor size but never result in complete eradication.
In contrast, photodynamic therapy or chemotherapy are two different methods used
for advanced-stage lung cancer. Furthermore, radiation therapy and chemotherapy have an
indiscriminate effect on cancerous and healthy cells.193, 194 Hence, there is an urgent need
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to improve current treatment options. Nanotechnology offers more precise and effective
treatments.195 Various types of drug delivery nano systems, including lipid-based,
polymeric, and inorganic NPs have been widely used for lung cancer treatment. 196
Chemotherapeutic agents are usually either encapsulated or conjugated or adsorbed on
these nanomaterials to improve existing chemotherapy.
1.4.2

Gold NPs-based drug delivery platforms for lung cancer
Although there are many different types of inorganic NPs only gold NPs have been

approved by the FDA to treat lung cancer.197 PEG-coated silica gold-nanoshell was used
for NIR facilitated thermal ablation of solid primary and metastatic lung tumors. 197 Due to
its nanoscale size, electrons at the gold surface can interact with light, resulting in a
phenomenon called surface plasmon resonance (SPR – see section 1.2). As per biomedical
application, it is vital to tune SPR absorption wavelength, so the wavelength falls within
the NIR region of the electromagnetic spectrum (650–1300 nm). 198 This is called the
‘biological window’ as there are no absorptions by other biological matrices in that
window. Therefore NIR light can penetrate deeper into the tissue. 198 Photodynamic therapy
(PDT) and Photothermal therapy (PTT) are two emerging cancer treatment approaches
with a lot of promise, and the materials employed in these two therapies are related to
optical interference. In PDT, a photosensitizer accumulates in cancerous sites, and when
exposed to a specific wavelength of light, cytotoxic free radicals are produced, resulting in
apoptosis and/or necrosis of cancerous cells.
While PTT employs nanomaterials with high photothermal conversion efficiency
to raise the temperature of cancerous areas, resulting in cancer cell death. Various lightresponsive nanomaterials have been investigated for PTT-against lung cancer. For
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example, gold-based nanomaterials, carbon-based nanomaterials (CNMs), black
phosphorous, and polydopamine-based nanomaterials. 198 Hauck et al. reported that the heat
produced by GNRs in conjunction with the chemotherapeutic drug cisplatin killed 78 %
more cancer cells than cisplatin alone.199 Combination therapy can reduce the toxicity of
chemotherapeutics by lowering the effective drug dosage.199 Xie and collaborators
fabricated hollow carbon nanospheres loaded with Dox and conjugated mitochondria
targeting peptide and hyaluronic acid moieties on the surface and observed PT activity
induced damage in lung cancer cells.200 Prasad and colleagues reported a synergistic
combination strategy of black phosphorus (BP)-based photothermal therapy and anti-CD47
antibody (aCD47)-based immunotherapy to improve cancer treatment. 201 Cao et al.
synthesized polydopamine NPs that carry photosensitizers and act as PT agents. Hence,
combining PTT and PDT showed enhanced antitumor therapy. 202 A phase II clinical trial
that investigated the effects of two well-known anticancer drugs under mild hyperthermia
conditions using poly(lactic-co-glycolic acid) (PLGA) coated Fe 3O4 NPs , which revealed
the promise of using PTT in conjunction with chemotherapeutics (NCT00178763). 203 The
use of gold nanomaterials in PTT has gained attention as it enters clinical trials for lung
carcinomas. AuroShells®, gold-silica nanoshells, have entered an open-label, singlecenter, single-dose efficacy pilot study for the treatment of primary and metastatic lung
tumors. (NCT01679470).204 Participants in this trial received an intravenous infusion of
PEG-coated AuroShells, followed by laser irradiation of lung tumors via fiber optic
bronchoscopy. The trial's primary outcomes were a reduction in tumor volume and the
absence of thermal lesions in individuals over six months. 204 Another study reported by ElSayed group demonstrated the feasibility of GNR based PTT in squamous cell carcinoma
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in mice.205 They used thiolated PEG that was covalently bound to the surface of the GNR
and injected it into squamous cell carcinoma and found a significant decrease in tumor
volume.206 Other studies Chiang et al. showed conductive polymeric nanomaterials
exhibits PTT and PDT, however high laser intensity have such as 2 W has been used to
generate photothermal activity.207
We have developed hybrid nano-assemblies composed of dual photothermal agents:
GNR and IR 780. Our hybrid nano-assemblies are composed of GNRs coated with
mesoporous silica shells that offer a surface for drug loading. Anticancer drug doxorubicin
(Dox) was loaded into a mesoporous silica shell. A near-infrared dye, IR 780, was used as
a photosensitizer to enhance the photothermal activity. The increased photothermal activity
offers ROS generation under less intense laser irradiation. 208 Cationic peptide GE-11 and
folic acid were conjugated to the surface of the nano-assemblies to specifically target the
epidermal growth factor receptor (EGFR) and folate receptor overexpressed on NSCLC
cells.209 This dual ligand-targeting approach enhances the cancer-targeting, increases
specificity, minimizes non-specific attacks on surrounding tissues, and improves the
therapeutic efficacy of anticancer drugs by enhancing cellular uptake.210
1.5

Nano diagnostics for bacterial infections
Even though enormous efforts have been made to prevent epidemics and death from

infectious diseases, it remains one of the primary healthcare challenges that significantly
influence humanity. As a result, developing specific, sensitive, accurate, quick, low-cost,
and simple-to-use diagnostic tools is in urgent demand. Nano diagnostics is defined as
utilizing nanotechnology in diagnostic applications. This technology has been extensively
explored to develop diagnostic tests with great sensitivity and the ability to detect infection
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before it occurs. Nano diagnostic platforms benefit from the unique features of
nanomaterials or nanostructures, which allow for quick and real-time detection utilizing
extremely small amounts of patient samples. Hence, nano diagnostic techniques hold much
promise as low-cost, user-friendly, and reliable devices. Most nano diagnostic applications
are currently focused on pathogen identification in infectious disorders and cancer
biomarkers in cancer therapy.211 For infectious diseases, nano diagnostics can achieve
simple, reliable, and fast conclusions by using blood, sputum, or urine samples from
patients. Furthermore, the sensitive nano diagnostics platforms, which have much promise
to be robust, inexpensive, and reproducible, could be useful for diagnosing infectious
diseases, especially in developing countries.211
1.5.1

Nanoparticle-based diagnosis for infectious disease
The distinct properties of NPs dictate nano diagnostic platforms and the ability to

detect clinical samples in very small volumes. Various NPs have been effectively used to
diagnose infectious disorders, including metallic NPs,212 fluorescent NPs,213, and magnetic
NPs.214 Because of their high surface area-to-volume ratio and reactive surface atoms, NPs
can be functionalized with affinity ligands capable of binding to pathogen-associated
analyte targets.215 These functionalized NPs transduce the binding events into optical, 216
electric,217 mechanical,218, or magnetic output signals.215
1.5.1.1 Gold nanoparticles (AuNPs)
Gold nanoparticles (AuNPs) have unique physiochemical (inert and nontoxic) and
optical properties, making them ideal for clinical diagnosis, therapies, and other
multidisciplinary research.214 Upon light irradiation on AuNPs, it causes a surface plasmon
resonance (SPR) which can be used to induce a color shift or localized heating. 219 AuNPs
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have the following distinguishing features:

(1) a large surface area allowing

functionalization with biomolecules,220 (2) intense bright colors allowing easy colorimetric
bio-recognition,221 (3) high degree of control over shape and size,222 (4) long term stability
in a wide range of solvents and PH conditions,223 (5) excellent optical performance due to
a strong SPR.224 The most common application of SPR to infectious disease diagnostics is
the lateral flow test (LFT), a well-known assay technique exemplified by the home
pregnancy test.225 When functionalized AuNPs attach to their target analytes and aggregate
on the LFT test strip, their optical signals are apparent as red lines; in this case, the AuNPs
absorb light in the green region of the visible light spectrum and emit light in the red
region.226 Recently, Moitra et al. have developed a simple, quick, and specific visual
colorimetric

SARS-CoV-2

detection

test

using

AuNPs. 227

Specific

antisense

oligonucleotides (ASOs) for the N phosphoprotein of SARS-CoV-2 were modified by thiol
ligand and conjugated on AuNPs. When the target RNA sequence SARS-CoV-2 was
present, thiol-modified ASOs conjugated AuNPs aggregate, resulting in a change in SPR
with a detection time of 10 minutes.227
1.5.1.2 Fluorescent nanoparticles
Quantum dots (QDs) are semiconductor-based fluorescent nanostructures with a
diameter of 1–10 nm that exhibit many physicochemical properties, including
photostability and high quantum yield.228 QDs are brighter and more stable than organic
fluorophores, and they have broad absorption and narrow emission spectra, which is
beneficial for simultaneous excitation and detection.229 The detection of bacteria such as
Escherichia coli (E. coli),230 Salmonella typhimurium,231 Mycobacterium bovis,232, and oral
bacteria has been studied extensively using ligand-conjugated QDs. 233 In another example,
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Zhang et al. have diagnosed Hepatitis B through the immunoassay using the QDs
nanobeads with detection limit as low as 78 pg of hepatitis B surface antigen, indicating
the diagnosis of infectious diseases.234
1.5.1.3 Magnetic nanoparticles (MNPs)
MNPs have been used to detect bacteria in the past few decades and have been
viewed as extremely promising nanomaterials due to their distinctive physical features,
which include magnetic properties, structural qualities, and the ability to be easily
modified.235 The magnetic properties of nanosized MNPs differ from conventional
magnetic materials. Fe atom has a strong magnetic moment due to four unpaired electrons
in its 3d orbitals. As shown in Scheme 1.6, there are four different types of magnetism
exhibited in crystals; (1) In paramagnetic state, the magnetic moments are randomly
oriented and when an external magnetic field is applied to the crystal, it has a small net
magnetic moment, and when the field is removed, the magnetic moment is zero. 236 (2) Even
in the absence of an external magnetic field, all magnetic moments are aligned in a
ferromagnetic state.237 (3) In antiferromagnetic state, the crystal shows no net magnetic
moment if the antiparallel magnetic moments are of the same magnitude. 237 (4) In a
ferrimagnetic crystal are like antiferromagnetic materials, two types of atoms with different
magnetic moments are aligned in an antiparallel fashion, resulting in ferrimagnetic material
with a net magnetic moment.237 Both magnetite [Fe3O4] and maghemite [Fe2O3] are
ferrimagnetic.237

Superparamagnetism is one type of magnetism that occurs in

ferromagnetic and ferrimagnetic nanostructures. This feature is size-dependent, and it
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Scheme 1.6. Magnetic spin alignments in various types of magnetic states.
usually occurs when NPs are as small as 10–20 nm.238 Because these NPs are so small,
they do not have several domains like large magnets do; instead, they form a single
magnetic domain and behave as a "single spin" with great magnetic susceptibility. 238 Thus,
when a magnetic field is applied, these NPs provide a stronger and faster magnetic response
than bulk magnets.238 By taking advantage of the magnetic properties of MNPs, MNPsmediated diagnosis carry out based on separation and detection of MNPs coupled with
target biomarkers under an applied magnetic field. For example, superparamagnetic MNPs
have been used to develop a magnetic immunoassay.239 The target analyte permits MNPs
to form a sandwich conformation, resulting in a local magnetic field that the sensor can
detect after an external field is utilized to induce a magnetic moment in the MNPs. 239
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1.5.2

Nanodevice-based diagnosis for infectious disease
Many novel diagnostic methods are under investigation using nanotechnology to

develop nanodevice-based diagnostic systems for the diagnosis of infectious diseases. 240
Multiple assays can be incorporated into a single nanodevice.241 This would result in a
reduction in the sample volume, material consumption, and processing time. 241 For
example, using microfluidics, high-throughput and multiplexed assays have been
developed to detect blood-borne infectious agents such as Human immunodeficiency virus
(HIV) in serum samples.242 Another example is a developed lab-on-a-chip to detect MDRTB.243 This lab-on-chip consists of a single disposable device and microfluidic PCR and
microarray modules. The platform includes a temperature control system and an optical
reader, which allow for automatic microarray analysis and the generation of a user-friendly
diagnostic report of MDR-TB.243 For specific detection of Mtb using SPR, Prabhakar et.
al., employed cysteine modified NH2-end peptide

-thiol end

labeled DNA probes mounted onto BK-7 gold-coated glass plates. 244
Furthermore, nanotechnology-based systems have the potential to develop portable,
robust, and affordable point-of-care testing (POCT) platforms to detect infectious diseases
in developing countries.245 For example, researchers have created a smartphone dongle
using gold and silver nanoparticles that can be used as a POCT system to test infectious
diseases such as HIV and syphilis.246 They demonstrated that a full immunoassay, which
is usually performed in the laboratory, can be integrated into a smartphone accessory to
achieve nanotechnology-based POCT.246 The variety of POCT nano diagnostics systems
has been developed by researchers, including magnetic barcode assay using magnetic
nanoprobes and paper-based POCT (lateral flow system) using silver NPs. 211 The magnetic
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barcode system has also been used successfully for multiplex detection of the most
common infectious bacteria, including Mtb, Staphylococcus aureus, methicillin-resistant
Staphylococcus aureus, and Klebsiella pneumoniae.247,

248

Geissler et al. reported the

paper-based POCT that used to detect yellow fever virus, Ebola virus, and dengue virus. 249
More improved nano diagnostics focusing on the development of the challenging diagnosis
of infectious diseases are considerably required if the patient is infected with more than
one pathogen, such as HIV.
1.5.3

Diagnostics for TB
TB diagnostics methods are divided into four categories: traditional methods,

immunological methods,250 molecular methods,251, and novel nano diagnostics methods.252
The traditional methods include conventional microscopy with acid-fast bacilli (AFB)
staining culture methods that are time-consuming and labor-intensive. 251 Immunological
approaches, such as the Enzyme-linked immunosorbent assay (ELISA), Tuberculin Skin
Test (TST), and IFN-Gamma Release Assay (IGRA), have been developed for the
detection of TB/latent TB infection (LTBI).253 However, these methods fail to distinguish
between latent TB and active TB infection. The molecular methods include Xpert MTB/Rif
assay, nucleic acid amplification-based tests (NAAT), that is, polymerase chain reaction
(PCR), line probe assay (LPA), Loop-mediated isothermal amplification (LAMP) and can
detect Mtb within a few hours to days in suspected TB patients.253 Despite all advances in
TB diagnosis, there is no accurate, rapid, inexpensive, point-of-care test available
for Mtb detection particularly for developing nations where resources are very limited.
Taking all of these factors into account, a nano diagnostic for TB detection is urgently
required.
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1.5.4

Nanoparticle-based diagnosis for TB
In past decades various nano diagnostics systems have been developed for the

molecular diagnostics of TB. NPs such as gold, silica, and MNPs have been widely used
for TB diagnostics. As mentioned earlier, AuNPs hold promise in developing colorimetricbased diagnostic tests due to having excellent optical properties. Baptista et al. were the
first to use AuNPs in TB diagnosis by conjugating DNA probes with AuNPs for
colorimetric detection of Mtb.254 When complementary DNA is present, the nanoprobe
solution remains pink (no DNA probe aggregation) at wavelength 526 nm, however, when
complementary DNA is absent, the solution turns purple (due to high NaCl concentration
causing nanoprobe aggregation).254 Compared to other diagnostic procedures, such as
InnoLiPA-Rif-TB, the method developed by Baptista et al. is more accurate.254 The test
was more sensitive than smear microscopy and easily observed for detection. The main
advantage of this method is that it has a low risk of contamination (since it is performed in
a single tube), and it is rapid, detection time is 15 min per sample. 254
Indirect immunofluorescence microscopy has been developed to detect Mtb using
silica NPs coupled with fluorescent dye.255 In this test, SYBR Green I-mediated assay
stained only bio-conjugated fluorescent silica NPs, yielding fluorescent signals five times
stronger than the traditional fluorescence isothiocyanate (FITC)-based detection approach.
The detection time is less than 2 hours, and it is regarded as a promising method for the
rapid detection of Mtb.255 Various biosensors have also been developed by researchers for
Mtb detection.251 Moreover, MNPs have been shown to have a wide range of exciting and
promising applications in medical diagnostics and therapy. Superparamagnetic iron oxide
nanoparticles SPIONs, composed of magnetite [Fe3O4] or maghemite [Fe2O3] NPs are
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widely used in cell tracking, drug therapy, and drug delivery.256 Lee et al. developed a
technique in which mycobacteria were targeted by MNPs with a large Fe core and a thin
ferrite shell, then concentrated in a microfluidic chamber and identified using nuclear
magnetic resonance. The diagnostic platform's clinical efficacy was tested by detecting TB
using the bacillus Calmette-Guérin (BCG) surrogate for Mtb. Several studies have reported
the use of diagnostic magnetic resonance (DMR) in conjunction with iron oxide
nanoparticles to detect Mtb.257,

258

A nanoparticle-based colorimetric biosensing assay

(NCBA) to identify acid-fast bacilli (AFB) in decontaminated sputum samples was
described by Bhusal et. al., in 2019.259 Using glycan-coated magnetic nanoparticles
(GMNP), the researchers were able to isolate AFB from decontaminated sputum samples
using a magnet. Followed by the complex was stained and observed under a light
microscope to check GMNP-Mtb interaction. Because the Mtb cell envelope is rich in
complex carbohydrates and glycoproteins, which can bind with the GMNP, the GMNP
captures Mtb cells via glycan-glycoprotein interaction. The method detected 102 CFU/mL
with 100% sensitivity.259
To summarize, NPs have been used in various studies to improve the diagnosis of
TB. The results were promising in many cases, indicating that the use of nanotechnology
to improve the sensitivity of infectious disease diagnosis is effective. However, many Mtb
biomarkers have not yet been evaluated with NPs. In this thesis, we have synthesized multicore silica-coated magnetic nanoparticles (SMNPs), these SMNPs are then conjugated to
plant lectins Concanavalin A (Con A) and Aleuria aurantia lectin (AAL). The lectins Con
A and AAL were chosen of their strong binding affinity for mannose (dissociation constant
Kd 2.8 M) and arabinose (dissociation constant Kd 16 M), respectively.260 These lectins
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conjugated SMNPs exhibited excellent magnetic properties. Following incubation of these
SMNPs with mycobacteria, large visible agglomerates form due to cross-linking of SMNPs
with mycobacteria. Furthermore, these large agglomerates could be easily separated using
a magnet. This is discussed in detail in chapter 5.
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CHAPTER

2.

NEAR-INFRARED

RESPONSIVE

TARGETED

DRUG

DELIVERY SYSTEM THAT OFFERS THE CHEMO-PHOTOTHERMAL
THERAPY AGAINST BACTERIAL INFECTION
2.1

Introduction
Antibiotic remedies have been used to date to treat bacterial infections.

Chemotherapeutic antibiotics have since revolutionized medicine, with their high treatment
efficiency and ease of manufacture leading to widespread usage. However, overuse has
driven the development of multi-drug resistance (MDR) in bacteria, dramatically
decreasing antibiotic efficacy and increasing the risks of infection-related mortalities. 261
MDR bacterial infection has caused 2.8 million illnesses and 35,000 deaths in the United
States in the past few years.261 Therefore, newer therapeutic options are required to combat
this increasing problem.262,

263

Targeted drug delivery is an attractive alternative to

traditional oral broad-spectrum non-targeted small molecule antibiotics in capsules. 105, 264
But even with cutting-edge antibiotic delivery strategies, antibacterial activity still relies
upon the therapeutic efficacy of the encapsulated drug.
Combination nano-therapy combining an antibiotic with a different modality of
treatment such as photothermal (PT), magnetothermal therapies have recently emerged to
the surface of antibacterial therapies.182, 265-267 Recently, Wang et al. have developed a new
strategy for effectively killing Gram-positive bacteria based on vancomycin (Van)-
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modified gold nanostars (AuNSs).265 The Van-modified AuNSs (AuNSs@Van) can not
only selectively recognize methicillin-resistant Staphylococcus aureus (MRSA) but also
kill 99% MRSA under near-infrared laser irradiation (808 nm for 10 min, 2.5 W/ cm 2) in
vitro and in vivo as compared to free drug. Additionally, AuNSs@Van shows satisfactory
biocompatibility and antibacterial activity in treating a bacterial infection in vivo. 265 In
terms of magnetothermal therapies, magnetic nanoparticles (MNPs) have recently been
used as hyperthermia agents to treat bacterial infections. 268 MNPs would absorb
electromagnetic radiation and then convert the magnetic energy to localized heat when
placed in an alternating magnetic field with a high frequency and amplitude. 268 A powerful
nanocarrier based MNPs for antibiotics and silver nanoparticles (Ag NPs) delivery
designed by Xing group.267 This nanocarrier penetrates Staphylococcus aureus biofilm and
significantly enhances the biofilm disruption in an external magnetic field. 267 Studies have
shown that combination therapy (combitherapy) approaches combining PTT and antibiotic
therapy to combat bacterial infections works better.181-183 Another work done by Quing et
al. reported combined chemo-PTT offering engineered nano-structure against methicillinresistant Staphylococcus aureus (MRSA) bacterial infection.105 Ma et al. also reported
strategies for chemo-PTT therapy against Escherichia coli and Staphylococcus aureus.269
Both reported combinational therapies against bacteria lack nanomaterials' targeting ability
towards the bacteria surface. Our approach allows targeted antibiotic delivery to the
bacteria cell surface, which increases the drug's efficacy and reduces off-target toxicity.
Among available nanoplatforms, gold nanoplatforms are used most extensively in PTT.
These include gold nanospheres, nanorods (GNRs),270, 271 nanocages,172 nanoshells,272, 273
nanostars,176 and they all been successfully used both in vitro and in vivo. GNRs exhibits
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strong longitudinal absorbance at the NIR I window of 700–1000 nm with excellent
application in the photo-induced therapies.274 Additionally, by adjusting aspect ratios,
GNRs can easily attenuate a strong absorption at a particular wavelength. 275 Yang et al.
have recently reported the immobilization of gold nanorods (GNRs) on the surface of
titanium via electrostatic interaction.276 This GNR-modified surface was resistant to the
gram-positive and gram-negative bacteria, and with NIR irradiation enhancing the
photothermal impact and high antibacterial activities.276 Based on the literature and
application of GNRs as a photothermal agent in drug delivery, we used GNRs in this thesis
that absorbs NIR light and generates PT activity. GNRs were coated in a mesoporous silica
shell (GNR@MSNP) to improve drug loading capability. Porous inorganic shells are
widely used in drug delivery applications due to their large pore volume, pore size and
surface area.174,

277-279

Therefore, drug (bedaquiline, BDQ) loaded into GNR@MSNP

assembly and then GNR@MSNP@BDQ was encapsulated in a thermo-sensitive liposome
(TSL, GNR@MSNP@BDQ@TSL) which gives PT activity of GNRs. Liposome
encapsulation offers controlled drug release and stops premature release before the nanoassembly approaches the target.280,

281

Drug selected was BDQ, a novel antibacterial

therapeutic against tuberculosis (TB). The heat generated from the GNRs upon NIR
exposure causes the TSL to undergo a phase transition and become permeable, releasing
encapsulated drug BDQ. Exposure to NIR laser generates hyperthermia, leading to
permeability in the bacterial cell membrane, causing leakage of bacterial cell content and
subsequent cell death.282 To guide the liposome to the mycobacteria surface, mycobacteria
recognizing antimicrobial peptide (AMPs)

NZX was used. 283 AMPs are small

oligopeptides that have lately shown promise in combating antibiotic resistance
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mechanisms due to their capacity to lyse bacterial membranes, resulting in broad-spectrum
actions that target microorganisms ranging from viruses to parasites. The key feature of
AMPs is their capacity to selectively disrupt bacterial membranes while causing no harm
to mammalian cells, making them safe to use. NZX is an antimycobacterial peptide with a
peptide sequence “GFGCNGPWSEDDIQCHNHCKSIKGYKGGYCARGGFVCKCY”.
Tenhald et al. investigated the impact of the NZX peptide on Mtb in vitro and in vivo. In
both in vitro and in vivo infection models, they discovered that NZX is proteolytically
stable and nontoxic to mammalian cells, but it targets and kills Mtb at concentrations
comparable to conventional antibiotics. Since, AMPs can also exert a degree of
antibacterial activity, and are therefore far more attractive than other biomarker targeting
ligands.284 As a result, NZX is an appealing targeting peptide to use in our nano-assemblies.
With the addition of NZX peptide, the final nano-assembly abbreviates as
GNR@MSNP@BDQ@TSL@NZX.
TB is a life-threatening infectious disease.285 Pulmonary TB is caused mainly by
Mycobacterium tuberculosis (Mtb) bacteria, an intracellular pathogen. Active TB is
symptomatic, while latent TB is asymptomatic and difficult to treat. In latent pulmonary
TB, Mtb can lie dormant in lung tissue, unaware of the immune system for years. 143
Immune cells such as macrophages cannot eradicate the Mtb bacteria while within lung
tissue cells. Antibiotics are ineffective when accessing macrophages and eradicating
intracellular Mtb.154 Antibiotics are quickly cleared from macrophages before they act on
intracellular Mtb.154 Hence treating intracellular Mtb is very challenging. Our nanoassembly is designed to target and kill these mycobacteria that survive within the lung
epithelial cells. Previous nanotechnology-based drug delivery systems designed to target
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a

b

Scheme 2.1. (a) Schematic illustration of the final nano-assembly stepwise synthesis:
GNR@MSNP@BDQ@TSL@NZX. (b) Application of final nano-assembly:
GNR@MSNP@BDQ@TSL@NZX for targeting and killing Msmeg using 808 nm NIR
laser light.
Mtb include recent work done by Tenland and co-workers.159 Tenland et al. used
mesoporous silica nanoparticles as a porous drug delivery nanocarrier loaded with
antibacterial peptide NZX, which also can target intracellular Mtb residents in lung
macrophage.159, 283 They demonstrated an 88% reduction in Mtb in in-vivo studies. Ali and
co-workers reported GNRs as a delivery vehicle delivering antibiotic rifampicin, GNRs
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also act as a source of inherent bactericidal activity against Mtb.10 Li et al. reported
combined antimycobacterial and PTT using core-shell upconversion nanoparticles carrying
anti-tuberculotic drug rifampin.286 All these drug delivery systems suffer from a lack of
targeting ability towards intracellular Mtb.
Our engineered nano-assembly also displayed (a) stability in medium (b) no
premature drug release (c) increased internalization into infected host cells due to having
TSL and NZX peptide (d) control release of drug through melting of TSL. The final nanoassembly GNR@MSNP@BDQ@TSL@NZX (Scheme 2.1) was observed to have the best
antibacterial activity against Mycobacterium smegmatis (Msmeg) in a series of in-vitro
experiments. Msmeg is a biosafety level 1 (BSL-1) mimic of Mtb. We also assessed the
ability of the nano-assembly to target and kill 99.9% Msmeg internalized within lung
epithelial cells.
2.2
2.2.1

Experimental
Materials and Instruments
Hexadecyltrimethylammonium bromide (CTAB, 99%), L-ascorbic acid (AA,

98%), silver nitrate (AgNO3, 99%), hydrogen tetrachloroauric (III) acid trihydrate
(HAuCl4·3H2O, 99.9%), sodium borohydride (NaBH4, 98%), were used for gold nanorod
synthesis and purchased from Sigma-Aldrich (St. Louis, USA). Tetraethyl orthosilicate
(TEOS,

98%),

3-aminopropyl-triethoxysilane

(aminopropyl)trimethoxysilane (APTMS) (97%),

(APTES,

97%),

3-

rhodamine B isothiocyanate isomer

(RITC), were used for mesoporous silica shell synthesis and purchased from SigmaAldrich (St. Louis, USA). N-hydroxysulfosuccinimide sodium salt (sulfo-NHS), 1-ethyl3-(3-dimethylaminopropyl)- carbodiimide (EDC, 98%) were used for conjugation of
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peptides and purchased from Alfa Aesar (Massachusetts, USA). Sodium hydroxide
(NaOH, 98.5%) was purchased from Lab Chem (Pennsylvania, USA). Ammonium nitrate
(NH4NO3, 99%) was purchased from ACROS Organics. Water was used from a Milli-Q
water ultrapure water purification system (Millipore. Absolute ethanol (200 proof), sodium
lauryl sulfate (SLS), chloroform (CHCl3), HPLC grade acetonitrile (ACN), water with 1%
trifluoroacetic acid (TFA, 1% v/v) HPLC grade were purchased from Fisher Scientific Inc.
(Massachusetts, USA).
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol and 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene

glycol)-2000]

(DSPE-PEG 2000 amine) and mini extruder kit were used for liposome preparation and
purchased from Avanti Polar Lipids Inc., (Alabama, USA). N-(2-hydroxyethyl) piperazineN’-(2-ethanesulfonic acid) (HEPES solution), MES buffer, 2’,7’-Dichlorofluorescin
diacetate (DCFH-DA) reactive oxygen species kit (ROS) assay kit and cell counting kit
WST-8 were purchased from Sigma-Aldrich (St. Louis, USA). Msmeg strain mc2 155
(ATCC® 700084) was purchased from American Type Culture Collection (Vancouver,
USA). Mycobacteria media DifcoTM Middlebrook 7H9 broth, DifcoTM Middlebrook 7H10
agar, BBLTM Middlebrook ADC enrichment, and BBLTM Middlebrook OADC enrichment
were purchased from Becton Dickinson (New Jersey, USA). A549 (ATCC® CCL-185l)
lung cancer cells were also purchased from ATCC. Synthesized NZX peptide was
purchased from ProteoGenix (Schiltigheim, France). MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) cell proliferation kit, live/dead BacLightTM bacterial
-diamidino-2-phenylindole (DAPI) and calcein-AM were
purchased from ThermoFisher Scientific (Massachusetts, USA). Ham’s F-12K nutrient
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mixture with L-glutamine (F-12K, 1X),

fetal bovine serum (FBS, 10%), trypsin EDTA

(2.21 mM), and Penicillin Streptomycin (Pen-Strep, 1X) was purchased from Corning
(New York, USA).
The particle size was determined using a Dynamic Light Scattering (DLS) Malvern
Zetasizer, Malvern Panalytical Inc., (Massachusetts, USA). Transmission electron
microscopy (TEM) images were obtained on an FEI Tecnai Osiris operating at an
accelerating voltage of 200 kV. Nitrogen adsorption-desorption was performed using a
surface area and porosity analyzer (Autosorb iQ-C-MP/XR, USA). Absorbance spectra of
particles and optical density measurements were performed with a Spectramax M2
Molecular Devices Ltd., plate reader (Silicon Valley, USA). Fourier-Transform Infrared
(FTIR) spectroscopic analysis was done using Nicolet is50 ATR FTIR ThermoFisher
Scientific (New Jersey, USA). Thermogravimetric analysis (TGA) was performed on a
Discovery Q500, TGA from TA Instruments (Massachusetts, USA). High-Performance
Liquid Chromatography (HPLC) analysis was performed using a Hitachi Primaide
Separation module and a 1430 diode array detector equipped with a reverse-phase SunFire
C18 column.
The 808 nm laser diodes (G pin code) of 200 mW and 500 mW power intensities,
laser diode controller (LDC210C), laser diode temperature controller (TED200C), laser
diode mount (LDM56), digital thermometer, and 25 mm objective lens (LA1560) were all
purchased from Thor Labs Inc., (New Jersey, USA). The fluorescence microscopy images
were taken from the CKX53 inverted fluorescence microscope, Olympus (USA).
Mammalian cells were quantified using an automatic cell counter (Corning, USA). All
aseptic bacteria techniques and sterile mammalian cell culture were conducted in a separate

51

1300 Series A2 biosafety cabinet (ThermoFisher Scientific). Shaking incubator (Corning,
USA) and CO2 incubator (ThermoFisher Scientific) was used for bacteria and mammalian
cell culture incubation. Sterile disposables, sterilized glassware, and medium were used for
all experiments. Unless specifically mentioned, all liquid media were sterilized using a
benchtop BioClave liquid sterilizer (Ward’s Science, New York, USA).
2.2.2

Synthesis of gold nanorods (GNRs)
A modified seed-mediated method by El-Sayed et al. was used for GNRs

synthesis.48 CTAB coated seeds were prepared by chemical reduction of gold salt with
NaBH4. Briefly, a HAuCl4 solution (0.25 mL, 0.01 M) was mixed with a CTAB solution
(7.5 mL, 0.1 M) in a 25 mL round bottom flask under stirring. An ice-cold NaBH 4 solution
(0.6 mL, 0.01 M) was injected quickly under vigorous stirring. The solution turned
immediately brownish yellow color, suggesting the formation of the gold seeds. The
mixture was kept undisturbed at 30 °C for another 3-4 h to ensure the complete degradation
of unreacted NaBH4. All the solutions were prepared from a stock solution to get
reproducible results. The growth solution consisting of CTAB (600 mL, 0.1M), HAuCl 4
(30 mL, 0.01M), AgNO3 (4.8 mL, 10 mM) and H2SO4 (12 mL, 0.5 M) was stirred together
in a 1000 mL round-bottom flask. The growth solution was equilibrated at 30 °C while
stirring for 10 min. Ascorbic acid (4.8 mL, 0.1 M) was quickly injected into the growth
solution with vigorous stirring. The solution turned colorless immediately. Gold seeds (1.4
mL) were added and stirred for 5 min and then left to age overnight. The prepared GNRs
were purified via two cycles of centrifugation at 12000 rpm for 15 min and then redispersed into 150 mL of water for further modification.
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2.2.3

Synthesis of mesoporous silica shell coated gold nanorods (GNR@MSNPs)
GNR@MSNPs were synthesized according to the protocol developed by Matsuura

et al. with some minor modifications.74 Firstly, 100 mL of purified GNRs were transferred
into an aqueous solution of CTAB (500 mL, 0.8 mM) then the basicity of the solution was
adjusted to pH 10-11 with NaOH (0.1 M). After equilibration at 30 °C for 10 min, a solution
of TEOS/APTES/ethanol (400 L, 20 L, and 1380 L respectively, total 1.8 mL) was
added into the mixture by three times injecting 0.6 mL with gentle stirring. The reaction
mixture was allowed to react at 30 °C overnight. The synthesized GNR@MSNPs were
centrifuged at 12000 rpm for 15 min once and then re-dispersed in 120 mL of ethanolic
NH4NO3 (0.75 mM) at 45 °C and kept overnight to remove CTAB. The final
GNR@MSNPs were purified by centrifugation (10000 rpm for 10 min) and re-dispersed
in ethanol.
2.2.4

RITC-labelled GNR@MSNPs synthesis
The RITC precursor was prepared in the following manner. RITC (8.0 mg, 0.015

mM in ethanol) was stirred overnight with APTMS (5.2 mL, 0.03 mM) in anhydrous
ethanol (15.0 mL) at 42 °C to obtain the RITC-APTMS precursor. RITC-labeled
GNR@MSNPs were synthesized via the same procedure as GNR@MSNPs except that the
TEOS/APTES/ethanol solution was replaced by TEOS/RITC-APTMS/ ethanol solution
(400 mL, 20 mL, and 1380 mL respectively, total 1.8 mL) while the injected volume at
each 30-minute interval stayed the same. This reaction was performed in the dark.
2.2.5

Surface and pore volume determination of GNR@MSNPs

Autosorb iQ-C-MP/XR (Quantachrome, USA), and the cumulative pore volume was
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(BJH) model.
2.2.6

Drug loading in GNR@MSNPs
GNR@MSNPs (21 mg) was mixed with BDQ (7 mg) in 10 mL of DMSO while

stirring overnight at 37 °C. The ratio of GNR@MSNPs and BDQ used in the entire study
was 3:1 w/w (GNR@MSNPs 21 mg: BDQ 7 mg). The BDQ loaded GNR@MSNPs
samples were collected by centrifugation at 10000 rpm for 10 min and vacuum dried to
obtain a dry powder. The encapsulation efficiency and drug loading of BDQ in
GNR@MSNPs were determined by using a standard calibration curve. To construct a
standard calibration curve for BDQ, BDQ (0.1 mg) was resuspended in 1 mL of HEPES
and then diluted to concentrations of 1-

Drug (BDQ) encapsulation efficiency

and drug loading were determined by HPLC.287-289

(2.1)
=
× 100%

(2.2)
=
× 100%

2.2.7

Encapsulation of GNR@MSNP@BDQ in TSL
TSLs were prepared by a lipid film-based method previously reported in the

literature.104 Briefly, DPPC (85% molar ratio), cholesterol (10% molar ratio), and DSPE-
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PEG2000 amine (5% molar ratio) were dissolved in 2 mL of CHCl 3 and evaporated in a
rotary evaporator, yielding a thin lipid film. This thin lipid film was rehydrated in 10 mM
HEPES buffer containing GNR@MSNP@BDQ (2 mg/mL) before being extruded 15 times
through two stacks of Nuclepore, Whatman polycarbonate membranes with a pore size of
800 nm (GE Healthcare, New York, USA) using a mini extruder set (Avanti Polar Lipids,
Alabama, USA). The resultant nano-assembly (GNR@MSNP@BDQ@TSL) was stored at
4 °C until use.
2.2.8

Conjugation of bacteria targeting NZX peptide on TSL
GNR@MSNP@BDQ@TSL were conjugated with NZX via the EDC activation

method, activating the NZX peptide's carboxyl group to react with the primary amines of
DSPE-PEG2000 amine in the liposomes. NZX 0.1 mg/mL was dissolved in 0.1 M MES,
0.5 M NaCl, pH 6.0 (reaction buffer) and then activated with 10 fold molar excess of EDC
(pH = 4.0)

and 25 fold molar excess of sulfo-NHS for 30 min. Liposomes

(GNR@MSNP@BDQ@TSL) were added to the reaction mixture and reacted 24 h at 37
°C. The molar ratio of NZX: liposome was maintained at 10:1. After 24 h, the reaction
mixture was purified by centrifugation at 10000 rpm for 15 min at 25 °C to remove excess
unreacted EDC.
2.2.9

TGA analysis of various nano-assemblies
TGA was carried out under argon gas (99.999%) where dried GNR@MSNP@BDQ

(~ 1 mg) was heated at a rate of 5 °C /min to 100 °C and then kept at isothermal at 100 °C
for 15 min followed by 5 °C /min ramp to 700 °C. The BDQ loaded in GNR@MSNPs
was calculated by analyzing the weight loss difference between GNR@MSNPs and
GNR@MSNP@BDQ. Similarly, the TSL content was analyzed by measuring the weight
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loss difference between GNR@MSNP@BDQ and GNR@MSNP@BDQ@TSL. Finally,
the amount of peptide was calculated by measuring the weight loss difference between
GNR@MSNP@BDQ@TSL and GNR@MSNP@BDQ@TSL@NZX.
2.2.10 Colloidal stability study of nano-assemblies
The

stability

of

GNR@MSNP

and

liposome

coated

GNR@MSNP

(GNR@MSNP@TSL) was conducted at 37 °C to mimic the static condition in an in vitro
experiment. Nano-assemblies were dissolved in mammalian cell culture medium to a 1
mg/mL concentration and incubated at 37 °C for five days.

290

Kah et al. reported

calculating an aggregation index (AI) as a stability parameter to determine the stability of
GNRs.291 AI is a measure of the LSPR peak broadening. AI is calculated by dividing the
total area under the curve (AUC) of the absorbance spectra of the GNRs LSPR band from
600 to 900 nm by the LSPR peak intensity (equation 2.3).291 AI calculates an equivalent
bandwidth of longitudinal peak for a spectrum normalized to the LSPR peak intensity. A
similar analysis was performed for GNR@MSNP and GNR@MSNP@TSL stability
studies. The higher AI indicates a higher degree of aggregation, hence lower colloidal
systems stability.291, 292
(

600

)=

900
(2.3)

2.2.11 Photothermal studies
The thermo-optical setup used for this purpose is shown in Scheme 2.2. The setup
was used with two separate NIR diode lasers with 500 and 200 mW laser intensities
(L808P500MM and L808P200) (Thor Labs, USA). The laser diode was fixed in a
temperature-controlled mount (LDM56) (Thor Labs, USA), which is connected to the laser
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diode controller (LDC210C, Thor Labs, USA). A laser diode controller was used to control
the intensity of the laser output power. The laser diode temperature controller (TED200C,
Thor Labs, USA) helped maintain a stable output power wavelength and prevent heating
that can damage the laser diodes. The laser beam was focused to a spot size of ~ 2 mm
diameter, with a 25 mm focal length objective lens to the middle of a single well in a 96
well plate. A thermocouple monitor was used to monitor the temperature of the solution
upon exposure to the laser. The entire study used a power intensity of 500 mW as 200 mW
was insufficient to induce required hyperthermia effects. Various weight concentrations of
the final nano-assemblies ranged from 50, 100, 500, and 1000 g/mL (calculated with
respect to the weight of GNR@MSNPs) GNR@MSNP@BDQ@TSL@NZX were
irradiated with the 808 nm NIR diode laser (500 mW) for a time period of 1 min –15 min.
A digital thermocouple monitored the temperature change.
2.2.12 NIR laser triggered drug release from nano-assemblies

Scheme 2.2. Schematic illustration of the laser setup used for photothermal studies.
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Nano-assemblies such as GNR@MSNP@BDQ, GNR@MSNP@BDQ@TSL, and
GNR@MSNP@BDQ@TSL@NZX were dispersed in 3 mL of release media (0.5 % w/w
SLS in 10 mM HEPES buffer, pH 7.2), then incubated at 37 °C with constant agitation. At
predetermined time intervals (2, 4, 6, 8, 12, 18, 24, 36, 48, and 72 h), the suspension was
exposed to the NIR laser (808 nm, 500 mW) for 15 min and then centrifuged at 15000 rpm
for 15 min, the supernatant collected and replaced with the same volume of fresh
prewarmed (37 oC) release media. The pellet was resuspended in the new release media
and further incubated. Each sampled aliquot of the supernatant was passed through a 0.22
m nylon filter. The drug release was quantified by HPLC (equipped with UV detector):
HPLC Hitachi Primaide separation module equipped with a 1430 diode array detector and
a reverse phase SunFire C18 column. Elution was performed using a mobile phase
composed of a linear gradient of ACN and TFA at 0.1% (v/v) in water. BDQ was eluted
using linear-gradient mode with 50:50 TFA: ACN for 2 min, 30:70 TFA: ACN 2.1 – 15.1
min, and final column wash using 50:50 TFA: ACN ratio from 15.2 to 18 min. The
injection volume was 20 µL, and the absorbance was recorded at 230 nm. The operating
temperature was 40 °C, and the flow rate was kept at 1.2 mL/min. Calibration curve for
BDQ was generated using 1.0, 2.5, 5.0, 7.5 and 10.0 µg/mL of BDQ diluted in the release
media release media: 0.5% w/v SLS containing 10 mM HEPES, pH 7.2. To quantify the
BDQ release without laser exposure, a similar experiment was conducted in the absence of
the NIR laser light exposure. HPLC quantified the BDQ release from the final nanoassembly.
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2.2.13 Msmeg culture and viability assays
Msmeg were grown at 37 °C in Middlebrook 7H9 medium supplemented with 10%
ADC and 0.05% glycerol. WST-8 cell viability assays were conducted using assay
Msmeg (108 CFU/mL), 170

instructions. Briefly, in a flat-bottom 96-

L of Middlebrook broth, and an aliquot of 20 L of various nano-assemblies added and
shaken (2000 rpm) at 37 °C on a shaker bed for 24 h. After 24 h incubation, the bacterial
viability was determined by a WST-8 assay. The absorbance was recorded at 450 nm using
a plate reader, and high absorbance at 450 nm was interpreted as higher viability of the
bacterial cells. The viable count of bacteria in each well was quantified using standard
spread plate methods followed by the colony counts. From each well, a volume of 10 µL
was serially diluted and spread onto the nutrient agar plates and incubated at 37 °C for 24
h. Agar plates with 30 to 300 colonies were counted, and the viable bacteria was reported
as CFU/mL.
2.2.14 NIR responsive antibacterial activity
The viability of bacteria treated with nano-assemblies with and without NIR laser
(808 nm, 500 mW) exposure was determined by WST-8 cell viability assay and verified
by

the

colony

counting.

Antibacterial

activity

of

(a)

GNR@MSNPs

(b)

GNR@MSNP@BDQ (c) final nano-assembly GNR@MSNP@BDQ@TSL@NZX (e)
BDQ (f) NZX was determined by WST-8 assay and colony counts. Various sample
concentrations of a-f from 0.01determined. MIC is the minimum inhibitory concentration, i.e., the lowest concentration of
drug that effectively inhibits the growth of bacteria. Furthermore, the antibacterial activity
of the nano-assemblies with or without NIR laser exposure was analyzed by colony counts.
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The viable percentage count of bacteria treated with the material in presence and absence
of laser was calculated using the following:

%

(

=
(

)

× 100%

(2.4)

)

The initial colony count was kept at 108 CFU/mL, and the test count (CFU/mL) was
obtained after treatment.
2.2.15 ROS quantification
DCFH-DA was used as a fluorescent probe to assess ROS generation in bacteria.
Msmeg (108
concentration)

of

GNR@MSNP@BDQ

and

final

nano-assembly

GNR@MSNP@BDQ@TSL@NZX for 4 h. Bacteria alone is used as a negative control.
After incubation, all samples were exposed to NIR laser (808 nm, 500 mW) for 15 min.
-DA) and incubating for 1 h.
Fluorescent intensity was quantified at 525 nm, with excitation at 490 nm. Samples were
also observed by fluorescence microscopy.
2.2.16 Live-dead assay

To further investigate the antibacterial, PT effect, and targeting capacity of
the nano-assemblies, a live/dead assay was conducted. In a flat bottom 96-well plate,
Msmeg (108
final nanoo

C), the samples

were irradiated with the NIR laser (808 nm, 500 mW) for 15 min. The supernatant
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was removed by centrifugation at 5000 rpm for 10 min, and the pellet was washed
3x with HEPES. The bacteria treated with nano-assemblies were stained with SYTO
9 and propidium iodide (PI) for 30 min at 37°C. Finally, the live and dead cells were
examined under an inverted fluorescence microscope.
2.2.17 A549 cell proliferation
A549 cells were grown in T75 flasks in a complete growth medium. Complete
growth medium was prepared by mixing Ham’s F-12K nutrient mixture with L-glutamine
(F-12K) (1X, 445 mL),

FBS (10%, 50 mL), and Pen-Strep (1X, 5 mL) followed by

sterile filtration. The cells were grown in 20 mL of the fresh and prewarmed medium at 37
°C in a humidified atmosphere of 5% CO2. Cells viability was assessed in trypan blue
assay, and cells were counted through an automatic cell counter.
2.2.18 Cellular uptake by nano-assemblies
In order to image the cellular uptake of the final nano-assembly,
GNR@MSNP@BDQ@TSL@NZX was labeled with the red fluorescent dye RITC. A549
cells (103 cells/mL) were cultured on a 24 well plate for 24 h until complete adhesion. After
adhesion and confluence (~ 90%), A549 cells were incubated at 37 °C with RITC-

washed 3x with cold PBS and followed by calcein-AM (10 M) and Hoechst dye (10 M),
staining for 30 min at 37 °C. The samples were analyzed through an inverted fluorescent
microscope.
2.2.19 Cellular uptake mechanism by nano-assemblies
A549 cells (103 cells/mL) were cultured on a 24 well plate for 24 h until complete
adhesion occurred and then pre-treated with different endocytosis inhibitors:
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fluorescent microscope was used to qualitatively evaluate the uptake of the nano
assemblies by lung cells. An increase in red fluorescence intensity within the lung cells is
related to the high uptake of nano-assemblies. To quantitatively determine cellular uptake
of nano-assemblies, the lung cells (A549) were lysed with 0.5% Triton X-100 in the
presence of 0.2 M NaOH. A fluorescence microplate reader was used to measure the
fluorescence intensity at excitation and emission wavelengths of 544 and 576 nm,
corresponding to the excitation and emission of RITC. The fluorescence intensity of the
lysed samples was measured. The fluorescence intensity of the controls (without inhibitor)
was set as 100%. The reduction fluorescence intensity of the samples (with inhibitor) was
measured in comparison to the control.
2.2.20 Intracellular antibacterial and targeting capacity of nano-assemblies
A549 cells (103 cells/mL) were seeded in a 24 well plate and incubated overnight
in a 5% CO2 at 37 oC. An aliquot of 5 L Msmeg (17 x 104 CFU/mL) was added per well
of A549 cells and incubated for 30 min at 37 oC. After incubation, the supernatant was
discarded, and the infected cells were washed twice with PBS (1X). Then the mammalian

kill the remaining extracellular bacteria without affecting the intracellular bacteria. The

GNR@MSNP@BDQ@TSL@NZX, then exposed to NIR laser (808 nm, 500 mW, 15 min)
and incubated for an additional 24 h. After overnight incubation, the cells were stained
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with calcein-AM (10 M) and Hoechst dye (10 M) for 30 min at 37 °C. The samples were
analyzed through confocal fluorescent microscopy. Finally, A549 cells were lysed in
distilled water for 3 h. The cell lysate was plated on agar, and the bacterial colonies were
quantified. The number of colonies reflects the viable intracellular Msmeg present after
treatment.
2.2.21 Mammalian cell viability assay
Cell viability was evaluated by using an MTT assay. A549 cells were seeded onto 24
well plates at a 1 × 103 cells/well (1 mL per well). After reaching 90% confluence, they
were treated with various concentrations (1.0, 0.5, and 0.1 mg/mL) of GNR@MSNPs,
GNR@MSNP@BDQ, and final nano-assembly GNR@MSNP@BDQ@TSL@NZX.

MTT solution (1 mg/mL) was added to each well, and the cells were further incubated for

each well. The absorbance intensity was determined at 590 nm by a microplate reader.
Results were presented as the percentage (%) with respect to untreated control A549 cells.
2.3
2.3.1

Results and Discussion
Morphology characterization of nano-assemblies
The morphological characterization of nanomaterials was done mainly by electron

microscopy such as Transmission Electron Microscopy (TEM). It is a powerful imaging
tool for characterizing nanomaterials as it provides visualization of the shape, size,
homogeneity, and lattice structure of nanomaterials at the atomic level. 119 Here, the
morphologies of nano-assemblies were examined on TEM. The fabrication of the final
nano-assembly GNR@MSNP@BDQ@TSL@NZX was achieved in a stepwise manner, as
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Figure 2.1. Characterization of nano-assemblies by TEM and STEM. (I) TEM images of
(a) GNR (Scale bar = 50 nm), (b) GNR@MSNP (Scale bar = 100 nm) and (c)
GNR@MSNP@BDQ@TSL (Scale bar = 20 nm). HAADF images of
GNR@MSNP@BDQ@TSL which indicted presence of (e) gold, (f) silica, (g) oxygen,
(h) carbon and (i) merged images (Scale bar = 30 nm).

illustrated in Scheme 2.1a. GNRs were synthesized via a seed method described by ElSayed et al. with some minor modifications.48 As shown in Figure 2.1a, the average length
and width of GNRs were 42 ± 3.8 nm 11.2 ± 1.1 nm, and the calculated average aspect
ratio is 3.8:1. The GNRs displayed a uniform and well-disposed rod-like morphology
(Figure 2.1a). GNRs coated with a porous silica shell were synthesized by a modified
protocol from Matsuura et al.74 CTAB was used as a soft template, which creates the
mesoporous silica shell structure during the polymerization of silane around the GNRs (to
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give GNR@MSNP). TEM images (Figure 2.1b) show GNRs encapsulated in a mesoporous
silica shell (GNR@MSNP). The silica shell has an average thickness of 15 ± 3 nm, and its
porous structure can be clearly seen by TEM (Figure 2.1b). BDQ, an anti-tuberculosis drug,
was encapsulated into the porous structure of the GNR@MSNP to create
GNR@MSNP@BDQ. The GNR loaded mesoporous structure was wrapped by TSL to
give GNR@MSNP@BDQ@TSL. The size of GNR@MSNP@BDQ@TSL was found to
be 80 ± 3 nm (n = 20, n particle number) by TEM analysis and was calculated by Image J
software. The liposomal layer was visible through TEM as shown with red double headed
arrow (Figure 2.1c). The shape of GNR@MSNP dictates the oblong shape of the TSL
layer. High-angle annular dark-field scanning transmission electron microscopy (HAADFSTEM) images (Figure 2.1e-i) show the presence of the elements of gold (Au), silica (Si),
oxygen (O), and carbon (C) present in the layers of GNR@MSNP@BDQ@TSL. The
merged image in Figure 2.1i clearly shows the individual layers overlaid on each other to
show the final construct of GNR@MSNP@BDQ@TSL. HAADF images reveal the
presence of carbons from the long hydrocarbons chains of lipids used to form the TSL.
This proves the presence of TSL surrounding GNR@MSNP@BDQ as indicated by the red
double-headed arrow in the merged image of Figure 2.1i. The combined TEM (Figure 2.1c)
and HAADF-STEM (Figure 2.1i) images clearly show the TSL coating surrounding
GNR@MSNP@BDQ.
2.3.2

Elemental analysis of nano-assemblies
Energy-dispersive X-ray spectroscopy (EDS) is an analytical method for the

chemical characterization of materials. Generally, EDS systems are attached to an electron
microscopy instrument like TEM. EDS captures and analyzes the characteristic x-rays
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a

Figure 2.2. EDS profile
GNR@MSNP@BDQ@TSL.

mapping

of

b

(a)

GNR@MSNP@BDQ

and

(b)

generated from the material when a high-energy electron beam focuses on the material.
Excitation and relaxation of the electrons in the sample generate x-rays, which have
discrete energies determined by the orbital structure of each element present in the
sample.293 This allows for a fast, effective, and precise analysis of the elemental
composition of materials. EDS analyzed the chemical composition of GNR@MSNPs and
GNR@MSNP@TSL. The EDS spectra of GNR@MSNPs (Figure 2.2a) displayed the
peaks of gold (Au), oxygen (O), and silica (Si). Copper (Cu) peak was present in the EDS
spectra because a Cu mesh TEM grid was used as a substrate. EDS spectrum of
GNR@MSNP@BDQ@TSL (Figure 2.2b) shows the peaks for elements Au, Si, O, and C.
Phospholipids in the TSL layer can be indicated using a phosphorous peak (P) present in
the EDS spectrum (Figure 2.2b). However, the peaks for P and Au overlap with one another
(see Figure 2.2b). Therefore, to avoid confusion of using overlapping P peaks to indicate
the presence of TSL, we have used the presence of carbons (C) to indicate the presence of
the TSL layer. TSL is composed of lipids with a long chain hydrocarbon; for example,
DPPC lipid has a 40-carbon alkyl chain. HAADF-STEM image in Figure 2.1h shows the
clear presence of C in the outermost TSL layer. The merged image in Figure 2.1i clearly
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b

Figure 2.3. (a) zeta potential (b) UV-vis absorbance spectra of nano-assemblies.
shows the presence of C in the exterior of the nano-assembly.
2.3.3

Surface charge
The zeta potential was measured after the addition of each layer to monitor the

change in surface charge. The altered surface zeta potential is shown in Figure 2.3a. The
zeta potential of GNRs was 28 ± 0.59 mV, possibly due to the presence of positively
charged CTAB on the surface. After silica coating, the surface charge was reduced to 23.54 ± 0.8 mV due to abundant Si-OH groups. BDQ is hydrophobic and shows high
solubility in DMSO and little or no solubility in water. Therefore, zeta potential for BDQ
was not obtained. After loading BDQ to MSNP, the zeta potential increased to +2.27 ±
0.76 mV. We hypothesize this is possibly due to the reduction in the available surface OH
groups after the loading of BDQ. TSL coating increased the zeta potential to +7.25 ± 0.6
mV due to amines groups from DSPE-PEG 2000 amine on the surface. The cationic peptide
NZX conjugated to the to the abundant -NH2 groups present on the surface of the liposome
through EDC coupling chemistry, which is responsible for the final increase the zeta
potential up to +11.6 ± 0.88 mV.
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2.3.4

Optical properties of nano-assemblies
a

b

Figure 2.4. (a) FT-IR spectra of nano-assemblies (b) N2
isotherm of GNR@MSNP.
The optical properties of nano-assemblies were analyzed by UV-Vis spectroscopy.
The UV-vis spectra indicated two characteristic absorption peaks of GNRs: transverse
surface plasmon resonance (TSPR) peak at 514 nm and longitudinal surface plasmon
resonance (LSPR) peak at 790 nm. With the mesoporous silica coating, the LSPR peak
underwent a red shift towards 805 nm due to the change in the local refractive index of the
surrounding medium and changes in geometry. The laser was selected to match the new
absorbance at 805 nm. There was no observable shift in the LSPR peak with the loading of
BDQ drug and TSL wrapping (Figure 2.3b).
2.3.5

Functional group characterization of nano-assemblies
The FT-IR spectra of the different components of the fabrication step are presented

in Figure 2.4a. GNRs show -CH2 symmetric and asymmetric vibrations at 2847 cm-1 and
2870 cm-1, respectively. The presence of a peak at 1473 cm-1 corresponds to the -CH2
scissoring modes of vibrations. In the fingerprint region, the bands at 960 and 817 cm -1 are
consistent with C-O stretching and in-plane C-H bending vibrations. The appearance of a
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peak at 1064 cm-1 (Si-O-Si stretching) and the disappearance of symmetric (2847 cm -1) and
asymmetric (2870 cm-1) vibrations which were seen in GNR, proves the mesoporous silica
coating on the surface of GNRs. After BDQ loading, the characteristic peaks from benzene
rings, C- H stretching: 2922 cm-1 and 2914 cm-1, and C-C stretching: 1407 cm-1, were
observed. The presence of N-H stretching at 1662 cm -1 and C-N stretching at 1230 cm-1
shows the primary amine group of BDQ, which confirms the successful loading of BDQ
to the nano-assembly. The symmetric and anti-symmetric -CH 2 stretching 2848 cm-1 and
2918 cm-1 confirms the presence of the lipid layer on the surface of GNR@MSNP@BDQ.
NZX was conjugated to the abundant -NH2 groups present on the surface of TSL through
EDC coupling chemistry. The -COOH groups of the peptide were activated with EDC and
reacted with sulfo-NHS.13 The sulfo-NHS of the peptide reacts with the –NH2 groups on
the TSL. The conjugation of NZX peptide on TSL introduces amide I and II bands at 1650
and 1540 cm-1 and C-O stretching vibration at 1241 cm-1.
2.3.6

Porosity analysis of mesoporous silica shell

physisorption of gas on a solid surface, where the adsorption and desorption isotherms of
nitrogen gas are used to quantify the surface area, pore size, and pore volume of a
nanomaterial.119 The N2 adsorption-desorption isotherm and pore size distribution curves
of GNR@MSNP are given in Figure 2.4b. This exhibits a typical type IV isotherm with a
narrow pore size distribution with a mean of 19.13 ± 1.2 Å. This verifies the mesoporous
character of the MSNP shell. Through BET, the total surface area and pore volume of
GNR@MSNP were quantified to be 53.852 m 2g-1 and 0.23 mLg-1, respectively.
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Figure 2.5. TGA analysis of various nano-assemblies.
2.3.7

TGA of various nano-assemblies
Thermogravimetric analysis (TGA) monitors the mass change while the sample is

heated, from which a thermogram is recorded as the percent weight loss versus the
temperature.119 The quantitative analysis of nano-assemblies after each synthesis step was
done through TGA. The results are shown in Figure 2.5. Percentage (%) weight loss
between the GNR@MSNP@BDQ and GNR@MSNP was calculated to determine the
amount of BDQ loaded onto GNR@MSNP. The BDQ loading was found to be 16 ± 0.5 %
in

GNR@MSNP.

Additionally,

the

percentage

weight

loss

between

GNR@MSNP@BDQ@TSL and GNR@MSNP@BDQ displayed that the coated lipid
layer was 10 ± 1.6% of GNR@MSNP@BDQ@TSL. Finally, NZX peptide loading on
GNR@MSNP@BDQ@TSL

was

quantified

by

TGA

analysis

between

the

GNR@MSNP@BDQ@TSL@NZX and GNR@MSNP@BDQ@TSL. The total peptide
NZX loading was 12 ± 1.5 % on GNR@MSNP@BDQ@TSL.
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2.3.8

Drug loading and encapsulation efficiency
The encapsulation efficiency (EE) and loading content of BDQ were calculated

using the HPLC. First of all, the standard calibration curve of BDQ was obtained using an
HPLC, as shown in Appendix Figure A.1. The encapsulation efficiency and drug loading
efficiency of BDQ were analyzed to be 65.0 ± 0.5 % and 14.6 ± 0.9%, respectively.
2.3.9

Colloidal stability
Colloidal stability of nanomaterials is crucial when it comes to drug delivery

applications. Thus, we wanted to check if our nano-assemblies were stable in physiological
conditions and could be used in-vitro or or not. The colloidal stability of GNR@MSNP
and GNR@MSNP@TSL were monitored using UV-vis spectroscopy and DLS analysis.
The localized surface plasmon resonance (LSPR) of gold nanoparticles (NPs) is highly
affected by nanoparticle aggregation.294 When plasmonic NPs are aggregate individual
plasmon oscillation can couple with each other through near-field interactions, resulting in
coupled LSPR modes.295 This impacts the distribution of the electric field around the nanostructure.294-296 As a consequence, particle aggregation results in a UV-vis spectral red
shift, broadening and reducing LSPR peak intensity.297 This was confirmed by a color shift
of the colloid gold NPs from deep red to purple, which is characteristic of unstable
plasmonic colloidal systems.298 The stability of GNR@MSNP and GNR@MSNP@TSL)
was conducted at 37 °C in mammalian cell culture media for 5 days. As shown in Figure
2.6a, the LSPR peak intensity for GNR@MSNP is reduced in cell culture media after day
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Figure 2.6. Colloidal stability analysis of GNR@MSNP and GNR@MSNP@TSL. UVvis spectra of (a) GNR@MSNP (b) GNR@MSNP@TSL at 37°C, in cell culture media
(c) aggregation index (AI) of GNR@MSNP and GNR@MSNP@TSL (d) zeta potential
of GNR@MSNP and GNR@MSNP@TSL in cell culture media at 37°C.
1 as compared to GNR@MSNP@TSL. It is seen that GNR@MSNP is not stable in
mammalian cell culture media after day 1 at 37 °C. However, with the additional TSL
coating (Figure 2.6b) GNR@MSNP@TSL can be seen to be stable in cell culture media at
37 °C until day 5.

Aggregation index (AI) was calculated for GNR@MSNP and

GNR@MSNP@TSL, seen in Figure 2.6c. The higher AI indicates a higher degree of
aggregation, i.e., lower colloidal systems stability.291, 292 AI for GNR@MSNP was higher
and increased with time in media at 37 °C. In GNR@MSNP@TSL, the AI values were low
and constant with time in media at 37 °C. Therefore GNR@MSNP@TSL shows better
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Figure 2.7. Photothermal properties of nano-assemblies (a) Photothermal effect of final
nano-assembly GNR@MSNP@BDQ@TSL@NZX at different concentrations using
an 808 nm, 500 mW, laser for 15 min. (b) The temperature profile of
GNR@MSNP@BDQ@TSL@NZX (1 mg/mL) with different laser power intensities

colloidal stability than GNR@MSNP. Zeta potential was measured to check the stability
of the nano-assemblies. As shown in Figure 2.6d, the zeta potential of GNR@MSNP
changed from day 0 to day 5 from -23.5 ± 0.7 mV up to +5.0 ± 0.9 mV. This continuous
change in zeta potential in media suggests that GNR@MSNP is not stable. In contrast,
GNR@MSNP@TSL has shown a constant zeta potential value +10.6 ± 0.7 mV up to 5
days. These observations reveal that GNR@MSNP@TSL is stable in cell culture media
for up to 5 days. The UV-vis spectral analysis of LSPR peak intensities, AI results, and
zeta potential values indicates that GNR@MSNP@TSL has more colloidal stability than
GNR@MSNP. Photographic evidence of the comparative stability of the two solutions,
GNR@MSNP@TSL and GNR@MSNP, is shown in Appendix Figure A.2. All the above
stability parameters indicate that liposomal coating improves the nano-assembly's colloidal
stability, promoting their suitability for antibacterial applications both in-vitro and in-vivo.
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2.3.10 Photothermal performance of GNRs
The photo/thermo-responsive properties of nano-assembly were evaluated via a
series of experiments. An 808 nm laser diode was selected to match the LSPR peak
associated with the final nano-assembly GNR@MSNP@BDQ@TSL@NZX. The
photothermal efficiencies of the final nano-assemblies were evaluated in-vitro, after
irradiation with 808 nm laser at 500 mW for 15 min. A 25 mm objective lens was used to
tightly focus the laser light onto the sample (spot size ~ 2 mm, diameter). Figure 2.7a shows
the photothermal capacity of the final nano-assembly GNR@MSNP@BDQ@TSL@NZX
at different concentrations. Under these conditions, the temperature of the final nanoassembly GNR@MSNP@BDQ@TSL@NZX increased to 58 ± 3.0 °C at its highest

control containing 10 mM HEPES solution increased by only 2 °C, indicating that the
temperature elevation was caused primarily by the PT effect of GNRs. The temperature
increase of the final nano-assembly GNR@MSNP@BDQ@TSL@NZX was positively
correlated to the concentration, laser power intensity, and irradiation time (Figure 2.7a and
Figure 2.7b).
2.3.11 NIR laser triggered drug release
NIR-triggered drug release study of nano-assemblies ware performed in 0.5% w/w
SLS in 10 mM HEPES buffer with and without NIR laser irradiation. As shown in Figure
2.8a GNR@MSNP@BDQ without laser irradiation, cumulatively released 65.1 ± 1.4%
of BDQ within 10 hours. With laser irradiation, GNR@MSNP@BDQ cumulatively
released 78.9 ± 1.8% in the same span of 10 hours. This indicates that the subsequent
temperature increase with laser irradiation has increased the non-specific release of BDQ.
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Figure 2.8. NIR triggered drug release. (a) The cumulative drug release profile of BDQ
from various nano-assemblies with and without laser irradiation (808 nm, 500 mW, 15
min). (b) Schematic representation of NIR triggered degradation of the liposome followed
by the release of BDQ from the final nano-assembly.

GNR@MSNP@BDQ@TSL demonstrated only a 48.32 ± 1.5% BDQ release in a similar
time frame, without laser irradiation. The presence of TSL has helped to reduce the nonspecific release of the encapsulated drug compared to that of GNR@MSNP@BDQ with
similar conditions (without laser).

However, triggered with laser irradiation,

GNR@MSNP@BDQ@TSL released 90.2 ± 1.4% of BDQ within 10 h. Final nano75

assembly GNR@MSNP@BDQ@TSL@NZX demonstrated a similar behavior with 92.7
± 1.5% of BDQ release upon laser irradiation, while only 50.1 ± 0.9% of BDQ was released
in the absence of laser (Figure 2.8a). It is apparent from the above results that TSL plays a
role in reducing premature BDQ release. Laser-irradiation generates localized heat from
GNR, which subsequently weakens the interactions between the mesoporous silica matrix
and enhances the permeability of the TSL (Figure 2.8b). TSL is composed of a thermosensitive lipid DPCC (85% molar ratio); melting of DPCC increases the permeability of
TSL.299 The drug, BDQ, release profile upon laser irradiation suggests that the melting of
the TSL resulted in the release of the drug from final nano-assemblies (Figure 2.8a). The
melting of TSL (48 ± 3 °C) was further evaluated by calcein dye release assay that proved
that upon laser irradiation, the calcein dye release with respect to laser irradiation time and
temperature is explained in Appendix A.1 (Appendix Figure A.3.).
2.3.12 Antibacterial phototherapy of Msmeg
The in vitro antibacterial activity of the nano-assemblies against Msmeg was
determined using WST-8, a colorimetric bacterial viability assay, and a bacterial colony
counting assay. WST-8 produces a yellow color formazan dye (absorb at 460 nm) upon
reduction of tetrazolium by dehydrogenase enzymes in live bacteria. 300 The absorbance of
produced formazan was measured at 460 nm, which is proportional to the number of live
bacteria.300 The MIC was reported with respect to the encapsulated BDQ in the nanoassemblies at their MIC concentrations. The MIC established by colorimetric assay and
verified by colony counting, The MIC of the free drug BDQ was 40 ng/mL. The MIC of
the final nano-assembly GNR@MSNP@BDQ@TSL@NZX (with laser) was 2 ng/mL
with respect to the encapsulated BDQ (Table 2.3.1).
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Table 2.3.1. MIC of the materials (MIC was reported with respect to encapsulated BDQ
in the nano-assemblies). *
Nano-assemblies

MIC (ng/mL) of BDQ

BDQ

40 ± 1.5

NZX

400 ± 1.8

GNR@MSNP@BDQ

25 ± 1.8*

GNR@MSNP@BDQ + Laser

10 ± 1.5*

GNR@MSNP@BDQ@TSL@NZX

30 ± 1.9*

GNR@MSNP@BDQ@TSL@NZX + Laser

2 ± 0.8*

GNR@MSNP

NA

This shows that BDQ encapsulated in the final nano-assembly is 20 -fold efficacious than
the free drug BDQ. The higher efficacy is due to the combitherapy of PTT working together
with an antibiotic.
The quantitative antibacterial efficacy of nano-assemblies was further analyzed
using colony counts and expressed as a percentage of viable bacteria (Figure 2.9a). The
antibacterial activity of the nano-assemblies was compared to one another using percentage
of viable bacteria present after treatment with various nano-assemblies with and without
laser (Figure 2.9a). The percentage of viable bacteria cells obtained from bacteria colony
counts from agar plates as seen in the photographs of Figure 2.9b. Msmeg exposed to
GNR@MSNP@BDQ@TSL@NZX (with laser) exhibited 5 ± 1.2 % bacterial viability,
and GNR@MSNP@BDQ@TSL@NZX (without laser) had 78 ± 1.9 % bacterial viability.
Therefore, it is clear that laser irradiation is vital to the antibacterial effect of the final nanoassembly. Msmeg exposed to GNR@MSNP@BDQ with and without laser exhibited 33 ±
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Figure 2.9. In-vitro antibacterial and PT activity. (a) Percentage of viable bacteria after
treatment with the nano-assemblies with and without laser irradiation. (b) Photographs
displayed the effect of laser on nano-assemblies after treating with Msmeg by colony count.
(c) Schematic illustration of how final nano-assembly GNR@MSNP@BDQ@TSL@NZX
targets and kills bacteria (grey color bacteria- dead bacteria) upon laser irradiation. The
Data were presented as the mean ± SD (n=3). ns (non-significant), ** p < 0.01, *** p <
0.001, and **** p < 0.0001. A, **** p < 0.0001 indicated the data to be more significant
when compared to *** p < 0.01 and ** p < 0.01 by One-way ANOVA.

2.1 % and 68 ± 1.5 % bacterial viability, respectively. Because of the lack of TSL,
GNR@MSNP@BDQ with laser exposure cause a high release of BDQ. Msmeg treated
with the only laser and GNR@MSNP (without laser) had similar bacterial viability (98 ±
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1.7); therefore, little or no antibacterial activity was seen with GNR@MSNP. However,
when Msmeg was treated with GNR@MSNP with laser had 78.5 ± 2.5 bacterial viability.
This is due to PT activity, the viability of bacteria decreased compared to in the absence of
laser (GNR@MSNP without laser). Photographs of selected bacterial plates after treatment
with nano-assemblies can be seen in Figure 2.9b, and they can be clearly related to the MIC
results.

Figure

2.9c

shows

a

hypothetical

illustration

of

GNR@MSNP@BDQ@TSL@NZX effectively target and kill bacteria upon laser
irradiation.
It has been established previously that bacteria can produce ROS in response to
heat stress during PT treatment.301, 302 Therefore establishing the presence of ROS and
quantification of ROS is useful when the antibacterial efficacy of the material is related to
PT activity.302 ROS produced was measured quantitatively by a fluorescent ROS assay,
and fluorescence produced was imaged through fluorescence microscopy (Figure 2.10).
Msmeg + laser displayed slight green fluorescence (Figure 2.10a-b), suggesting that Msmeg
produces a small quantity of ROS when exposed to a laser. In contrast, a comparatively
more significant amount of ROS was generated when Msmeg was treated
GNR@MSNP@BDQ

+

laser

(Figure

2.10a-d).

Msmeg

treated

with

GNR@MSNP@BDQ@TSL@NZX + laser displayed further green fluorescence (Figure
2.10a-f), indicating higher ROS production. Quantitative analysis of ROS production,
measured as fluorescence intensity, is shown in Figure 2.10b. These results are consistent
with the fluorescent images (Figure 2.10b).
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Msmeg +
GNR@MSNP@BDQ
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Figure 2.10. Reactive oxygen species (ROS) determined after treating Msmeg with nanoassemblies. Induced ROS is indicated by green fluorescence (a-a) Msmeg + without laser
exposure, (a-b) Msmeg + with laser, (a-c) Msmeg + GNR@MSNP@BDQ + without laser,
(a-d) Msmeg + GNR@MSNP@BDQ + with laser, (a-e) Msmeg +
GNR@MSNP@BDQ@TSL@NZX
+
without
laser,
(a-f)
Msmeg
+
GNR@MSNP@BDQ@TSL@NZX + with laser. Scale bars represent 1 m. (b)
Quantitative determination of ROS generation detected by fluorometric intracellular ROS
assay. A, **** p < 0.001 indicates that data are statistically significant by One-way
ANOVA.
Live/dead assay was also done to complement the other antibacterial assays. In the
live/dead assay, SYTO9 and PI fluorescent stains were used to stain intact and damaged
bacterial cells (Figure 2.11). SYTO 9 green fluorescent dye penetrates the cell membrane
of both live and dead bacterial cells, while PI red fluorescent dye penetrates bacterial cells
with damaged membranes.303 In the presence of both stains, bacteria with intact cell
membranes appear fluorescent green, whereas cell membrane-compromised bacteria
appear

in

red

fluorescent.

BDQ,

GNR@MSNP@BDQ

+

laser,

and

GNR@MSNP@BDQ@TSL@NZX + laser were incubated with Msmeg and stained with
SYTO9/PI, and results were observed through fluorescence microscopy. Msmeg treated
with BDQ showed more green and less red fluorescence, indicating more live bacteria than
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Figure 2.11. Fluorescence microscopy images of the live/dead assay. Fluorescence
microscopy images showing the presence of live bacteria (green) and dead bacteria (red)
following treatment of Msmeg with (a) BDQ (b) GNR@MSNP@BDQ + laser, and (c)
GNR@MSNP@BDQ@TSL@NZX + laser
.

dead bacteria (Figure 2.11a). GNR@MSNP@BDQ + laser increased red-fluorescent
intensity, suggesting some bacteria cells had compromised cell membranes (Figure 2.11b).
Msmeg treated with final nano-assembly GNR@MSNP@BDQ@TSL@NZX + laser had
high bacterial aggregation with a high amount of red fluorescence, compared to free BDQ
and GNR@MSNP@BDQ + laser. Aggregation can also be related to NZX mediated
targeting and subsequent cross-linking of bacteria (Figure 2.11c).
2.3.13 Cellular uptake mechanism of nano-assemblies
Fluorescent microscopy was used to visualize the intracellular uptake of the nanoassemblies by A549 lung cells. As shown in Figure 2.12a cytoplasm of lung cells was
stained with calcein, a green fluorescent dye (Figure 2.12a-a). Nucleus stained with
Hoechst blue, fluorescent dye (Figure 2.12a-b), and nano-assemblies with RITC red
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fluorescent dye (Figure 2.12a-c). Figure 2.12a-d shows red fluorescent nano-assemblies
were distributed in the lung cell close to the nucleus. Figure 2.12a-e clearly shows the
yellow/orange color, resulting from calcein's green color merging with the red fluorescence
from the RITC-stained nano-assemblies. This proves GNR@MSNP@BDQ@TSL@NZX
was effectively taken up by the A549 cells and distributed throughout the cells after 3 h of
incubation.
The mechanism for the internalization of nano-assemblies into the lung cells was
monitored by fluorescence microscopy (Figure 2.12b). The cellular uptake mechanism of
RITC labeled GNR@MSNP@BDQ and GNR@MSNP@BDQ@TSL@NZX in lung cells
was determined under different endocytosis inhibited conditions. Specific endocytosis
inhibitors: chlorpromazine - an inhibitor of clathrin-mediated endocytosis, nystatin –
inhibitor for caveolin-dependent endocytosis, and wortmannin- macropinocytosis inhibitor
were investigated to study the mechanism of cellular uptake. We have also quantified the
cellular uptake of nano-assemblies using fluorescent assays. The fluorescence microscopy
images reveal little or no visible red fluorescent GNR@MSNP@BDQ@TSL@NZX in
chlorpromazine treated lung cells (Figure 2.12b). This indicates chlorpromazine-treated
lung cells show inhibited uptake of GNR@MSNP@BDQ@TSL@NZX. However, uptake
of GNR@MSNP@BDQ@TSL@NZX into lung cells was not hindered when treated with
wortmannin and nystatin (Figure 2.12b). These observations suggested that nanoassemblies trafficking occurred preferably through clathrin-mediated endocytosis.
To investigate the role of TSL in cellular uptake, we quantified the cellular uptake
of

nano-

assemblies

nano-

assemblies
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Figure 2.12. Selective cellular uptake of GNR@MSNP@BDQ@TSL@NZX by A549
cells.
(a)
Intracellular
uptake
of
the
final
nano-assembly
GNR@MSNP@BDQ@TSL@NZX by A549 cells. A549 cells are stained with calcein dye
(green), cell nucleus stained with Hoechst dye (blue), nano-assemblies were labelled with
red fluorescent RITC dye (red). Scale bar: 10 m. (b) Evaluation of cell uptake mechanism
of nano-assemblies by A549 cells under different endocytosis inhibitory conditions fluorescence microscopy - A549 cells shown in bright field and nano-assemblies were
tagged with RITC (Scale bar = 10 mm). (c) Shows quantitative intracellular uptake of
GNR@MSNP@BDQ and GNR@MSNP@BDQ@TSL@NZX by A549 cells after
inhibitor treatment.

GNR@MSNP@BDQ by measuring intracellular fluorescent intensity using a fluorescent
microplate reader. As shown in Figure 2.12c, chlorpromazine - an inhibitor of clathrinmediated

endocytosis-

significantly

inhibited

GNR@MSNP@BDQ

and

GNR@MSNP@BDQ@TSL@NZX delivery into lung cells. The quantified intracellular
uptake of GNR@MSNP@BDQ and GNR@MSNP@BDQ@TSL@NZX was 3.5 ± 1.2 %
and 15.34 ± 2.5 %, respectively. Even in the presence of an inhibitor, a higher amount of
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GNR@MSNP@BDQ@TSL@NZX uptake was found in lung cells, which points out that
the inclusion of TSL and NZX increases the ability to internalize. GNR@MSNP@BDQ
has consistently shown lesser uptake throughout all inhibitory assays (Figure 2.12c).
These studies collectively suggested that the nano-assemblies mediated drug
delivery occurred preferably through clathrin-mediated endocytosis, and nano-assemblies
internalization enhanced due to having liposome and NZX cationic peptide. Liposome
coating enhances cellular uptake of nano-assemblies due to interaction with the lipophilic
cell membrane, allowing cellular entry of nanoparticles by various endocytosis
pathways.304 In addition, TSL was modified with cationic peptide NZX, so due to
electrostatic interaction with the negatively charged cell membrane, the cellular uptake was
higher for GNR@MSNP@BDQ@TSL@NZX.
2.3.14 Intracellular antibacterial activity of nano-assemblies
The intracellular antibacterial activity of GNR@MSNP@BDQ@TSL@NZX was
assessed by quantifying their ability to target and kill intracellular Msmeg bacteria. A
schematic illustration of Msmeg infection studies with A549 cells is shown in Figure 2.13a.
A549 lung cells were infected with a concentration of 17 x 104 CFU/mL Msmeg. From the
starting concentration, 8 x 104 CFU/mL of Msmeg was internalized into the lung cells.
Msmeg internalized into lung cells were quantified using bacterial colony count. The
Msmeg infected lung cells were treated with a 50

g/mL concentration of

GNR@MSNP@BDQ and the GNR@MSNP@BDQ@TSL@NZX in the presence of laser.
After treating with nano-assemblies, lung cells were lysed, and lysates were plated on agar
plates. After treatment, lung cells treated with GNR@MSNP@BDQ@TSL@NZX + laser
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Figure 2.13. Intracellular antibacterial activities in Msmeg infected A549 cells. (a)
Schematic illustration of the bacterial infection and treatment studies with A549
cells: A- infection of A549 cell with Msmeg, B- treatment with nano-assemblies CNZX mediated adhesion of GNR@MSNP@BDQ@TSL@NZX to Msmeg, D- the
disintegration of TSL and BDQ release after NIR laser exposure, E- complete
degradation of Msmeg. (b) Photographs of agar plates of cultured intracellular
Msmeg
remained
after
treatment
with
GNR@MSNP@BDQ
and
GNR@MSNP@BDQ@TSL@NZX. (c) Intracellular bacteria were targeting the
capacity of nano-assemblies by A549 cells analyzed through fluorescent microscopy.
A549 cells are stained with calcein dye (green), Msmeg bacteria and A549 cell nucleus
stained with Hoechst dye (blue), nano-assemblies were labeled with red fluorescent RITC
dye (red). Scale bars represent 5 m
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had 22 CFU/mL of intracellular Msmeg (Figure 2.13b). This is a significant decrease of
over 99.9% of intracellular Msmeg. In contrast, treatment with GNR@MSNP@BDQ (with
laser) reduced intracellular Msmeg only up to 3 x 104 CFU/mL (Figure 2.13b), which is a
37.5% reduction in intracellular Msmeg. These results demonstrate the targeting ability and
high antibacterial efficacy of the laser-irradiated GNR@MSNP@BDQ@TSL@NZX,
which inhibits 99.9% intracellular Msmeg (Figure 2.13b). The ability of nano-assemblies
to target Msmeg within lung cells was also evaluated by confocal fluorescence microscopy.
A549 cell cytoplasm was stained with Calcein green, fluorescent dye, Msmeg, and A549
cell

nucleus

stained

with

Hoechst

blue

fluorescent

dye.

GNR@MSNP@BDQ@TSL@NZX and GNR@MSNP@BDQ were conjugated with
RITC - red fluorescent dye. The fluorescence merge image (Figure 2.13c-d) clearly shows

Figure 2.14. Percentage cell viability of A549 cells after incubation with different
concentrations of irradiated nano-assemblies: GNR@MSNP, GNR@MSNP@BDQ
and GNR@MSNP@BDQ@TSL@NZX after 24 h.
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that GNR@MSNP@BDQ@TSL@NZX surrounding the intracellular Msmeg bacteria
resident in lung cells. While little or no GNR@MSNP@BDQ are seen within lung cells
infected with Msmeg (Figure 2.13c-h). These results agree with TEM analysis where
morphological changes on bacteria was observed upon treatment with laser irradiated nanoassemblies (Appendix A.2 and Figure A.4.). Furthermore, MTT assay, a mammalian cell
viability assay, was conducted to evaluate any cytotoxic effect of laser and nano-assemblies
treatment on lung cells. Lung cells were treated with GNR@MSNP, GNR@MSNP@BDQ,
and GNR@MSNP@BDQ@TSL@NZX with laser irradiation. As shown in Figure 2.14,
A549 lung cells did not show significant cytotoxicity, and lung cell viability was close to
100%. A live-dead assay was also performed to evaluate cytotoxicity towards lung cells.
The methods and results are explained in Appendix A.3 and Figure A.5. After laser
treatment, it is clear that both the MTT assay and the live-dead assay have negligible
cytotoxic effects on lung cells.
The

overall

results

indicate

that

the

final

nano-assembly

GNR@MSNP@BDQ@TSL@NZX with laser treatment serves as an effective drug
delivery platform that combines the antimicrobial efficacy of the antibiotic with PTT to
target and inhibit even intracellular mycobacteria.
2.4

Conclusion
With the rise in antibiotic-resistant bacteria, novel therapeutic approaches have to be

engineered

to

reduce

the

dependency

on

small-molecule

antibiotics.

The

GNR@MSNP@BDQ@TSL@NZX is a complex nano-assembly that is a drug delivery
platform and a conduit for PTT. Our multifaceted platform offers (1) synergistic therapy
of small molecule antibiotics and PTT (2) targeted antibiotic delivery (3) NIR triggers the
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release of antibiotics. The GNR@MSNP@BDQ@TSL@NZX were prepared by BDQ
loading to GNR@MSNP and encapsulating within NZX tagged TSL. Upon irradiation
with NIR laser light, GNRs convert light into heat, causing melting of TSL, which induces
the

release

of

antibiotics.

Targeting

peptide

NZX

guides

the

GNR@MSNP@BDQ@TSL@NZX to approach the bacterial cell surface. BDQ
encapsulated in GNR@MSNP@BDQ@TSL@NZX was 20-fold more efficacious than
free drug equivalent. The final nano-assembly was capable of targeting and inhibiting
99.9% intracellular mycobacteria residing within A549 cells. This work provides a proofof-concept unique therapeutic approach to treat pathogenic infections and reduce the
dependency on conventional antibiotics.
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3

CHAPTER 3. HOST-TARGETED MULTIFUNCTIONAL NANO-THERAPY
FOR ERADICATION OF INTRACELLULAR BACTERIAL INFECTION

3.1

Introduction
One-third of the world’s population is infected with Mtb (latent TB), while about

10% suffer from clinical symptoms of active TB.285 In 2020, WHO reported almost 10
million new cases and 1.5 million deaths caused by TB, making it one of the most virulent
diseases.285 During the early infection stages, macrophages are known to phagocytose
mycobacteria.305 However, several strategies for survival and replication within
macrophages have been developed by Mtb.305 Normally, in case of any bacterial infection,
phagosome fuse with lysosome where acid-secreting enzymes such as acid hydrolyse and
protease destroy any encapsulated pathogens. However, this step does not occur in Mtb
infected host cells. After internalization in host macrophages, Mtb is encapsulated within
the phagosome but escapes the fusion with lysosomes. This prevents phagolysosome
formation, suppressing the production of intracellular reactive oxygen species (ROS),
reactive nitrogen species (RNS), and pro-inflammatory cytokines, hence creating a path
for survival and replication for Mtb.306, 307
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Traditional antituberculosis treatment includes first-line therapy for 6 to 9 month
involving four antibiotics in a sequential combination (isoniazid, rifampin, pyrazinamide,
and ethambutol).308 Recently, two drugs have been approved against multi-drug resistant
Mtb: bedaquiline (BQ) and delamanid.152 Anti-tuberculotic drugs have a significant
challenge for entering macrophages to eradicate the Mtb.154 Even after entering the
macrophage, the drug is rapidly cleared from the macrophage before the drug acts on
intracellular Mtb. Moreover, poor patient compliance during lengthy TB treatment plays a
role in generating drug-resistant strains. The sub-optimal period of antibiotic exposure
allows Mtb to mutate and become resistant. Therefore, it is necessary to develop hostdirected therapies targeting intracellular Mtb by reactivating the host's defense
mechanisms.
In recent years, host-directed therapy has become an emerging method to target
infected host cells to increase host defense mechanisms to treat diseases. 309,

310

Immunotherapeutic nanoparticles (NPs) have been used previously for TB infection, in
which researchers have used polymeric NPs functionalized with an immune-modulating
-Glucan and rifampicin drug was also loaded into the NPs core, which
could be released in a sustained manner.311 Choi’s group have develope

-Glucan NPs,

which can be used for genetic material delivery and immune response enhancement. 312
Recently, Hwang et al. conjugated single-

-glucan onto silica NPs. These NPs

also encapsulated isoniazid drug, which could be released in a sustained manner. However,
these nanoparticles were observed to minimally activate peripheral blood mononuclear
cells (PBMCs) as both the silica NPs and INH-loaded silica/glucan NPs stimulated the
PBMCs at similar levels to control.313 All these combinational therapies still lack a specific
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targeting ability towards immune cells. Therefore, incorporating host-targeting molecules
provides opportunities in the design of targeted nanocarriers to enhance efficiency and
reduce adverse effects.
In our work, we proposed fabricating host-targeting nano-

-Glucan

and FA as a host-targeting ligand that specifically binds to dectin-1 and folate receptors
present on the macrophage, respectively. We have screened both ligands for their free
ligand-receptor binding affinity. The project has carried forward free ligands that show
-Glucan as it showed a higher binding
affinity toward dectin-1 receptors. The binding affinity between ligands and receptors plays
a vital role in determining the therapeutic potential of any nanocarriers. 309 Hence, we have
systematically tested the impact of varying sizes o
-

-Glucan conjugated nano-assemblies
-Glucan conjugated nano-

assemblies increased host response against intracellular Msmeg by increasing host defense
mechanisms such as enhancing ROS/RNS generation. The composition of fabricated nanoassemblies was similar to our previously designed nano-assemblies. 100 Briefly, these nanoassemblies consisted of a gold nanorod (GNR) core (act as a photosensitizer) and
mesoporous silica (MS) shell containing TB antibiotic bedaquiline (BQ), GM@BQ. This
assembly would be wrapped within a thermo-sensitive liposome (L), (GM@BQ)L shell
that has tagged with host-

-Glucan. The final host-targeting nano-

assemblies (HTNs) are abbreviated as (GM@BQ)L-Glu. Upon NIR laser exposure, the BQ
released from nano-assemblies and thereby activated macrophage by enhancing
phagosome maturation and inducing phagolysosome formation. Tailleux and co-workers
reported that antibiotic BQ activates host immune response by promoting phagosome
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acidification and phagolysosome formation.153 Therefore, we hypothesize that our
(GM@BQ)L-Glu can also induce phagosome acidification and phagolysosome formation
upon the release of BQ. Guided by our previous work,100 we hypothesized that the hosttargeting nano-assemblies (HTNs) would be effective against Msmeg through a combined
approach of (1)

binding to specific receptors present on Msmeg infected host

(macrophages) (2) upon binding, would enhance internalization of HTNs to the
macrophage (3) upon internalizing would subsequently elicit an increase in ROS, and RNS
(4) upon exposure to NIR laser irradiation would trigger the release of anti-tuberculotic
drug BQ from HTNs, and released BQ activates macrophage thereby killing intracellular
bacteria (5) induce PT activity that would trigger apoptosis mechanisms in Msmeg infected
macrophage which preventing further spread of the bacteria. The designed host-targeted
nano-assemblies (GM@BQ)L-Glu was found to be 10-fold more efficacious compared to
free drug equivalent. (GM@BQ)L-Glu was capable of targeting and inhibiting 99.9% of
intracellular Msmeg residing within macrophages. This research will contribute to how
nanoplatforms can be designed to modulate hosts’ responses against intracellular bacterial
infections. The work proposed here will help evaluate complementary techniques and gain
knowledge extending to future studies against fighting intracellular infections.
3.2

Experimental

3.2.1

Materials and Instruments
Chemicals used for gold nanorod, and mesoporous silica shell synthesis were

similar as described in Section 2.2.1. Coumerine-6, 4’,6’-diamidino-2-phenylindole
(DAPI,

-Glucan, succinic anhydride, Phorbol 12-myristate 13-acetate

(PMA) were purchased from Sigma-Aldrich (St. Louis, USA). Lipids used for liposome
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preparation were similar as explained in section 2.2.1. Msmeg bacteria strain and its culture
preparation were also similar as described in Section 2.2.1. THP-1 macrophage cells were
purchased from American Type Culture Collection (ATCC, CCL-185) (Virginia, USA).
The LysoTracker™ Red DND-99, ER-Tracker™ Red, CellEvent™ Caspase 3/7 Green
Detection Reagent, Live/dead® viability kit, was purchased from ThermoFisher Scientific
(New Jersey, USA). Fluorometric intercellular ROS kit, Nitrite assay kit, and MES buffer
were purchased from Sigma-Aldrich (St. Louis, USA). RPMI 1640 media, fetal bovine
serum (FBS, 10%), trypsin EDTA (2.21 mM), and penicillin-streptomycin (Pen-Strep, 1X)
were obtained from Corning (New York, USA). The instruments were used for
characterization of nano-assemblies were similar as described in Section 2.2.1.
3.2.2

THP-1 cell culture
A human monocyte cell line, THP-1, was grown in T75 flasks in a complete growth

medium. The complete growth medium was prepared by mixing RPMI 1640 medium (445
mL), FBS (10%, 50 mL), and Pen-Strep (5 mL) followed by sterile filtration. The cells
were grown in 20 mL of a fresh and prewarmed medium at 37 °C in a humidified
atmosphere of 5% CO2. To differentiate THP-1 cells into macrophages, phorbol 12myristate 13-acetate (PMA) was used at a concentration of 100 nM. Cell viability was
assessed by the Trypan blue assay and counted using an automatic cell counter.
3.2.3

Screening of ligand-receptor binding between free ligands and host
(macrophage) receptors
We have screened two host-

-Glucan and FA to test their binding

affinity toward dectin-1 and folate receptors, respectively. Firstly, the calibration curve for
-

-Glucan (5-50 nM ~ 1-10
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ug/mL) interacted with Congo red 5

-Glucan) for 30

minutes at room temperature with constant stirring. The calibration curve was prepared by
recording the absorbance value at 546 nm using UV-Vis spectroscopy as shown in
Appendix Figure B.1.a. Similarly, the various concentrations of free Glu (5-50 nM ~ 1-10
ug/mL) interacted with Congo red (5 ug/mL) for 30 min at room temperature with stirring.
This tagged glucan was incubated with macrophage (104 cells/well) for 3 h. The excess
unbound ligand was washed off with HEPES buffer 3 times. Then, the absorbance of the
ligand-receptor complex was recorded at 546 nm. The concentration of ligand-receptor
complex and total receptor concentration was calculated from a calibration curve. The
binding affinity (Kd) was calculated by running a saturation binding experiment on Prism
8 from GraphPad Software (San Diego, CA, USA).
Similarly, a calibration curve for folic acid (FA) was carried out, the various
concentration of free FA 5-50 mM ~ 2-20 mg/mL was prepared. The calibration curve was
prepared by recording the absorbance value at 310 nm using UV-Vis spectroscopy, as
shown in Appendix Figure B.1.b. Similarly, various concentration of free FA (5-50 mM ~
2-20 mg/mL) were incubated with macrophage (104 cells/well) for 3 h. After that, the
excess unbound ligand was washed off with HEPES buffer 3 times. Then, the absorbance
of the ligand-receptor complex was recorded at 310 nm. The concentration of ligandreceptor complex and total receptor concentration was calculated from a calibration curve
as shown in Appendix Figure B.1. The binding affinity (Kd) was calculated by saturation
binding experiment and calculations done through Prism 8 from GraphPad Software (San
Diego, CA, USA).
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3.2.4

Synthesis of gold nanorods (GNRs)
GNRs were synthesized as described in chapter 2 (See Section 2.2.2).

3.2.5

Synthesis of mesoporous silica shell coated gold nanorods (GMs)
GMs were synthesized as described in chapter 2 (See Section 2.2.3).

3.2.6

BQ encapsulation in GMs
GMs (40 mg) were mixed with BQ (10 mg) in 20 mL of water while stirring

overnight at 37 °C. The ratio of GMs and BQ used in the entire study was 4:1 w/w (GMs
40 mg: BQ 10 mg). The BQ-loaded GM samples (GM@BQ) were collected by
centrifugation at 12,000 rpm for 10 min and vacuum dried to obtain a dry powder. The
encapsulation efficiency and drug loading of BQ in GM@BQ were determined by using a
standard calibration curve. Calibration curve for BQ was generated using 1.0, 2.5, 5.0, 7.5
and 10.0 µg/mL of BQ diluted in the release media (release media: 0.5% w/v SLS
containing 10 mM HEPES, pH 7.2) using RP-HPLC (Appendix Figure B.3.).

(3.1)
=

Initial amount of drug added

× 100%

(3.2)
=

3.2.7

× 100%

Liposome preparation
Liposomes were prepared, as described by Patel et al. with minor modifications.

Briefly, DPPC (85% molar ratio), cholesterol (10% molar ratio), DSPE-PEG(2000) amine
(5% molar ratio), and green fluorescent Coumerine-6 (0.1 mg) were dissolved in 2 mL of
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chloroform and evaporated in a rotary evaporator, yielding a thin lipid film. This lipid film
was rehydrated in 2 mL of HEPES buffer and extruded 15 times through a polycarbonate
membrane (pore size 800 nm) using a mini extruder. Here, the prepared liposome was a
thermo-sensitive liposome, as the amount of DPPC used in liposome preparation was the
highest in molar ratio compared to cholesterol and DSPE-PEG(2000) amine. As previously
studied, these liposomes become permeable at temperatures ~ 50 °C. 100 Coumerine-6 is
widely used to make nano-assemblies green fluorescent. 314
3.2.8

Synthesis of COOH- -Glucan
et al.

315

The synthesis scheme was shown in Appendix Scheme B.1 -Glucan (5 mg, 0.011 mM)

was first dissolved in 5 mL of DMSO at 60 °C for 24 h with a continuous and mild stirring.
The following day, succinic anhydride solution (10 mg, 0.1 mM in DMSO) was added to
the solution drop by drop. The solution mixture was let stirring at 60 °C for 24 h, and the
mixture was transferred to a dialysis tubing (MWCO: 6-8 kD). The dialysis against DI
water went for 3 days. Finally, the mixture was freeze-dried, and the remaining product
was a sponge3.2.9

Conjugation of COOH- -Glucan on liposome
To prepare, COOH- -Glucan coupled on liposome (L-Glu), COOH- -Glucan was

conjugated to the liposomal shell by amide conjugation as shown in Appendix Scheme B.1.
EDC was used to ac

-Glucan. Once activated, these groups

would react with the amine group of DSPR-PEG (2000) amine in the liposomal shell.
COOH- -Glucan (5 mg) was dissolved in 0.1 M MES containing 0.5 M NaCl at pH 6.0
(reaction buffer) and then incubated with a 10-fold molar excess of EDC (pH = 4.0) and
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25-fold molar excess of sulfo-NHS for 30 min. Amine group-containing liposomes were
added to the solution having carboxylic acid-

-Glucan and then reacted for 24 h

at 37 °C. The molar ratio of COOH- -Glucan: liposome was kept at 10:1. After 10 h, the
reaction mixture was purified by centrifugation at 12,000 rpm for 15 min at 25 °C to

3.2.10 Congo red as

-Glucan structure modification
-Glucan.

This experiment was performed according to Palacios et al. with minor modifications.316
-Glucan was established by helix-coil
transition analysis. Congo red was dissolved in different concentrations (10-100 g/mL) in
DMSO to optimize the concentrations of the dye. Congo red dye alone and dextran were
- glucan and dextran) were dissolved in DMSO at 1
mg/mL and were added to Congo red solutions. Spectra were recorded using a plate reader
in intervals of 1 nm from 400 to 650 nm.
3.2.11 Conjugation of folic acid (FA) on liposome
To prepare, folic acid-coupled liposome (L-FA), folic acid (FA) was conjugated to
the liposomal shell by amide conjugation as shown in Appendix Scheme B.2. EDC was
used to activate the carboxylic groups of FA. Once activated, these groups would react
with the amine group of DSPR-PEG (2000) amine in the TSL shell. FA (476 g) were
dissolved in 0.1 M MES containing 0.5 M NaCl at pH 6.0 (reaction buffer) and then
incubated with a 10-fold molar excess of EDC (pH = 4.0) and 25-fold molar excess of
sulfo-NHS for 30 min. Amine group-containing liposomes were added to the solution
having carboxylic acid-activated FA and then reacted for 24 h at 37 °C. The molar ratio of
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FA: liposome was kept at 10:1. After 10 h, the reaction mixture was purified by
centrifugation at 12,000 rpm for 15 min at 25 °C to remove excess unreacted EDC. This
was
3.2.12 Encapsulation of GM and GM@BQ into host-targeting ligand conjugated
liposomes (L-Glu or L-FA)
To prepare (GM)L-Glu, (GM)L-FA, (GM@BQ)L-Glu, and (GM@BQ)L-FA, 1 mg
of GM and GM@BQ was resuspended in a liposome (L-Glu or L-FA, 2 mL, 10 mg/mL)
in HEPES buffer and mixed for 20 min in an ice bath. Nano-assemblies were separated
from empty liposomes by centrifugation at 12,000 rpm for 5 min with repeated (3x)
washing in HEPES. Similarly, (GM)L of 1000 nm size were prepared using filter pore size
of 1000 nm filter. The resultant (GM)L-Glu, (GM)L-FA, (GM@BQ)L-Glu, and
(GM@BQ)Land encapsulation efficiency were determined by a standard calibration curve of BQ, as
shown in Appendix Figure B.3.
3.2.13 Determination of ligand density by TGA
For TGA analysis, measurements were carried out under argon (99.999%), where
dried (GM)L-Glu and (GM)L-FA at a constant heating rate of 5 o C/min to 100 °C and
then kept isothermal at 100 oC for 15 min followed by ramping 5 oC/min to 700 °C. Two
sets of each analysis were carried out. The percent weight difference (%) before and after
targeting ligand conjugation, together with the percent weight (%) after functionalization
L

(nmol/nm2

Glucan and FA on HTNs was calculated as shown in Appendix Section B.3.
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-

3.2.14 Ligand density by phenol sulphuric acid assay
Calibration curves were obta

-Glucan where various concentrations (10-

-Glucan in 1 mL of DMSO were placed in boiling tubes. Add 1 mL of 2.5 N
HCL and hydrolyzed glucan by keeping it in a boiling water bath for 1 h. The mixture was
cooled at room temperature and neutralized with sodium carbonate until effervescence
ceased. Then it was centrifuged at 15000 rpm for 10 min and collected the supernatant. 1
mL of supernatant was added in 24 well plates, following that 100

L of 5% phenol

solution and 500 L of 96% H2SO4 were added. Then it was incubated at room temperature
for 30 min. Finally, UV-Vis spectra of the resulting solutions were recorded at 490 nm,
-Glucan concentration. This calibration curve is used
to calculate the ligand density on HTNs, as shown in Appendix Figure B.4

-Glucan

coupled on HTNs were subjected to the same assay where freshly-

-Glucan

conjugated HTNs with varying size 100 and 200 nm and varying concentration (150-200
nM ~30–50 ug/mL) in 1 mL DMSO, and the solutions were treated with phenol/H 2SO4
following the same protocol described above. Then un-functionalized HTNs were treated
similarly with phenol/H2SO4, and the absorbance at 490 nm was used as the background
deducted from the total signals

-Glucan conjugated HTNs. The density

-Glucan immobilized was then determined using the calibration curve.
3.2.15 Fluorescent competitive binding assay
-Glucan conjugated HTNs solutions, (GM)L-Glu of various concentrations (11000 nM) and FA conjugated HTNs, (GM)L-FA (1-1000 mM) were prepared in HEPES
buffer. The HTNs were tagged with Coumerine-6 dye, a fluorescent molecule with an
excitation peak at 457 nm and an emission peak at 501 nm. The fixed concentration of
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-Glucan (200 nM) and FA (200 mM) were prepared separately. For the
competition assay, the various concentration of (GM)L-Glu (1-1000 nM) was mixed with
-Glucan (200 nM). Similarly, FA conjugated HTNs (1-1000 mM)
were mixed with a fixed concentration of FA (200 mM). These resulting solutions were
placed in macrophages (104 cells/well) followed by incubation for 3 h at 37 °C. After that,
the excess unbound ligand was washed off with HEPES buffer 3 times. Then final
fluorescence was recorded with an excitation peak at 457 nm and an emission peak at 501
nm. The dose-response curve will be obtained by plotting the normalized fluorescent
intensity (%) against the log value of the varying concentration of HTNs. The IC 50 value
was obtained from the dose-response curve by running a competitive binding experiment
on prism software. Three sets of data at each concentration were collected, and the mean
intensity values were used. The apparent dissociation constant K D was estimated by the
Cheng-Prusoff equation:

(3.3)

=
1+

[ ]

Where IC50 is the ligand concentration displaying 50% of specific binding, [M] is the
concentration of free ligand, Kd

-Glucan with dectin-

1, and free FA with folate. The KD

-Glucan conjugated

HTNs with dectin-1 and FA conjugated HTNs with folate.
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3.2.16 Surface area and pore volume determination of nano-assemblies
The surface area of GMs and GM@BQ were determined using the
Brunaue

model.
3.2.17 TGA analysis of nano-assemblies
TGA was carried out under argon (99.999%), where dried GM, GM@BQ,
(GM@BQ)L, and GM@Dox)L-Glu (ca. 1 mg) were heated at a rate of 5 oC/min to 100
°C and then kept isothermal at 100 oC for 15 min followed by ramping 5 oC/min to 700 °C.
The BQ loaded in GM was calculated by analyzing the weight loss difference between GM
and GM@BQ. Similarly, the liposome content was analyzed by measuring the weight loss
difference between GM@BQ and (GM@BQ)L. Finally, the amount of ligand was
calculated by measuring the weight loss difference between (GM@BQ)L and
(GM@BQ)L-Glu.
3.2.18 Stability analysis of nano-assemblies
The stability studies were carried out by following the protocol in our previously
reported study.100 Briefly, GM and (GM@BQ)L-Glu solution were stored at 4, 25, and 37
°C in cell culture media for 5 days. The nano-assemblies were monitored daily, and their
stability was characterized by UV absorbance to track the longitudinal surface plasmon
resonance (LSPR) intensity, aggregation index (AI), and zeta potential to monitor the
change in surface charge.
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3.2.19 Intracellular uptake of nano-assemblies by macrophage
Intracellular uptake of nano-assemblies was checked by confocal microscopy.
THP-1 (104 cells/ mL) were seeded on 24-well plates with PMA stimulation for 24 h
incubation to differentiate into a macrophage. Then the cells were infected with a volume
Msmeg (17 × 103 CFU/mL) was added to each well and incubated for 2 h. After
incubation, the supernatant was discarded, and the infected cells were washed twice with
0.1 M HEPES buffer. Then, the culture medium was replaced with a medium supplemented
with 40 ng/mL BQ to kill the remaining extracellular bacteria without affecting the
intracellular bacteria. Then, the cells were treated with Coumerine-6 stained (GM)L and
(GM)L-Glu (50 g/mL) for 6 h. Afterward, the cells were washed twice with HEPES and
subsequently incubated with Hoechst dye for 30 min at 37 °C. After washing twice with
HEPES, the cells were observed by a confocal microscope.
3.2.20 Mechanism for intracellular uptake of nano-assemblies
THP-1 cells (104 cells/ mL) were seeded on 24-well plates with PMA stimulation
for 24 h incubation that differentiated into a macrophage. Macrophages were pretreated
g/mL, and
-Glu,

assemblies' uptake by macrophage. Enhancement of green fluorescence intensity within
the macrophage is related to the high uptake of nano-assemblies.
3.2.21 Intracellular ROS detection
ROS generation inside infected macrophages was measured with a cell-permeable
dye 2, 7-dichlorofluorescein diacetate (DCFH-DA). THP-1 cells (10 4 cells/ mL) were
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seeded on 24-well plates with PMA stimulation for 24 h incubation to differentiate into a
macrophage and then Msmeg infection for another 2 h. After 2h of infection, the medium
was removed, and the samples were washed with 0.1 M HEPES buffer two times.
Subsequently, the macrophage cultures were maintained in a growth media supplement
with 40 ng/mL of BQ for 30 min and then infected macrophages were washed with 0.1 M
HEPES to remove the extracellular bacteria. The infected macrophages were exposed to
GM

-Glucan, COOH- -Glucan, (GM)L, and (GM)L-Glu (50 g/mL) for 1 h. Following

that, NIR laser treatment was given and incubated for 5 h. After exposure, cells were
incubated with 100 L of DCFH-DA for 1 h at 37 °C. Fluorescent intensity was quantified
at 525 nm, with excitation at 490 nm. Samples were also observed by fluorescence
microscopy.
3.2.22 Measurement of reactive nitrogen species.
According to the manufacturer's instructions, nitrite accumulation/release into
culture’s supernatants was measured by Nitrite assay kit (Griess reagent). THP-1 cells (10 4
cells/ mL) were seeded on 24-well plates with PMA stimulation for 24 h incubation to
differentiate into a macrophage. Then infected with Msmeg

-Glucan,

COOH- -Glucan, (GM)L, and (GM)L-Glu (50 g/mL) for 1 h. Following that, NIR laser
treatment was given and incubated for 24 h. Culture supernatants of respective groups
from various time points (0, 2, 4, 6, 8, and 24 h) were mixed with an equal volume of Griess
reagent I and II incubated at room temperature for 10 min, and the absorbance was
measured at 540 nm using a microplate reader. The standard series were prepared as per
the manufacturer’s instructions, as shown in Appendix Figure B.5. Briefly, 1-10 nmol/well
nitrite standards were prepared in a 96-well plate using nitrite assay buffer. Then after
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Griess Reagent I (10 L), Griess Reagent II (10 L), and nitrite assay buffer (80 L) were
added to each well plate. For each background correction well, add 10 L of Griess Reagent
I and 90 L of Nitrite Assay Buffer and mix well. The absorbance was taken at 540 nm in
end-point mode at room temperature using a plate reader.
3.2.23 Photothermal study and NIR-triggered drug release
The laser setup is explained in chapter 2 (See Section 2.2.11). First, the
photothermal effect due to the presence of GNR was evaluated by comparing various
weight concentrations of (GM@BQ)L-Glu ranging from 50, 100, 500, and 1000 g/mL
(calculated with respect to the weight of GM) were irradiated with the 808 nm NIR laser
(500 mW) for 15 minutes. Various nano-assemblies GM@BQ ± laser, (GM@BQ)L ± laser,
and (GM@BQ)L-Glu ± laser were dispersed in 3 mL of release media (0.5 % w/w SLS in
10 mM HEPES buffer, pH 7.2), then incubated at 37 °C with constant agitation. At
predetermined time intervals (2, 4, 6, 8, 10, and 12 h), the suspension was exposed to the
NIR laser (808 nm, 500 mW) for 15 min and then centrifuged at 15000 rpm for 15 min. At
the indicated time point, samples were taken out and then centrifuged, and the supernatant
was collected and replaced with prewarmed release media. Each sampled aliquot of the
supernatant was passed through a 0.22 m nylon filter. Quantification of the drug release
was performed by HPLC.
3.2.24 MIC determination of the nano-assemblies
Msmeg was cultured at 37 °C in Middlebrook 7H9 medium supplemented with 10%
ADC and 0.05% glycerol on a shaking incubator (200 rpm) at 37 °C. Two hundred

(GM@BQ)L, and (GM@BQ)L-

g/mL were added
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to a 96-

Msmeg (108 CFU/mL) was added to each well and finally

treated with NIR laser (808 nm, 500 mW, 15 min), then shaken at 37 °C in a shaking
incubator for 24 h. On the following day, the viability of bacteria was determined by the
cell viability WST-8 colorimetric assa

agent, WST-8 at 37 °C on a shaker bed for 2 h. The absorbance was recorded at 460 nm.
3.2.25 In situ ablation of intracellular bacteria
To determine intracellular MIC, THP-1 cells (10 4 cells/ mL) were seeded on 24well plates with PMA stimulation for 24 h incubation to differentiate into a macrophage.
Msmeg (17 × 103 CFU/mL) was added
to each well and incubated for 2 h. After incubation, the supernatant was discarded, and
the infected cells were washed twice with 0.1 M HEPES buffer. Then, the culture medium
was replaced with a medium supplemented with 40 ng/mL BQ to kill the remaining
extracellular bacteria without affecting the intracellular bacteria. The infected macrophages
were cultured in a fresh medium in the presence of BQ and (GM@BQ)L-Glu having
g/mL. After 1 h of incubation, the NIR laser exposure was given
and then incubated for an additional 24 h. The survival of intracellular Msmeg was assessed
by lysing the macrophages with 0.5% Triton X-100, and serial dilutions of the lysate were
plated on Middlebrook 7H11 agar plates. The survival rate of intracellular Msmeg was
determined by the colony counting method. The colony-forming unit (CFU) on plates was
counted, which indicates the intracellular MIC of nano-assemblies as well as % viability
of bacteria after treatment with nano-assemblies.
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To further confirm the intracellular bacterial viability, the LIVE/DEAD BacLight
Bacterial Viability Kit (Molecular Probes) was used to visualize the viable and dead
bacterial cells within macrophages. As described above, the macrophages (10 4 cells/ mL)
were seeded on 24-well plates, and the infection was established as described earlier in this
section. Infected macrophages were incubated with a LIVE/DEAD BacLight bacterial
viability staining solution for 30 min. After washing with 0.1 M HEPES buffer, cells were
visualized under confocal microscopy.
3.2.26 Detection of phagosome acidification
THP-1 cells (104 cells/ mL) were seeded on a 2 well chamber slide with PMA
stimulation for 24 h incubation to differentiate into a macrophage. Following that, the
macrophages were infected with Msmeg and exposed to BQ, and (GM@BQ)L-Glu ± laser
(50 g/mL) for 6 h. These treated cells were then incubated with 1 g/ml Acridine Orange
(AO) for 15 min to detect acidic vesicular organelles (AVOs) under a confocal microscope.
In AO-stained cells, the acidic compartments showed a degree of acidity which appeared
as red fluorescence. The nucleus and cytoplasm emitted green fluorescence upon excitation
with the same wavelength of light. As controls, macrophages and Msmeg infected
macrophages were incubated with 1

g/ml Acridine Orange (AO) for 15 min and

visualized under a confocal microscope.
3.2.27 Assessment of phagolysosome formation
To study whether nano-assemblies were internalized into the differentiated
macrophages and simultaneously induced phagolysosome formation, we seeded Msmeg
infected macrophages in a 2-well chamber slide and incubated the cells with and
(GM@BQ)L-Glu + laser (50

g/mL) for 3 h at 37 °C. Then, the treated cells were
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incubated with 50 nM ER-Tracker Red and LysoTracker Red D99 at 37 °C for another 3
h, then observed under a confocal microscope. ER-Tracker Red and LysoTracker Red D99
were used to track nano-assemblies inside cells. LysoTracker Red D99 selectively stains
the acidic lysosomal compartment and detect phagolysosome formation. 317
3.2.28 PT induced apoptosis in an infected host
To investigate the modulation of cell death by (GM@BQ)L-Glu-mediated PTT, the
expression of Caspase-3/7 within each NIR-treated sample was examined. Activation of
caspase-3 is an important event during apoptosis. Thus, caspase expression was analyzed
by fluorescence microscopy using the Cell Event Caspase-3/7 Green Detection Reagent
(ThermoFisher Scientific) to confirm cell death by apoptosis. For this experiment, THP-1
cells (104 cells/ mL) were seeded on a 24 well plate with PMA stimulation for 24 h
incubation to differentiate into a macrophage. Then, infected with Msmeg and treated with
GM, BQ, and (GM@BQ)L-Glu (50 g/mL) for 3 h at 37°C. Next, the cells were exposed
to PTT treatment for [(GM@Dox) LI]-PF (NIR 808 nm laser, 500 mW, 15 min), and
incubation was continued for another 3 h at 37 °C. Before use, the CellEvent Caspase-3/7

samples underwent PTT, the NP-3/7 Green Detection Reagent. Samples were allowed to
incubate for an additional 30 min before analysis and then imaged using a fluorescence
microscope. The fluorescent intensity was quantified at 525 nm, with excitation at 490 nm.
Next, to check the viability of bacteria, the treated cells were lysed in distilled water for 3
h. The cell lysate was plated on agar, and the bacterial colonies were quantified. The
number of colonies reflects the viable intracellular Msmeg present after treatment.
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3.2.29 Cytotoxicity assay
THP-1 cells (104 cells/ mL) were seeded on a 24-well plate with PMA stimulation
for 24 h incubation to differentiate into a macrophage, infected with Msmeg and exposed
to GM, BQ, and (GM@BQ)L-Glu ± laser with varying concentration (1-50 g/mL) for 6
1 mg/mL) was added to each well, and the cells
were further incubated for 4 h. After incubation, the supernatant was discarded, and 150

by a microplate reader. Results were presented as the percentage (%) with respect to
untreated control THP-1 cells. We carried out a similar assay to check the cytotoxic effect
of NIR laser and nano-assemblies on healthy macrophages (without Msmeg infection).
THP-1 cells (104 cells/ mL) were seeded on a 24-well plate with PMA stimulation for 24 h
incubation to differentiate into a macrophage, then exposed to NIR laser and (GM@BQ)LGlu (50 g/mL) for 6 h. The rest of the step was similar as described above in the assay.
3.3
3.3.1

Results and Discussion
Determination of binding affinity between free ligands and receptors
We have developed an absorbance-based binding assay to determine the binding

affinity of targeting ligands -Glucan and FA with dectin-1 and folate receptors, present
on macrophages, respectively. -Glucan has been tagged with Congo red dye, which gives
a

b

Figure 3.1. Absorbance-

-Glucan and, (b) FA.
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absorbance at 546 nm and FA gives absorbance at 310 nm.318, 319 In a typical assay, the
standard calibration curve was prepared by varying the concentration of targeting ligands
and recording the absorbance at 546 nm. Free ligand concentration was displayed on the
x-axis, while ligand-receptor absorbance was plotted on the y-axis. (As shown in Appendix
Figure B.1.). Similarly, the various concentrations of targeting ligands interacted with a
fixed concentration of receptors present on macrophages and incubated for 3 h. After that,
unbound ligands were washed off 3 times with HEPES buffer. Then the absorbance of the
ligand-receptor complex was recorded at 546 nm. The concentration of ligand-receptor
complex [LR] was calculated from standard calibration series as shown in Appendix
Section B.1. The concentration of receptor [R] was also calculated from the standard
calibration curve (Appendix Section B.2), the receptor binding saturation was achieved at
25 nM concentration of ligand, and ligand-receptor binding is 1:1, as reported
previously.320, 321 Hence, the [R] was 25 nM ~ 1.8 × 107 of dectin-1 receptor in one cell,
and for FA, [R] was 40 mM ~ 2.3 × 1015 of folate receptor in one cell (Calculation is shown
in Appendix Section B.2.). The binding affinity between ligand-receptor (K d), calculated
by plotting free ligand concentration [L] on the x-axis and [LR]/[R] on Prism software. The
Kd

-Glucan- dectin-1 receptor and FA-folate receptor was found to be 3.6 nM and 11.1

mM, respectively, as shown in Figure 3.1.
3.3.2

Fabrication of HTNs
The stepwise synthesis of HTNs is illustrated in Scheme 3.1. The NIR light-

sensitive agent, GNR, was synthesized via a seed method as described by El-Sayed et al.
with some minor modifications.48 Followed by mesoporous silica shell was grafted onto
the surface of the GNR by a modified protocol from Matsuura et al.74 CTAB was used as
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Scheme 3.1. Stepwise synthesis scheme of host targeting nano-assemblies (HTNs).

a soft template, which creates the mesoporous silica shell structure during the
polymerization of silane around the GNRs (to give GM). 322 Simultaneously, the liposomes
were synthesized by the extrusion method using the DPPC, cholesterol, and DSPEPEG(2000) amine, along with Coumerine-6 dye. The Coumerine-6 is a green fluorescent
molecule used to stain nano-assemblies.323 The phospholipid DPPC, which is used in an
85% molar ratio, makes this liposome thermo-sensitive due to its melting point at 43 °C.
Cholesterol in the lipid layer enhances membrane fluidity.324 The large PEG group of
DSPE-PEG(2000)amine is known to improve drug delivery efficiency, increase systematic
circulation time, reduce immunogenicity, and offer stealth properties, which facilitates the
binding of the targeting ligands onto the liposome.325, 326 The liposome layer provides
stability to the nano-assemblies, improving cellular uptake and offering surface to
conjugates targeting ligands. Next, to achieve host target specificity and increase uptake
-Glucan and folic acid conjugated
separately to the surface of the liposome through EDAC chemistry and named as L-Glu
110

and L-FA, respectively (as shown in Appendix Scheme B.1 and Scheme B.2

-Glucan

is known for its binding to dectin-1 receptor which evade host immune mechanism by
altering ROS and RNS production.327 On the other hand, folic acid has affinity towards
folate receptors, which are overexpressed on a large number of macrophages. 328 Finally,
as-prepared GM was encapsulated within the ligand conjugated liposome by reacting them
in an ice bath, where the amphiphilic phospholipids self-assemble around the GM to create
a lipid layer and the final nano-assembly was abbreviated as (GM)L-Glu and (GM)L-FA.
Also called as host targeting nano-assemblies (HTNs).
3.3.3

Morphology and size characterization of HTNs
The morphological characterization of HTNs was done by TEM. GNRs were

synthesized via a seed method described by El-Sayed et al. with some minor
modifications.48 As shown in Figure 3.2a, the average length and width of GNRs were 45
± 4.4 nm and 11.8 ± 2.7 nm, respectively and the calculated average aspect ratio is 3.8:1.
The GNRs displayed a uniform and well-disposed rod-like morphology. GNRs coated with
a porous silica shell were synthesized by a modified protocol from Matsuura et al.74 CTAB
was used as a soft template, which creates the mesoporous silica shell structure during the
polymerization of silane around the GNRs (to give GM). TEM images (Figure 3.2b) show
GNRs encapsulated in a mesoporous silica shell (GM). The silica shell has an average
thickness of 16 ± 3 nm, and its porous structure can be clearly seen by TEM (Figure 3.2b).
The GNR loaded mesoporous structure was wrapped by liposome to give (GM)L. The size
of (GM)L was found to be 90 ± 3 nm (n = 20, n particle number) by TEM analysis and was
calculated by Image J software. The liposomal layer was visible through TEM, as shown
in Figure 3.2c. The shape of GM dictates the oblong shape of the liposomal layer. High-
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Figure 3.2. Characterization of nano-assemblies by TEM and STEM. (I) TEM images of
(a) GNR (Scale bar = 5 nm), (b) GM (Scale bar = 20 nm) and (c) (GM)L (Scale bar = 30
nm). HAADF images of (GM)L which indicted presence of (e) gold, (f) silica, (g) oxygen,
(h) carbon and (i) merged images (Scale bar = 30 nm).

angle annular dark-field scanning transmission electron microscopy (HAADF-STEM)
images (Figure 3.2e-h) show the presence of the elements of gold (Au), silica (Si), oxygen
(O), and carbon (C) present in the layers of (GM)L. The merged image in Figure 3.2i
clearly shows the individual layers overlaid on each other to show the final construct of
(GM)L. The combined TEM (Figure 3.2c) and HAADF-STEM (Figure 3.2i) images
clearly show liposome coating surrounding GM. The varying sizes of HTNs were analyzed
by DLS. Two types of HTNs were prepared by using varying sizes of pore filters 800 and
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I
a

b

Figure 3.3. EDS profile mapping of (a) GM and (b) (GM)L.
1000 nm, and the DLS results were found to be 808 ± 7 and 1020 ± 12 nm, respectively.
3.3.4

Elemental analysis of HTNs
The chemical composition of GM and (GM)L was analyzed by Energy-dispersive

X-ray spectroscopy (EDS). The EDS spectra of GM (Figure 3.3a) clearly displayed the
peaks of gold (Au), oxygen (O), and silica (Si). Copper (Cu) peak was present in the EDS
spectra (Figure 3.3a) because a Cu mesh TEM grid was used as a substrate. EDS spectrum
of (GM)L (Figure 3.3b) shows the Au, Si, O, and C peaks. The presence of C peaks was
used to indicate the existence of a liposomal layer.
3.3.5

Ligand density determination of HTNs
We measured the ligand density of both hosts targeting ligands on HTNs by TGA,

as shown in Figure 3.4. To minimize the influence of volatiles, samples were dried under
vacuum at room temperature for 3 days before TGA measurements. The weight loss
difference and the percent weight of (GM)L-Glu at 700 °C were used to estimate the
-Glucan on (GM)L, according to the calculations (as shown in Appendix
Section B.3.), given 53.7 ± 0.5 nmol/nm2. Similarly, a density of 12.9 ± 1.1 nmol/nm2 was
obtained for FA on (GM)L by the weight loss difference between (GM)L and (GM)L-FA.
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Figure 3.4. Typical TGA graphs of (GM)L, (GM)L-FA and (GM)L-Glu.
-Glucan ligands on (GM)L was higher
than FA. Higher molecular weight (MW) ligands have higher ligand loading on
nanoparticles and have a higher binding affinity than low MW ligands. 329,

330

Hence,

-Glucan (20K MW) as a host-targeting ligand is an attractive and beneficial
candidate compared to lower MW of FA.
-Glucan) ligand density with varying
-Glucan on (GM)L. The Phenol-H2SO4 assay, a colorimetric method
widely used to measure carbohydrate concentrations in solution and on solid surfaces, was
employed to measure the carbohydrate ligand density on the nano-assemblies. 331,

332

Calibration curves were obtained by treating various concentrations of each carbohydrate
with phenol/sulfuric acid, and the absorption at 490 nm was plotted against the
carbohydrate concentration (Appendix Figure B.4.). The calibration curve was used to
calculate the ligand density on (GM)L-Glu or HTNs. Here, we want to determine how the
size of nano-assemblies and varying concentrations of ligands impacted ligand density. To
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address that question, the ligand density experiments for (GM)L-Glu were carried out by
dissolving freshly-prepared (GM)L-Glu with varying sizes 100 and 200 nm (varying ligand
concentration 150-200 nM ~30–50 g/mL) in 1 mL DMSO, and the solutions were treated
with phenol/H2SO4 following the same protocol described methods. The un-functionalized
(GM)L were treated similarly with phenol/H2SO4, and the absorbance at 490 nm was used
as the background deducted from the total signals measured from the (GM)L-Glu.

Table 3.3.1. Ligand density as the function of the size of nano-assemblies
and concentration of ligands by phenol sulphuric acid assay.
Size
of
HTNs

Conc.
of Ligands
added (nM)

Conc.
of ligands
obtained (nM)

Ligand density
(No. of glucan/ HTNs)

100

150
175
200
150

18.1 ± 4.1
44.9 ± 2.5
96.6 ± 3.1
2.8 ± 1.1

120
297
645
19

175

14.3 ± 2.1

95

200

29.6 ± 1.3

197

200

The den

-Glucan ligands immobilized was then determined using the calibration

curve. As shown in Table 3.3.1, smaller HTNs 100 nm size with higher concentration 96.6
-Glucan per (GM)L, while 200 nm size HTNs with
-Glucan per (GM)L (Calculations
was in Appendix Section B.4). It has been previously studied that the smaller nanoparticles
occupied more ligands due to higher surface curvature, which offers more available volume
to accommodate bulky ligands.120 Our results indicated that the smaller size of (GM)L-Glu
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a

b

c

Figure 3.5. (a) Fluorescence-based competition binding assay. (b) The dose response curve
of Glu-HTNs and (c) FA-HTNs, where IC50 value was obtained.
occupied more ligands than bigger size, and the ligand density on (GM)L is concentrationdependent.
3.3.6

Binding affinity by fluorescence competition binding assay
The fluorescence competition binding assay has been widely used to study the

binding affinity of ligand conjugated nanoparticles.113, 333 As shown in Figure 3.5a, we
developed a fluorescence competition assay to determine the binding affinity of HTNs

116

conjugated targeting ligands with its receptors using a fluorescently labeled targeting
ligand conjugated HTNs and a free competing ligand. In a t

-Glucan

conjugated HTNs, (GM)L-Glu of varying concentrations, and a fixed concentration of a
-Glucan were incubated with THP-1 cells for 3 h at 37 °C. The
unbound (GM)L-Glu and free ligand remained in the supernatant, corresponding to the
amount of (GM)L-Glu that did not bind dectin-1 receptors. These unbound particles were
washed off with HEPES buffer, and final fluorescence was measured with excitation at 457
nm and emission at 501 nm.
As shown in Figure 3.5b, the dose-response curve was obtained by plotting
normalized fluorescent intensity against the log value of the varying (GM)L-Glu
concentration using Prism 8 from GraphPad Software (San Diego, CA, USA). From this
concentration-response curve, the IC50 value was determined by running a competition
binding experiment on Prism software, and the apparent dissociation constant K D was
computed according to the Cheng Prusoff equation 3.4.
(3.4)

=
1+

[ ]

Where [M] is the concentration of the free ligand, Kd is the dissociation constant of the
-Glucan-dectin-1 receptor (3.6 nM) and FA-folate receptor (11.3 mM), and
KD is the apparent dissociation constant of the HTNs with its respective receptors, IC 50
values are calculated, and results are presented in Table 3.3.2.
We have carried out a similar assay to check binding affinity between FA
conjugated HTNs, (GM)L-FA with folate receptors. As shown in Table 3.3.2, (GM)LGlu showed higher affinity for the dectin-1 receptor (KD, 0.11 ± 0.7 nM) as compared to
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(GM)L-FA-folate binding affinity (KD, 8.6 ±2.5 mM). We screened -Glucan as well as
FA as a host targeting ligands for binding affinity toward dectin-1 and folate receptors,
respectively. The results revealed that -Glucan had a stronger binding affinity and hence
was selected for further studies.

Table 3.3.2. Binding affinity of targeting ligand conjugated HTNs.
HTNs (100 nm)
(GM)L-Glu

IC50
6.38 nM

KD
0.11 ± 0.7 nM

Kd
3.6 nM

(GM)L-FA

9.47 mM

8.6 ± 2.5 mM

11.3 mM

The binding affinity is sensitive to many factors, including the nano-assemblies' size
and the density of ligands. In the present study, the ligand density and nanoparticle size
were varied, and their impacts on the binding affinities of the resulting (GM)L-Glu were
investigated. To check the effect of varying size and ligand density on binding affinity, the
-Glucan were added to the HTNs preparation
and incubated with macrophages. The apparent K D value of the resulting Glu-HTNs was
then determined using the fluorescence competition assay described above. The Table 3.3.3
show that the increased ligand concentration - increased ligand density - a high binding
affinity. In terms of the impact of varying sizes on binding affinity, an increase in the size
of HTNs and decreasing ligand density - a low binding affinity. Hence, we have selected
100 nm HTNs-Glu with higher ligand concentration (200 nM) which has 645 ligands, and
showed KD of 0.11 ± 0.7 nM, which was shown 35 times stronger binding affinity as
compared to free -Glucan-dectin-1 receptor Kd (3.6 nM).
The fluorescence-based competition binding assay was successfully used to
determine the KD values and evaluate the binding affinity of HTNs. We have conducted
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systematic studies to investigate the impacts of nano-assemblies size and ligand density on
the binding affinity of (GM)L-Glu. Findings from this study conclude that (GM)L-Glu can
be readily synthesized by varying size and ligand density and dramatically affects the
binding affinity.

Table 3.3.3. Binding affinity as a function of ligand density and size of Glu-HTNs
Size
(nm)
100

200

3.3.7

Concentration of
ligands added
(nM/mg of HTNs)
150

KD
(nM)

Kd
(nM)

57.35

Ligand density
(No. of glucan/
HTNs
120

1.06 ± 0.5

3.6

175

31.34

297

0.58 ± 1.2

3.6

200

6.38

645

0.11 ± 0.7

3.6

150
175

512
312

19
95

9.54 ± 1.1
5.81 ± 1.4

3.6
3.6

200

100

197

1.86 ± 1.2

3.6

IC50
(nM)

Surface charge of nano-assemblies
The altered surface zeta potential is shown in Figure 3.6a. The zeta potential of

GNRs was 28 ± 0.7 mV, possibly due to the presence of positively charged CTAB on the
surface. After silica coating, the surface charge was reduced to -23.5 ± 1.1 mV due to
abundant Si-OH groups. Liposomal coating increased the zeta potential to +12.34 ± 0.5
mV, owing to the presence of amine groups from DSPE-PEG 2000 amine on the surface.
The COOH- -Glucan was conjugated to the abundant -NH2 groups present on the surface
of the liposome through EDC coupling chemistry. This is responsible for the enhancement
of the zeta potential to +6.2 ± 0.8 mV.

119

a

b

Figure 3.6. (a) Zeta potential (b) UV-vis absorbance spectra of nano-assemblies.

3.3.8

Optical properties of nano-assemblies
The UV-vis spectra (Figure 3.6b) indicated two characteristic absorption peaks of

GNRs: the transverse surface plasmon resonance (TSPR) peak at 514 nm and the
longitudinal surface plasmon resonance (LSPR) peak at 790 nm. With the mesoporous
silica coating, the LSPR peak underwent a red shift towards 805 nm due to the change in
the local refractive index of the surrounding medium and changes in geometry. The laser
was selected to match the new absorbance at 805 nm. There was no observable shift in the
LSPR peak with the liposome wrapping and after ligand conjugation (Figure 3.6b).
3.3.9

-Glucan
Congo red assay has been widely used to confirm the triple helix structure of

polysaccharides.318 The polysaccharides exist in an ordered three-dimensional structure,
generally, triple-helical conformation, forming a complex with Congo red dye. 318 The
complex is stabilized by strong hydrogen bonds and hydrophobic interactions between the
polysaccharide and the dye molecule. The complex formation of polysaccharides with
Congo red is commonly evaluated by employing the shift in the visible absorption maxima
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Figure 3.7
max)

-Glucan.

of the Congo red spectrum. The dye concentration was optimized to give a high and

stable absorbance. The concentration of 50 M gave the best result, and it was chosen for
-Glucan was allowed to complex with Congo red in a 50

M

concentration. Dextran was used as a random-coil control, and its absorbance was similar
-Glucan, COOH- Glucan, and (GM)L-Glu showed a bathochromic shift (10 nm), which indicates that this
polysaccharide displayed a triple helical structure (Figure 3.7). Since COOH- -Glucan and
(GM)L-Glu also showed similar 10 nm bathochromic shift, which proved that even after
-Glucan and conjugation to (GM)L, the triple helix structure of
-Glucan exists.
3.3.10 FT-IR characterization of nano-assemblies
The FT-IR analysis were carried out after each fabrication step are presented in
Figure 3.8. As shown in Figure 3.8a, GNRs show -CH2 symmetric and asymmetric
vibrations at 2847 cm-1 and 2870 cm-1, respectively. The presence of a peak at 1473 cm-1
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a

b

Figure 3.8. FT-IR analysis of (a) various nanoglucan.

-glucan and COOH- -

corresponds to the -CH2 scissoring mode of vibration. In the fingerprint region, the bands
at 960 and 817 cm-1 are consistent with C-O stretching and in-plane C-H bending
vibrations. The appearance of a peak at 1064 cm-1 (Si-O-Si stretching) and the
disappearance of symmetric (2847 cm-1) and asymmetric (2870 cm-1) vibrations, which
were seen in GNR, proves the mesoporous silica coating is on the surface of GNRs. The
liposomal coating was verified by symmetric and anti-symmetric -CH 2 stretching at 2850
cm-1 and 2920 cm-1, which are the characteristic peaks for the long carbon chain of the
lipids used. Also, the -CH2 scissoring vibration around 1467 cm-1 and the PO2 symmetric
stretching vibration around 1039 cm-1 are from phospholipids, confirming the successful
liposome coating. In

-

with succinic anhydride. Hence, FTout. As shown in Figure 3.8

-glucan is modified
-glucan and COOH- -glucan carried

-glucan showed the strong peak at 3320 cm -1 attributed to

O–H stretching, the peak at 2931 cm-1 attributed to C–H stretching, and a peak at 1640 cm1

-glucan is modified with
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Merge

Figure 3.9. Intracellular uptake of nano-assemblies. (a) Intracellular uptake of the (GM)L
and (GM)L-Glu by macrophages. The cell nucleus and Msmeg bacteria were stained with
Hoechst dye (blue), nano-assemblies were labeled with a green fluorescent dye
(Coumerine-6). Scale bar: 10 m. Inbox image was showing Msmeg bacteria inside the
macrophages. Scale bar: 5 m. (b) Shows quantitative intracellular uptake of (GM)L and
(GM)L-Glu by macrophages.

succinic anhydride, a new peak appears at 1722 cm-1(strong C=O stretching vibration). The
FTIR results (Figure 3.8b) evidence that COOH- -glucan is successfully synthesized.
Furthermore, the FTIR spectra of (GM)L-Glu showed an intense broad peak at 1620 cm

1

(Figure 3.8a), which can be attributed to the new carbonyl (C=O) stretching of amide I
absorption of the newly formed amide bond with the NH2 of liposomes and COOH- glucan. The rest of the characteristic peaks at 3252 cm-1 attributed to O–H stretching, the
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peak at 2862 cm-1 attributed to C–

-

-

glucan is successfully conjugated on (GM)L.
3.3.11 Targeting efficiency/ Intracellular trafficking of HTNs
The intracellular distribution of fluorescently labeled HTNs was analyzed by
confocal microscopy to confirm that HTNs were present in the cells and surrounding the
Msmeg rather than absorbed into the cell membrane. After green fluorescent dye
(Coumerine-6) was encapsulated within HTNs, particle uptake (GM)L and (GM)L-Glu by
macrophages were visualized. The nucleus of cells and Msmeg were stained with blue
Hoechst dye. After 6 h of incubation, the (GM)L-Glu were more efficiently taken up and
surrounded by intracellular Msmeg (shown in Figure 3.9a in box) than the (GM)L (Figure
3.9a). Figure 3.9a shows that the (GM)L-Glu were more rapidly recognized and taken up
by Msmeg infected macrophages than the (GM)L. Furthermore, as shown in Figure 3.9b
(GM)L-Glu shows higher uptake, nearly 91%, while (GM)L showed only 20%. These
results clearly depict that macrophage recognition, targeting capacity, and subsequent
intracellular trafficking of tested nano-assemblies were positively correlated with the
targeting efficiency of (GM)L-Glu. Furthermore, an endocytosis inhibition study was
carried out to understand the intracellular trafficking mechanism of (GM)L-Glu.
Macrophages

were

treated

with

a

clathrin-mediated

endocytosis

inhibitor

-

chlorpromazine, a caveolin-medicated endocytosis inhibitor - nystatin, and a
macropinocytosis inhibitor -

-6

labeled (GM)L-Glu.334-336 The mechanism for the intracellular uptake of the (GM)L-Glu
into the macrophage was monitored by confocal microscopy (Figure 3.10).
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Figure 3.10. Evaluation of cell uptake mechanism of nano-assemblies by
macrophage cells under different endocytosis inhibitory conditions. Cell
nucleus stained with Hoechst (blue), nano-assemblies were labeled with a green
fluorescent dye (Coumerine-6). Scale bar: 10 m

The fluorescence microscopy images reveal little or no visible green fluorescent
Coumarine-6 labeled (GM)L-Glu in chlorpromazine treated macrophages (Figure 3.10),
which indicates chlorpromazine treated macrophages inhibited uptake of (GM)L-Glu.
However, uptake of (GM)L-Glu into macrophage was not hindered when treated with
wortmannin and nystatin (Figure 3.10). These observations suggested that the trafficking
of the (GM)L-Glu occurred through clathrin-mediated endocytosis.
3.3.12 HTNs triggered ROS and RNS induction within Msmeg infected macrophage
Pathogenic Mtb can scavenge (reactive oxygen and nitrogen species (ROS/RNS))
produced by host macrophages, thereby escaping host-initiated killing mechanisms.
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Therefore, by initiating ROS and RNS production within infected host macrophages, we
can restrict Mtb

-glucan is very well

known to activate macrophages to produce pro-inflammatory signals ROS/RNS. 337, 338 This
host-

-glucan binds to the dectin-1 receptor on macrophage surfaces,

subsequently activating various downstream signal transduction pathways that promote
intracellular ROS/RNS production.337, 338 Thus, we have studied if (GM)L-Glu can induce
the production of ROS and RNS within infected macrophages (Figure 3.11). The oxidative
burst induced by uptake of various nano-assemblies was evaluated by fluorescence imaging
and quantitative fluorometric measurements following incubation with a cell-permeable
fluorogenic dye 2,7’ –dichlorofluorescein diacetate (DCFH-DA). As shown in Figure
3.11a, control- the Msmeg infected macrophage was not showing ROS production which
proved that Msmeg

-glucan

and COOH- -

-glucan and
-glucan (COOH- -glucan) induce ROS within Msmeg infected

macrophage. As shown in Figure 3.11b, (GM)L – Laser was not showing green fluorescent
while (GM)L + Laser showed strong green fluorescent. This observation led to that that
ROS can be produced in response to heat stress during PT treatment. 100, 302 (GM)L-Glu –
Laser showed slight green fluorescent even in the absence of laser, which was due to
targeting ability (COOH- -glucan) of (GM)L-Glu. In contrast, (GM)L-Glu + Laser showed
very strong green fluorescent, which proved the host targeting effect of (GM)L-Glu and
PT treatment. The smaller box depicts the green fluorescent intracellular Msmeg, which
indicated that (GM)L-Glu + Laser has produced more ROS, indicating macrophage
activation and killed intracellular Msmeg (Figure 3.11b).
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Figure 3.11. Free radical generation. (a) ROS determination by DCFH-DA mediated
fluorescence observed within Msmeg infected macrophage as a control, Msmeg infected
-glucan and COOH- -glucan. (b) Msmeg infected
macrophage after exposure to (GM)L ± Laser and (GM)L-Glu ± Laser. (c) Quantitative
determination of ROS generation detected by fluorometric intracellular ROS assay. Data
was presented as the mean ± SD (n=3). ns (non-significant), ** p < 0.01, *** p < 0.001,
and **** p < 0.0001. A, **** p < 0.0001 indicated the data to be more significant when
compared to *** p < 0.01 and ** p < 0.01 by One-way ANOVA. (d) RNS determination
by nitrite assay.
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The quantitative determination of ROS production data measured as fluorescence
intensity is shown in Figure 3.11c. These results were consistent with the fluorescent
images (Figure 3.11a and Figure 3.11b). It has been previously studied the correlation of
reactive-nitrogen species (RNS ~ nitric oxide (NO)) production with mycobacterial
infection and macrophage activation.339, 340 Activated macrophages have been shown to
inhibit intracellular bacterial growth and kill at least 50% of intracellular bacteria via nitric
oxide synthase-2 (NOS2) dependent mechanisms. 341 As shown in Figure 3.11d, (GM)LGlu ± Laser exposure was seen to induce high amounts of NO (10 nmol/10 4 cells) within
Msmeg infected macrophage, indicating macrophage activation by the exposure of (GM)LGlu ± Laser as compared to (GM)L ± Laser (2 nmol/104 cells). Here, we observed that the
PT activity was not af

-glucan and COOH- -glucan had similar

NO production activity (9.6 nmol/104 cells), as (GM)L-Glu ± Laser which proved that the
-glucan on (GM)L.
The control, Msmeg infected macrophage ± Laser, showed minimal NO production,
proving that Msmeg has already deactivated the macrophage. Thus, the significant
induction of ROS and RNS upon exposure to (GM)L-Glu ± Laser is promising since it
indicates the activation of infected macrophages by these nano-assemblies.
3.3.13 Synthesis and characterization of HTNs@BQ
The stepwise synthesis of HTNs@BQ or (GM@BQ)L-Glu is explained in Scheme
3.2. The detailed synthesis of GNR, GM, liposome preparation, and ligand conjugation on
liposome were explained in section 3.2. BQ, an anti-tuberculosis drug, was encapsulated
into the porous structure of the GM to create GM@BQ. The thermo-sensitive liposome
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Scheme 3.2. Stepwise synthesis scheme of BQ loaded host targeting nano-assemblies
(HTNs@BQ).

was modified with COOH- -glucan by EDAC chemistry to give L-Glu (as shown in
Appendix Scheme B.1.). Finally, GM@BQ is encapsulated inside this prepared liposome
L-Glu to create (GM@BQ)L-Glu, abbreviated as HTNs@BQ. The drug loading content
(LC) and encapsulation efficiency (EE) are essential factors in nanoparticle-mediated
delivery applications. The BQ loading and encapsulation efficiency (EE) was quantified
using the standard calibration curve of BQ using RP-HPLC. EE% was calculated as 68.9
± 0.8 % and 65.1. 2 ± 3.5 % for GM@BQ and (GM@BQ)L-Glu, respectively. The LC was
calculated to be 15.1 ± 0.5 % and 14.1 ± 1.1 % for GM@BQ and (GM@BQ)L-Glu,
respectively.
The quantitative analysis of the HTNs@BQ after each synthesis step was done
through TGA. The results are shown in Figure 3.12a. Percentage (%) weight loss between
the GM@BQ and GM was calculated to determine the amount of BQ loaded onto GM.
The BQ loading was found to be 14.5 ± 1.1% onto GM. Additionally, the percentage of
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b

a

Figure 3.12. (a) TGA analysis of nano-assemblies, and (b) N2
isotherm of GM and GM@BQ.

weight loss between (GM@BQ)L and GM@BQ showed that the lipid layer was 11 ± 0.6%
of the weight of (GM@BQ)L. COOH- -glucan loading on (GM@BQ)L was 38 ± 1.5%.
N2 adsorption-desorption isotherm and pore size distribution curves of GM and
GM@BQ are given in Figure 3.12b. These nano-assemblies exhibit a typical type IV
isotherm with a narrow pore size distribution, having a mean of 18.25 ± 1.1 Å and 11.13 ±
1.4 Å for GM and GM@BQ, respectively. This verifies the porous character of the
mesoporous silica shell. Through BET, the total surface area and pore volume of GM were
quantified to be 50.788 ± 1.2 m2g-1 and 0.22 ± 0.3 cc/g, respectively. In contrast, GM@BQ,
the total surface area, and pore volume were quantified as 41.014 m 2g-1 and 0.16 cc/g,
respectively. The surface electrical charge, optical properties, and functional group analysis
of (GM@BQ)L-Glu were shown in Appendix Figure B.6.
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Figure 3.13. Fluctuation of LSPR peak intensity in (a) GM and (b) (GM@BQ)L-Glu at 4,
25, and 37 °C in culture media.

3.3.14 Colloidal stability study of nano-assemblies
The colloidal stability of the GM and (GM@BQ)L-Glu in the RPMI 1640 culture
medium at 4, 25, and 37 °C was investigated for 5 days, as shown in Figure 3.13 and Figure
3.14. The LSPR peak intensity for GM@BQ was shown in Figure 3.13a, indicating that
GM was not stable up to 5 days in any of the temperature conditions. In contrast, the LSPR
peak intensity for (GM@BQ)L-Glu was pretty stable at 4 °C and 25 °C as compared to 37
°C, which proved that stability was due to having a liposomal coating (Figure 3.13b).
Higher AI indicates a higher degree of aggregation, hence lower stability. 291, 292 As shown
in Figure 3.14a, AI for GM was higher and increased with time in media in all the
temperature conditions. While the AI values for (GM@BQ)L-Glu were low and constant
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Figure 3.14. (a) Aggregation index and (b) Zeta potential of GM and (GM@BQ)L-Glu at
4, 25, and 37 °C in culture media.
with time in media at all temperature conditions (Figure 3.14b). Similarly, the constant
zeta potential in media suggests that GM is not stable (Figure 3.14b). In contrast,
(GM@BQ)L-Glu, has shown a constant zeta potential value +6.6 ± 0.9 mV up to 5 days in
all temperature conditions (Figure 3.14b). These observations reveal that (GM@BQ)L-Glu
is stable in cell culture media for up to 5 days. All these results together concluded that
the (GM@BQ)L-Glu nano-assembly is stable and suitable for drug delivery applications.
3.3.15 NIR triggered drug release
The laser setup and photothermal properties of nano-assembly were explained in
chapter 2, section 2.3.10. Since the GNR is used as a photothermal agent in (GM@BQ)LGlu nano-assembly, the photothermal capacity was similar to previously developed nanoassemblies. The photothermal properties are concentration-dependent, as shown in
Appendix Figure B.7. In-vitro drug release profile of BQ from GM@BQ ± Laser,
(GM@BQ)L ± Laser, and (GM@BQ)L-Glu ± Laser was investigated using RP-HPLC for
12 h. As shown in Figure 3.15, BQ released at 6 h was found to be 70.2 ± 1.2% and 90.3
± 1.5% for GM@BQ - Laser and GM@BQ + Laser, respectively. This observation
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Figure 3.15. NIR-triggered BQ release from various nano-assemblies analysed by RPHPLC.
indicates the non-specific BQ release from the mesoporous structure of the silica shell.
While (GM@BQ)L + Laser released 94.2 ± 1.3% of BQ, (GM@BQ)L - Laser showed only
a 48.9 ± 1.2% BQ released in a similar time frame suggested that the liposome acts as a
protective layer that reduces the non-specific release of the encapsulated BQ.
(GM@BQ)L-Glu + Laser demonstrated a similarly high BQ release of 95.8 ± 1.0%. Only
50.7 ± 1.6% of BQ was released in the absence of laser (Figure 3.15). The results revealed
that the liposome plays a role in reducing premature BQ release.
3.3.16 Intracellular antibacterial activity of nano-assemblies
The antibacterial activity of various nano-assemblies was evaluated by WST-8
colorimetric bacterial viability assay. The MIC was reported with respect to the
encapsulated BQ in the nano-assemblies at their MIC concentrations, as shown in Table
3.3.4. The MIC of bare BQ was 40 ± 1.5 ng/mL, and the MIC of (GM@BQ)L-Glu + Laser
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Table 3.3.4. MIC of the materials (MIC was reported with respect to
encapsulated BQ in the nano-assemblies). *
MIC (ng/mL)
BQ encapsulated in nano-assemblies

Materials
BQ
GM@BQ
GM@BQ + Laser
(GM@BQ)L-Glu

40 ± 1.5
25 ± 1.8*
15 ± 1.5*
30 ± 1.9*

(GM@BQ)L-Glu + Laser

8 ± 1.8*

was 8 ± 1.8 with respect to the encapsulated BDQ (Table 3.3.4). Results proved that
encapsulated BQ in (GM@BQ)L-Glu + Laser is 5 -fold efficacious than the free drug BQ.
The intracellular antimicrobial activity of nano-assemblies was tested in macrophages invitro by the micro broth dilution method. For that, macrophages were infected with Msmeg,
followed by the treatment with (GM@BQ)L-Glu ± Laser and BQ of various
concentrations. As shown in

Table 3.3.5, Free BQ treatment showed 40 ± 1.3 ng/mL.

Msmeg infected macrophages treated with (GM@BQ)L-Glu + Laser resulted in 4 ± 0.8
intracellular MIC, which was 10 times lower than free BQ. These results clearly indicated
that (GM@BQ)L-Glu + Laser is 10 -fold more efficacious than the free drug BQ.
To explore whether (GM@BQ)L-Glu could eliminate the intracellular Msmeg upon
NIR light irradiation, macrophages were infected by Msmeg, treated with (GM@BQ)LGlu ± Laser and BQ at various concentrations. The survival of intracellular bacteria was
measured by counting bacterial colony-forming units(CFU), as shown in Figure 3.16a. The
colony count images, as shown in Figure 3.16a, displayed the minimum inhibitory
concentration (MIC) of (GM@BQ)L-Glu + Laser was 4 ng/mL, and minimum biocidal
concentration (MBC) was 2 ng/mL. In contrast, at those MIC and MBC concentrations,

134

Table 3.3.5. Intracellular MIC of the materials (MIC was reported with respect to
encapsulated BQ in the nano-assemblies). *
Materials

Intracellular MIC (ng/mL)
BQ encapsulated in nano-assemblies

BQ

40 ± 1.3

GM@BQ

23 ± 1.1*

GM@BQ + Laser

10 ± 1.3*

(GM@BQ)L-Glu
(GM@BQ)L-Glu + Laser

28 ± 1.4*
4 ± 0.8*

(GM@BQ)L-Glu - Laser and free BQ showed growth of Msmeg. This clearly indicates
that (GM@BQ)L-Glu + Laser reduced and killed the intracellular Msmeg compared to that
in absence of NIR light and free BQ, indicating the efficient inhibition and killing of
intracellular Msmeg by (GM@BQ)L-Glu upon NIR light irradiation.
Furthermore, nano-assemblies' quantitative intracellular antibacterial efficacy was
studied using colony counts and expressed as a percentage of viable bacteria (Figure
3.16b). Intracellular Msmeg exposed to (GM@BQ)L-Glu + Laser at MIC concentration (4
ng/mL) exhibited 5 ± 2.1 % bacterial viability and (GM@BQ)L-Glu - Laser had 70 ± 4.1
% bacterial viability. This observation clearly indicated that laser irradiation is vital to the
antibacterial effect of the nano-assembly. Free BQ had 82 ± 4.6 % bacterial viability, which
clearly explained that (GM@BQ)L-Glu + Laser nano-assembly was efficacious as
compared to free BQ.
To further confirm the intracellular antibacterial activity of (GM@BQ)L-Glu,
LIVE/DEAD BacLight bacterial viability assays were carried out and visualized under a
confocal microscope to distinguish between dead (labeled in red) and live bacteria (labeled
in green) within macrophages after treatment (Figure 3.17). Free BQ and (GM@BQ)L-Glu
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Figure 3.16. Intracellular antibacterial activity. (a) Images of colony-forming unit (CFU)
for Msmeg recovered on agar plate after treatment with (GM@BQ)L-Glu ± Laser and free
BQ at various encapsulated BQ concentrations (2-10 ng/mL). (b) Percentage of viable
bacteria after treatment with the nano-assemblies at MIC concentration (4 ng/mL)with and
without laser irradiation. The data are presented as the mean ± SD (n=3). A **** represents
p < 0.001, indicating that data are statistically significant by one-way ANOVA compared
with free BQ.

+ Laser was incubated with Msmeg infected macrophage followed by stained with
SYTO9/PI, and results were observed through confocal microscopy. Msmeg infected
macrophage was not treated with any nano-assembly and hence showed green fluorescent
bacteria inside macrophage with no red fluorescent, indicating the viability of bacteria
inside the macrophage. Msmeg infected macrophages, when treated with BQ, displayed
intense green and less red fluorescence, indicating the presence of more live intracellular
bacteria than dead bacteria. In contrast, Msmeg infected macrophage, when treated with
(GM@BQ)L-Glu + Laser, had a higher amount of red fluorescence along with high
bacterial aggregation as indicated by the white arrows (rod-shaped bacteria with red
fluorescence inside the macrophage) clearly seen (Figure 3.17). This result reveals that
(GM@BQ)L-Glu + Laser has killed intracellular Msmeg.
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Figure 3.17. Confocal microscopic images of the viable (green) and dead (red)
intracellular Msmeg within macrophage after the treatment with the BQ, and
(GM@BQ)L-Glu + Laser.

3.3.17 HTNs@BQ triggered phagosome acidification and phagolysosome formation
in Msmeg infected macrophage
Mtb manipulates host immune response in two ways; (1) inhibition of phagosome
maturation/acidification (2) phagolysosome inhibition, thereby avoiding its killing. Under
normal conditions, the V-ATPase pump present on the cell membrane of the phagosome
pumps protons into the phagosome.146 This increases the acidity of the phagosome and is
called the maturation of phagosome or acidification of phagosome. 146 In the case of Mtb
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infection, Mtb releases the protein tyrosine phosphatase (PTPA) protein.147 PTPA protein
binds to a subunit of the V-ATPase pump, which inhibits the activity of the V-ATPase. 147
Hence, inhibits phagosome acidification and inhibits phagosome maturation. In common
bacterial infection, the fusion of phagosome with lysosome leads to the formation of the
phagolysosome.143 Upon initiation of this process-

increases ROS/RNS production,

bactericidal enzymes, peptidase, reduces pH. All these processes together kill intracellular
bacteria.143 However, in Mtb infection, phagolysosome formation is inhibited by Mtb. In
this process, the phagosome and lysosome are prevented from fusing. Also, intracellular
Mtb can inhibit ROS/RNS generation and prevent a decrease in pH. Therefore, Mtb can
survive inside a phagosome by inhibiting phagolysosome formation. 143 Recently, Tailleux
and co-workers reported that antibiotic bedaquiline (BQ) activates host immune response
by promoting phagosome acidification and phagolysosome formation. 153 Therefore, we
hypothesize that our BQ loaded HTNs also induce phagosome acidification and
phagolysosome formation upon the release of BQ, as shown in Scheme 3.3.
After treating with (GM@BQ)L-Glu + Laser, the activation of macrophages can be
verified

by confocal

microscopy.

First,

we

have observed

the

phagosome

maturation/acidification by treating Msmeg infected macrophages with free BQ and
(GM@BQ)L-Glu ± Laser treatment followed by staining with acridine orange (AO) dye.
Macrophage alone and Msmeg infected macrophages were treated directly with AO dye.
In AO-stained cells, the acidic compartments were seen to be bright red fluorescence, the
intensity of the fluorescence being proportional to the degree of acidity. The nucleus and
cytoplasm emitted green fluorescence upon excitation with the same wavelength of light.
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Figure 3.18. Phagosome maturation in Msmeg infected macrophages (a) by BQ and
(GM@BQ)L-Glu ± Laser in Msmeg infected macrophage evaluated by Acridine orange
staining. Acridine orange stains nucleus and cytoplasm as green and AVOs as bright red.
Scale bar 50
. (b) Quantification estimation of red mean fluorescence intensity (MFI)
of macrophage and Msmeg infected macrophage treated with BQ and (GM@BQ)L-Glu ±
Laser. The data are presented as the mean ± SD (n=3). A **** represents p < 0.001,
indicating that data are statistically significant by one-way ANOVA compared with free
BQ.

As shown in Figure 3.18a, macrophages treated with AO stain displayed bright red
fluorescence, indicating that macrophages without Msmeg infection have acidic
compartments, thus capable of acidifying phagosome and killing bacteria. In contrast, the
Msmeg infected macrophage showed only green fluorescent and no red fluorescence,
which indicated that the macrophage had been arrested by Msmeg and stopped phagosome
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Figure 3.19. Phagolysosome formation in Msmeg infected macrophage. Confocal
microscopy imaging of (a) Colocalization of (GM@BQ)L-Glu (green), ER-Tracker (red),
Hoechst-stained nucleus, and Msmeg (blue) in the same vesicles in macrophages after
treatment with (GM@BQ)L-Glu + Laser. (b) Colocalization of (GM@BQ)L-Glu (green),
Lysosome tracker D99 (red), Hoechst-stained nucleus, and Msmeg (blue) in the same
vesicles in macrophages after treatment with (GM@BQ)L-Glu + Laser. Scale bar 50

maturation/acidification. Msmeg infected macrophage, when treated with BQ and
(GM@BQ)L-Glu - Laser showed less red fluorescence indicative of less acidity. However,
after treatment with (GM@BQ)L-Glu + Laser, the macrophages displayed very strong and
bright red fluorescence, suggesting that (GM@BQ)L-Glu + Laser has enhanced
phagosome acidification within Msmeg infected macrophages. The pH changes from
neutral (visualized as green) to acidic (red color), indicating the recruitment of vacuolar VATPases on the phagosome membrane and the progression of phagosome maturation. 342,
343

The quantitative estimation of red fluorescence intensity as shown in Figure 3.18b is

consistent with confocal images (Figure 3.18a).
Phagolysosome formation induced by coumarin-6-labeled (GM@BQ)L-Glu +
Laser was investigated using confocal microscopy. For that, Msmeg infected macrophages
were exposed to (GM@BQ)L-Glu + Laser. As shown in Figure 3.19, the cell nucleus and
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Scheme 3.3. Working hypothesis of how (GM@BQ)L-Glu induce (a)
phagosome maturation/acidification and, (b) phagolysosome formation.

Msmeg were stained with Hoechst (blue), ER-Tracker Red, and LysoTracker Red D99
dyes, which are highly selective for acidic organelles, were used as pH-dependent markers
of endosomal and lysosomal compartments, respectively. The coumarin-6-labeled
(GM@BQ)L-Glu were seen in green fluorescence. After 6 h of incubation with coumarin6-labeled (GM@BQ)L-Glu + Laser, significant colocalization of green fluorescent nanoassemblies into endosome and lysosome compartment as seen (see merged 1 Figure 3.19).
The merged image 2 in Figure 3.19 showed colocalization of nano-assemblies in both
endosomal and lysosomal compartments surrounding the intracellular Msmeg in
macrophage. Most bacteria reside in the arrested phagolysosomal compartment during Mtb
infection, and it is necessary to deliver the nano-assemblies in this environment. 344 Our
data suggest that nano-assembly (GM@BQ)L-

-Glucan-

dectin-1(ligand-receptor) mediated endocytosis. Furthermore, the liposomal coating of the
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nano-assembly (GM@BQ)L-Glu promotes facile uptake and subsequent trafficking deep
into intracellular compartments (Scheme 3.3). The in-vitro drug release profile of the
(GM@BQ)L-Glu validates that the thermo-sensitive liposomal shell melts, and BQ is
released upon NIR laser irradiation. The release of BQ induces phagosome maturation and
phagolysosomal formation (Scheme 3.3).
3.3.18 PT induces cell death within Msmeg infected macrophage
Two different forms of cell death are commonly observed in Mtb infected
macrophages (i) Necrosis: a death modality defined by cell lysis. Necrosis is a mechanism
used by bacteria to exit the macrophage, evade host defenses, and spread. (ii) Apoptosis: a
form of cell death that maintains an intact plasma membrane.345 Therefore, apoptosis of
infected macrophages is a promising host defense mechanism to clear intracellular Mtb.
By sequestering Mtb within apoptotic cells, the spread of bacteria to healthy cells can be
prevented.346, 347 It has been previously studied that NIR laser-induced PTT causes cell
death via apoptosis in macrophage and cancer cells.348, 349 Activation of caspase-3 is an
important event during apoptosis. Thus, caspase expression was analyzed by fluorescence
microscopy using CellEvent Caspase-3/7 Green Detection Reagent in order to confirm cell
death within Msmeg infected macrophage. Caspase-3/7 expression was analyzed in the
Msmeg infected macrophage after (GM@BQ)L-Glu mediated PTT in order to confirm cell
apoptosis (Figure 3.20). The fluorescence images as shown in Figure 3.20a displayed little
green fluorescence, when Msmeg infected macrophage was treated with BQ and
(GM@BQ)L-Glu – Laser. In contrast, the strong green fluorescence was observed when
Msmeg infected macrophage treated with (GM@BQ)L-Glu + Laser which clearly
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Laser as control

(GM@BQ)L-Glu
- Laser

BQ

(GM@BQ)L-Glu
+ Laser

b

Figure 3.20. Apoptosis of Msmeg infected macrophages by Caspase-3/7 assay. (a)
Macrophages are shown in bright field, and green fluorescent images correspond to the
expression of Caspase-3/7. (b) Quantitative analysis of green fluorescence density,
indicative of Caspase-3/7 expression for cells treated with nanomaterials, was detected by
a fluorometric assay. The data are presented as the mean ± SD (n=3). N.S = nonsignificant. A ** represents p < 0.1, and **** represents p < 0.001, indicating that data
are statistically significant by one-way ANOVA compared with free BQ.

suggested PT induced apoptosis as compared to (GM@BQ)L-Glu – Laser treatment. As
shown in Figure 3.20b, the quantified data from the fluorescence images presents a 3-fold
increase in green fluorescence intensity for (GM@BQ)L-Glu + Laser compared to
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Figure 3.21. Intracellular antibacterial activity after undergoing Caspase-3/7 assay. (a)
Images of colony-forming unit (CFU) for Msmeg recovered on agar plate after treatment
with (GM@BQ)L-Glu ± Laser and free BQ at various encapsulated BQ concentration (2
and 4 ng/mL).(b) Percentage of viable bacteria after treatment with the nano-assemblies at
MIC (4 ng/mL) and MBC (2 ng/mL) concentration with and without laser irradiation. The
data are presented as the mean ± SD (n=3). A **** represents p < 0.001, indicating that
data is statistically significant by one-way ANOVA compared with free BQ.

(GM@BQ)L-Glu – Laser. In comparison to free BQ, (GM@BQ)L-Glu + Laser represented
a 7-fold increase in green fluorescence intensity. Since caspase-3/7 indicates apoptotic cell
death activation, the data verify that the peak of apoptotic cell death occurs after exposure
to (GM@BQ)L-Glu + Laser.
To confirm the viability of bacteria after inducing apoptosis, treated macrophages
were lysed, and lysates were plated on agar plates. The colony count images of treatment
with (GM@BQ)L-Glu ± Laser, and BQ at MIC (4 ng/mL) and MBC (2 ng/mL)
concentration of (GM@BQ)L-Glu + Laser were shown in Figure 3.21. The photographs in
Figure 3.21a displayed that NIR laser as control has an abundance of Msmeg growth,
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indicating that NIR laser alone was not killing intracellular Msmeg. Treatment with
(GM@BQ)L-Glu + Laser at MIC (4 ng/mL) concentration had inhibited intracellular
Msmeg and at MBC (2 ng/mL) concentration completely eradicated intracellular Msmeg.
Figure 3.21b showed the percentage viability of Msmeg within macrophage at MIC (4
ng/mL) and MBC (2 ng/mL) concentration of (GM@BQ)L-Glu ± Laser and BQ. Those
were calculated from the counting colony-forming units. Msmeg infected macrophages,
after treatment with (GM@BQ)L-Glu + Laser at MBC concentration, had only 1 % viable
of intracellular Msmeg. When treated with (GM@BQ)L-Glu - Laser viable bacteria was at
45%, and with free drug BQ only, the viable bacteria was at 70%. These results demonstrate
the targeting ability and high antibacterial efficacy of the laser-irradiated (GM@BQ)LGlu, which kills 99 % intracellular Msmeg.
3.3.19 Cytotoxicity
The cytotoxic effect of nano-assemblies and laser on healthy macrophage and
Msmeg infected macrophage were carried out by MTT assay. Msmeg infected macrophages
were incubated with various concentrations (1-50 g/mL) of GM, BQ, and (GM@BQ)LGlu ± Laser. As shown in Figure 3.22a, in the absence of NIR laser GM and (GM@BQ)LGlu did not show any cytotoxicity. A similar result was found after treatment with BQ.
However, the cell viability of Msmeg infected macrophage after treatment with GM and
(GM@BQ)L-Glu + Laser was nano-assemblies’s concentration-dependent (Figure 3.22b).
(GM@BQ)L-Glu + Laser with higher concentration (50 g/mL) showed only 1% cell
viability of Msmeg infected macrophage, suggesting that intracellular Msmeg were killed
after treatment.
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Figure 3.22. Cyto-phototoxicity of nano-assemblies. (a,b) Msmeg infected macrophage cell
viability after treating with GM (carrier), BQ, and (GM@BQ)L-Glu ± Laser. (c) Healthy
macrophage cell viability upon exposure to ± Laser and (GM@BQ)L-Glu ± Laser.

This result supports the fact that the apoptosis of infected macrophages is an innate defense
to prevent bacteria from spreading to healthy cells and eventually clearing intracellular
bacteria.350-352
We also observed the cyto-phototoxicity of nano-assemblies on healthy
macrophages. For this experiment, healthy macrophage without Msmeg infection was
exposed to ± Laser and (GM@BQ)L-Glu ± Laser. As shown in Figure 3.22c, NIR laser146

treated macrophages and (GM@BQ)L-Glu ± Laser treated macrophages did not show any
cyto-phototoxicity. Healthy macrophages are professional phagocytes capable of inducing
phagosome acidification and phagolysosome formation.353 Hence (GM@BQ)L-Glu ±
Laser nano-assemblies were taken up by lysosome and degraded. This is why we did not
observe any cyto-phototoxic effect on the healthy macrophage.
3.4

Conclusion
In summary, we screened host-targeted nano-assemblies (HTNs) (a) to favorably

modulate the response of macrophages through specific ligand-receptor binding so that it
promotes higher cellular uptakes of HTNs and subsequently enhance ROS/RNS, (b) to
induce killing of intracellular Msmeg via NIR-triggered drug BQ release that can promote
host defense mechanism and (c) to eradicate intracellular Msmeg by inducing cell death of
Msmeg infected macrophages. For host (macrophage) targeting, host-specific ligands, such
-glucan (Glu), and folic acid (FA), were investigated. Free ligands and receptor binding
-Glucan conjugated HTNs have a
stronger binding affinity towards dectin-1 receptors than FA-

-

Glucan was selected as a host-targeting ligand for further study. Next, we systematically
studied the impact of varying sizes and ligand density on binding affinity. The nanoassemblies were composed of a gold nanorod (GNR) core (act as a photosensitizer) and
mesoporous silica (MS) shell containing TB antibiotic (BQ). Then after assembly would
be wrapped within a thermo-sensitive liposome (L) shell that has tagged with host targeting
ligands. Upon NIR laser exposure, the designed HTNs released BQ and activated
macrophages by enhancing phagosome maturation and inducing phagolysosome
formation. This is how (GM@BQ)L-Glu + laser altered host (macrophage) immune
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mechanism. BQ encapsulated in (GM@BQ)L-Glu was found to be 10-fold more
efficacious intracellularly compared to free drug equivalent. The final nano-assembly was
capable of targeting and killing 99 % intracellular Msmeg residing within macrophages.
Our work will collectively impact the field by investigating the essential roles of cuttingedge nanotechnology in host-targeted therapies for treating intracellular bacterial infection.
This may potentially reduce the drug dosage required, shorten the duration of treatment,
and reduce the emergence of drug resistance.
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4

CHAPTER 4. TARGETED DELIVERY OF LIPOSOMAL HYBRID GOLD
NANO-ASSEMBLY FOR ENHANCED PHOTOTHERMAL THERAPY
AGAINST LUNG CARCINOMAS

4.1

Introduction
Despite the tremendous efforts devoted to identifying an effective approach to fight

against cancer, precise cancer treatment is still a challenging task. Current therapeutic
mainstays available for cancer treatment, such as chemotherapy, surgery, and radiotherapy,
are known for their significant after-effects.354 These conventional therapies are not site
(tumor) specific and cause detrimental effects on surrounding cells, leading to further
complications such as toxicity, limited bio-distribution, and poor healing. 355-357 Thus, it is
crucial to develop an effective solution that can tackle the fundamental challenges of these
conventional treatments and provide targeted tumor-specific outputs without any
substantial damage to the viability of the surrounding tissues.
Nanomaterials that respond to externally applied physical stimuli such as light,
ultrasound, and magnetic fields have shown great potential for controlled and targeted
delivery of therapeutic agents by harnessing the unique optical, magnetic, and
physicochemical properties of metallic inorganic nanoparticles. In recent years,
photothermal therapy (PTT) has been widely explored. In PTT, nanomaterials act as a
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photothermal agent due to their optical properties in the near-infrared (NIR) region.
Photothermal heating occurs due to the absorption of NIR light by an ensemble of electrons
on the surface of specific conductive nanomaterials and the subsequent dissipation of that
energy as heat. A heat source is applied to the site of interest during PTT, and thermal
ablation is used to kill tumor cells.358 However, as a standalone treatment option, the use
of PTT is limited due to the lack of effect on metastatic abrasions outside of the area of
irradiation, which may lead to disease recurrence. To overcome these limitations and
increase PTT's efficacy, researchers have combined the use of NP-mediated photothermal
therapy with secondary therapeutic strategies.359 In nanoparticle-mediated PTT,
photoactive NPs are delivered to the tumors. When these NPs are exogenously irradiated
with laser light, synchronized oscillation of the conduction-band electrons occurs, which
generates heat. Increased temperature in the tumor causes cellular damage, such as protein
denaturation, DNA repair deformities, changes in the permeability of the cell membrane,
and subsequent tumor regression without damaging the surrounding healthy tissue. 360-362
Plasmonically active metal nanoparticles, such as gold nanoparticles (GNPs), black
phosphorus, carbon tubes, and polydopamine nanoparticles, are particularly effective
photothermal agents because of their large absorbance cross sections and tunable optical
properties, and highly efficient conversion of light into heat. 178 Colloidal gold has been
shown to have localized surface plasmon resonance (LSPR), which means that gold
nanoparticles can absorb light at specific wavelengths, resulting in photoacoustic and
photothermal properties, making them useful for hyperthermic cancer treatments and
medical imaging.363 By modifying the shape and size of GNPs can change their LSPR
photochemical activities and their photothermal and photoacoustic properties. 363 Gold
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nanostructures have many advantages that make them suitable for photothermal cancer
treatment, including being administered locally while minimizing non-specific
distribution, low cytotoxicity, the ability to be activated via near-infrared (NIR) laser light,
and the ability to penetrate deep into biological tissues.363 They can also be modulated to
create multifaceted cancer PTT and drug delivery systems, and hence gold nanostructures
have been a promising photothermal candidate for nanocarrier-mediated PTT applications
in cancer therapy.364 GNPs can absorb near-infrared (NIR) light through the surface
plasmon oscillation of free electrons.365 Additionally, by altering the synthesis conditions,
the aspect ratio of the nanoparticles can be controlled, which leads to precise control over
the absorption spectrum of GNPs. This controlled, fine-tuned regulation permits the
nanoparticles to absorb light of a particular wavelength and to exhibit excellent specificity
as a photothermal agents.361-366 Among available gold (Au) nanoplatforms, Au
nanoshells,367 Au nanospheres,368 Au nanorods,369 and Au nano-cages370 are used most
extensively in PTT. Studies have also exhibited the improved photothermal response of
gold nanocarriers with compatible outer shell coatings.371-374 Chen et al. reported that the
GNPs conjugated to the anti-cancer drug methotrexate (MTX) have demonstrated high
levels of tumor retention and enhanced therapeutic efficacy in a lung carcinoma mouse
model, compared with an equal dose of free MTX. Another study by Zhang et al. has
loaded doxorubicin on mesoporous silica-coated gold nanorods for light-mediated drug
delivery carriers for lung cancer treatments. The synergistic effects of chemotherapy and
hyperthermia-based treatments have been shown to increase cancer cell death. The
multifunctional polymeric nanoparticles formulation was developed by Cheng et al. for
combined chemotherapy and PT-based lung cancer treatment. 375 They have developed a
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complex nano-assembly in which paclitaxel-loaded polymeric nanoparticles were
conjugated with amine-terminal iron oxide nanoparticles (Fe 3O4) and quantum dots (QDs)
to obtain QD/Fe3O4/Taxol-loaded polymeric nanoparticles with optical and MR imaging
functionalities.375 Subsequently, poly(styrene sulfonate) (PSS)-coated gold nanorods were
introduced to attach to the QD/ Fe3O4/Taxol-loaded polymeric nanoparticle surface. These
nano-assemblies simultaneously achieve the photothermal ablation of tumor tissue and
destroy spherical polymeric nanoparticles, efficiently releasing encapsulated Taxol. 375
However, all of these reported treatments still lack a specific targeting ability towards
tumor cells. Therefore, the incorporation of small targeting molecules provides
unprecedented opportunities to design targeted nanocarriers to enhance efficiency and
reduce adverse effects. In contrast to normal cells, cancer cells overexpress multiple
surface receptors. To exploit this concept, we used a dual ligand-targeting approach to
develop a target-specific drug delivery nano-assembly.
In previous work, we have utilized a similar nano-assembly for the targeted
antibiotic delivery.100 Utilizing this system, the antibacterial activity was found 20 folds
more efficacious than the free drug equivalent.100 Gold nanorods (GNRs) were coated with
mesoporous silica shells (GM) that enhanced drug loading capability. Anticancer drug
doxorubicin (Dox) was loaded into a mesoporous silica shell (GM@Dox). Doxorubicin is
an anthracycline antibiotic known as a novel antitumor drug to treat various solid malignant
tumors. However, free doxorubicin has its own side effects when used in cancer therapy.
376

To reduce the side effects and improve the nano-assemblies' efficacy and stability,

GM@Dox was encapsulated further in a liposome. In liposome preparation, a thermosensitive phospholipid (DPPC) was used in a higher molar ratio, making this liposome
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Scheme 4.1. Proposed scheme for how nano-assemblies induce apoptosis in lung cancer
cells.
thermo-sensitive since the melting point of DPPC is ~ 43 °C. Encapsulating nanoassemblies inside a liposome also offers a controlled drug release and prevents any
premature drug release before the nano-assembly approaches the target site. 377 A nearinfrared dye, IR 780, was used as a photosensitizer to enhance the photothermal activity
with increased reactive oxygen species (ROS)-generation under laser irradiation. Hence,
the IR 780 dye was loaded with the liposome, and then GM@Dox was encapsulated inside
the liposome. The nano-assemblies were abbreviated as [(GM@Dox) LI]. Following that,
cationic peptide GE-11 and folic acid were conjugated to the surface of the nanoassemblies to specifically target the epidermal growth factor receptor (EGFR) and folate
receptor, respectively, which are overexpressed on cancer cells. This dual ligand-targeting
approach enhances the cancer-targeting specificity, minimizes non-specific attacks on
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surrounding tissues, and improves the therapeutic efficacy of anticancer drugs by
enhancing cellular uptake.210 The final nano-assemblies are abbreviated as [(GM@Dox)
LI]-PF, where GE-11 peptide is indicated as P and folic acid as F. The developed nanoassemblies were tested in-vitro and showed a 20-fold increase in effectiveness compared
to free Dox. [(GM@Dox) LI]-PF represents a simple, safe, and effective nanocarrier, which
can be used for a combination of targeted drug delivery and PTT treatment.
As shown in Scheme 4.1., we anticipate that our engineered nano-assemblies
[(GM@Dox) LI]-PF would effectively bind to cancer cells through receptors-directed
clathrin-mediated endocytosis pathway by targeting ligands GE-11 and folic acid. Then
upon NIR laser irradiation, the heat generated by GNR and IR 780 dye would melt the
thermo-sensitive liposome, to release encapsulated Dox. The chemo-photothermal effect
of the nano-assemblies would activate apoptotic cell death events, such as increasing ROS
production, reducing GSH and cellular ATP. Combinedly this would increase
mitochondrial dysfunction, to cause apoptosis through caspase activation.

4.2

Experimental

4.2.1

Materials and Instruments
Chemicals used for gold nanorod and mesoporous silica shell synthesis were

similar as described in Section 2.2.1. Coumerine-6, 4’,6’-diamidino-2-phenylindole
(DAPI,

-Glucan, succinic anhydride, Phorbol 12-myristate 13-acetate

(PMA) were purchased from Sigma-Aldrich (St. Louis, USA). Lipids such as 1,2dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG 2000
amine), used for liposome preparation were similar as explained in section 2.2.1.
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Doxorubicin, chlorpromazine nystatin, and wortmannin were purchased from SigmaAldrich (St. Louis, USA). GE11 peptide (Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-AsnVal-Ile) was obtained from Phoenix Pharmaceuticals, Inc (California, USA).
A549 lung cancer cells were purchased from American Type Culture Collection
(ATCC, CCL-185) (Virginia, USA). The CellEvent™ Caspase 3/7 Green Detection
Reagent, Live/deaad® viability kit, MitoProbe™ JC-1 assay kit, Tubulin Tracker™ Green
Detection kit, and Scientific and Invitrogen™ ATP Determination kit was purchased from
ThermoFisher Scientific (New Jersey, USA). Fluorometric intercellular ROS kit and MES
buffer were purchased from Sigma-Aldrich (St. Louis, USA). The GSH-Glo™ Glutathione
assay was purchased from Promega Corporation (Wisconsin, USA). (3- (4,5Dimethylthiazol-2-yl)-2,5-

-

diamidino-2-phenylindole (DAPI), and Calcein-AM were purchased from ThermoFisher
Scientific (Massachusetts, USA). Ham’s F- 12K nutrient mixture with L-glutamine (F12K, 1X), fetal bovine serum (FBS, 10%), trypsin EDTA (2.21 mM), and penicillinstreptomycin (Pen-Strep, 1X) were obtained from Corning (New York, USA). The
instruments were used for characterization of nano-assemblies were similar as described in
Section 2.2.1.
4.2.2

Synthesis of gold nanorods (GNRs)
GNRs were synthesized as described in chapter 2 (See Section 2.2.2).

4.2.3

Synthesis of mesoporous silica shell coated gold nanorods (GMs)
GMs were synthesized as described in chapter 2 (See Section 2.2.3).

4.2.4

RITC-labelled GMs synthesis
RITC-labelled GMs were synthesized as explained in chapter 2 (See Section 2.2.4).
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4.2.5

Surface area and pore volume determination of nano-assemblies
The surface area of GMs and GM@Dox were determined using the

model.
4.2.6

Dox encapsulation in GMs
GMs (40 mg) were mixed with Dox (10 mg) in 20 mL of water while stirring

overnight at 37 °C. The ratio of GMs and Dox used in the entire study was 4:1 w/w (GMs
40 mg: Dox 10 mg). The Dox-loaded GM samples (GM@Dox) were collected by
centrifugation at 12,000 rpm for 10 min and vacuum dried to obtain a dry powder. The
encapsulation efficiency and drug loading of Dox in GM@Dox were determined by using
a standard calibration curve. To construct a standard calibration curve for Dox, Dox (1 mg)
was resuspended in 1 mL of phosphate-buffered saline (PBS) and then diluted to
concentrations of 1, 5, 10, 2
by recording the absorbance value of Dox at 480 nm using UV-Vis spectroscopy, as shown
in Appendix Figure C.1.

(4.1)
=

× 100%

(4.2)
=

× 100%
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4.2.7

Loading of IR 780 dye inside the liposome
IR 780 dye was loaded in the liposome preparation step. Since IR 780 is

hydrophobic, it was dissolved with the lipids used to prepare the liposome. Liposomes were
prepared by a previously published lipid film-based method. 13 Briefly, DPPC (85% molar
ratio), cholesterol (10% molar ratio), DSPE-PEG(2000) amine (5% molar ratio), and IR
780 dye (0.8 mg) was dissolved in 2 mL of chloroform and evaporated in a rotary
evaporator, yielding a thin lipid film. This lipid film was rehydrated in 2 mL of PBS (0.5
x, pH 7.4) and extruded 15 times through a polycarbonate membrane (pore size 800 nm)
using a mini extruder. Here, the prepared liposome was a thermo-sensitive liposome, as the
amount of DPPC used in liposome preparation was the highest in molar ratio compared to
cholesterol and DSPE-PEG(2000) amine. As previously studied in our recent paper, these
liposomes become permeable at temperatures ~ 50 °C. 100 To check the photothermal effect
of IR 780, two different ratios of lipid: IR 780 (100:1 and 100:5 weight ratio) were prepared
using a similar lipid film-based method. The resultant product, liposome-IR 780 (LI), was
stored at 4 °C until further use.
4.2.8

Encapsulation of GM@Dox inside LI
To prepare [(GM@Dox) LI], 1 mg of GM@Dox was resuspended in LI (2 mL, 10

mg/mL) in PBS and mixed for 20 min in an ice bath. [(GM@Dox) LI] particles were
separated from empty liposomes by centrifugation at 12,000 rpm for 5 min with repeated
(3x) washing in PBS. The resulta
until further use.
The IR-780 loading and encapsulation efficiency was calculated using a standard
calibration curve of IR 780 at 780 nm using microplate reader as shown in Appendix Figure
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C.2. The Dox loading and encapsulation efficiency were determined by a standard
calibration curve of Dox, as shown in Appendix Figure C.1.
4.2.9

Conjugation of GE-11 and FA on [(GM@Dox) LI]
GE-11 and folic acid (FA) were conjugated to the liposomal shell by amide

conjugation. EDC was used to activate the carboxylic groups of GE-11 peptide and FA.
Once activated, these groups would react with the amine group of DSPR-PEG (2000)
amine in the TSL shell. GE-11 (435 L) and FA (30 L) were dissolved in 0.1 M MES
containing 0.5 M NaCl at pH 6.0 (reaction buffer) and then incubated with a 10-fold molar
excess of EDC (pH = 4.0) and 25-fold molar excess of sulfo-NHS for 30 min. Here the
concentration of GE-11 to FA was kept 100:1 molar ratio. Amine group-containing
liposomes [(GM@Dox) LI] were added to the solution having carboxylic acid-activated
GE-11 and FA and then reacted for 24 h at 37 °C. The molar ratio of GE-11:liposome was
kept at 10:1. After 10 h, the reaction mixture was purified by centrifugation at 10,000 rpm
for 15 min at 25 °C to remove excess unreacted EDC. The purified [(GM@Dox) LI]
conjugated with peptide (GE-11) and FA was abbreviated as [(GM@Dox) LI]-PF. This
Dox loading and encapsulation
efficiency were determined by a standard calibration curve of Dox as shown in Appendix
Figure C.1. Similarly, IR 780 loading and encapsulation efficiency were calculated by the
standard calibration curve of IR 780 as shown in Appendix Figure C.2.
4.2.10 Quantification of peptide GE-11 conjugation on nano-assemblies
The amount of peptide GE-11 bound on the surface of nano-assemblies was

-PF (1
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mg/ml), and [(GM@Dox) LI] (1 mg/ml, served as blank). After 60 min of incubation, the
absorbance was measured at 562 nm using a microplate reader. The results were compared
to a standard calibration curve of GE-11 solution in PBS (pH=7.0), ranging from 1.0-10
n Appendix Figure C.4.
4.2.11 Quantification of folic acid on nano-assemblies
The amount of folic acid conjugated onto the nano-assemblies was quantified by
constructing a calibration curve of folic acid at 310 nm using a microplate reader. The
L of [(GM@Dox) LI]-PF (1 mg/ml) and [(GM@Dox) LI] (1 mg/mL,
served as blank) were measured using a microplate reader. The results were compared to a

in Appendix Figure C.3.
4.2.12 TGA analysis of nano-assemblies
TGA was carried out under argon (99.999%), where dried GM, GM@Dox,
[(GM@Dox) LI], and [(GM@Dox) LI]-PF (ca. 1 mg) were heated at a rate of 5 oC/min to
100 °C and then kept isothermal at 100 oC for 15 min followed by ramping 5 oC/min to
700 °C. The Dox loaded in GM was calculated by analyzing the weight loss difference
between GM and GM@Dox. Similarly, the LI content was analyzed by measuring the
weight loss difference between GM@Dox and [(GM@Dox) LI]. Finally, the amount of
GE-11 and folic acid was calculated by measuring the weight loss difference between
[(GM@Dox) LI] and [(GM@Dox) LI]-PF.
4.2.13 Stability analysis of nano-assemblies
The stability studies were carried out by following the protocol in our previously
reported study.100 Briefly, GM and [(GM@Dox) LI]-PF solution were stored at 37 ° C in
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cell culture media for 5 days. The nano-assemblies were monitored daily, and their stability
was characterized by UV absorbance to track the longitudinal surface plasmon resonance
(LSPR) intensity, aggregation index (AI), and zeta potential to monitor the change in
surface charge.
4.2.14 NIR laser irradiation studies
The laser setup is explained in detail in chapter 2 (See Section 2.2.11) and our
previously reported study.100 First, the enhanced photothermal effect due to GNR and IR
780 was evaluated by comparing PT effects of various nano-assemblies such as GM@Dox,
LI, and [(GM@Dox) LI]-PF. All three nano-assemblies were exposed to an 808 nm NIR
laser (350 mW) for 15 min, and the changes of temperature were recorded using the
thermocouple monitor.
Furthermore, various weight concentrations of [(GM@Dox) LI]-PF ranging from
10, 50, 70, and 100 g/mL (calculated with respect to the weight of GM) were irradiated
with the 808 nm NIR laser (350 mW) for 15 min. Finally, two different concentrations of
liposome: IR 780 (100:1 and 100:5 weight ratio) were also irradiated with the 808nm NIR
laser (350 mW) for 15 min to investigate the role of IR 780 in photothermal activity.
4.2.15 NIR responsive in-vitro drug release of nano-assemblies
1 mg of [(GM@Dox) LI]-PF (having 50 g of Dox/mg of nano-assemblies) was
suspended in 3 mL of PBS buffer at pH 7.5 and 5.5 (release media). The nano-assemblies
were incubated at 37 °C for 120 min with or without laser irradiation for 15 min. (808 nm,
350 mW). At the pre-determined time point, the samples were taken out and centrifuged at
15,000 rpm for 15 min. The supernatant was collected and replaced with the same volume
of fresh, prewarmed (37 oC) release media. The pellet was resuspended in the new release
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media and incubated further. The collected supernatant was quantified by using a standard
calibration curve for Dox.
A similar experiment was carried out for GM@Dox ± Laser, [(GM@Dox) LI] ±
Laser, and [(GM@Dox) LI]-PF ± Laser to study the drug release profile of different nanoassemblies. Various nano-assemblies (having 50 g of Dox/mg of nano-assemblies) were
suspended in 3 mL of PBS buffer at pH 5.5 then incubated at 37 °C for 6 h, with or without
808 nm NIR laser irradiation (350 mW) for 15 min. At the indicated time point, samples
were taken out and then centrifuged, and the supernatant was collected and replaced with
prewarmed release media. The pellet was resuspended in the new release media and further
incubated. The Dox release was quantified from a standard calibration curve of Dox.
4.2.16 Intracellular trafficking of nano-assemblies in A549 cells
Calcein AM and DAPI were utilized to label the cytoplasm and nucleus of A549
cells, respectively. A549 cells were seeded in 2-well chamber slides and cultured overnight
with a density of 1 × 103 cells/well. Then, the cells were treated with [(GM@Dox) LI]-PF
(having 50 g of Dox/mg of nano-assemblies) for 3 h. The cells were cultured for another
3 h following 808nm NIR laser (350 mW) irradiation for 15 min. Afterward, the cells were
washed twice with PBS and subsequently incubated with Calcein AM and DAPI for 30
min at 37 °C. After washing twice with PBS, the cells were observed by a fluorescence
microscope. The experiments were performed twice, with and without Laser. Similarly, to
study the targeting ability of folic acid and GE-11 peptide, the intracellular uptake between
RITC-GM@Dox and RITC-[(GM@Dox) LI]-PF was carried out for 6 h, washed with PBS,
then observed by a fluorescence microscope.
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4.2.17 Cellular uptake mechanism of nano-assemblies
The cellular uptake mechanism of GM@Dox and [(GM@Dox) LI]-PF in A549
cells was determined under different endocytosis-inhibited conditions. The cells were
seeded into 24-well plates at a density of 1×103 cells/well for 24 h and then pre-treated
with different endocytosis inhibitors for 30 min. The final concentration of specific

RITC-GM@Dox and RITC-[(GM@Dox) LI]then lysed with 0.5% Triton X-100 in 0.2 M NaOH solution. A fluorescence microplate
reader was used to measure the red fluorescence intensity of RITC-GM@Dox and RITC[(GM@Dox) LI]-PF with excitation and emission wavelengths set at 544 and 576 nm,
respectively. The cellular uptake efficacy was expressed as the test wells' fluorescence
percentage over the control wells.
4.2.18 NIR-triggered cellular drug release of nano-assemblies
A549 cells were seeded in 2-well chambered cover glasses with a density of 1 ×
103 cells/well. After being incubated overnight at 37 °C, the medium was replaced by a
fresh medium containing [(GM@Dox) LI]-PF (having 50

g of Dox/mg of nano-

assemblies) and incubated for 3 h. After the 3 h incubation, the cells were exposed to an
808 nm NIR laser (350 mW) for 15 min. The cells were washed with PBS (2x) and imaged
at 0 and 15 min using an inverted fluorescence microscope. The red fluorescent intensity
from Dox was used to observe the NIR-triggered Dox release. The mean fluorescent
intensity of the released intracellular Dox was quantified using Fiji-win64 software.
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4.2.19 Cell cytotoxicity and phototoxicity studies
A549 cells were seeded in a 24-well plate (1×103 cells/well) and incubated for 24
h. The cells were treated with free Dox, GM@Dox, [(GM@Dox) LI] and [(GM@Dox)
LI]-PF (with varying encapsulated Dox concentrations inside the nano-assemblies: 1, 5,
10, 25, and 50 g/mL) and incubated for 3 h with 5% CO2 and 37 °C. A549 cells were
treated with GM carriers with varying concentrations of 1, 5, 10, 25, and 50 g/mL. After
3 h of incubation, the cells were irradiated with 808nm laser (350 mW) for 15 min and
further incu

g/mL) was added to each well, and

the plate was further incubated for 3 h. The culture medium in each well was replaced with
ted
without NIR laser after incubating with nano-assemblies. The percentage viability was
calculated by comparing untreated cells to treated cells, and the absorbance was measured
at 590 nm using a plate reader.
4.2.20 Live-dead assay
A549 cells were cultured in a 24-well plate (1×103 cells/well). When the cells
reached 80% confluency, the cells were incubated with free Dox, GM@Dox, [(GM@Dox)
LI], and [(GM@Dox) LI]-PF (having 50

g of Dox/mg of nano-assemblies) for 3 h.

Similarly, the cells were treated with 50 g /mL of GM carriers. After 3 h of incubation,
the cells were irradiated with 808nm laser (350 mW) for 15 min and further incubated for
3 h. Then, cells were washed twice with cold PBS and incubated for 30 min with the livedead reagent (2 µM Calcein AM and 4 µM ethidium bromide) according to the
manufacturer’s instructions. The samples were washed twice with PBS and imaged by
fluorescence microscopy.
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4.2.21 Intracellular ROS determination
The generation of reactive oxygen species (ROS) in cells was measured using a
ROS-sensitive fluorescent dye, 2,7-dichlorodihydrofuorescein diacetate (DCFH-DA), by
the previously reported method.378 This dye can be oxidiz

-dichlorofuorescein

(DCF) by ROS, which exhibits increased green fluorescence intensity. Briefly, A549 cells
(1×103 cells/well) were treated with free Dox, GM@Dox, [(GM@Dox) LI], and
[(GM@Dox) LI]-PF (having 50 g of Dox/mg of nano-assemblies) for 3 h. The cells were
treated with GM carriers at 50 g/mL. The cells were then treated with or without 808nm
NIR laser (350 mW) for 15 min and were allowed to continue incubating for another 3 h.
After treatment, the cells were washed twice with 1× PBS. Then, the treated cells were
incubated with 10 mM of DCFH-DA for 10 min, and the generated intracellular ROS was
examined under a fluorescence microscope. The fluorescence intensity was quantified at
525 nm, with excitation at 490 nm.
4.2.22 Intracellular reduced glutathione (GSH) measurement
Intracellular GSH levels were determined using a GSH-Glo glutathione assay kit
(Promega, Madison, WI, USA), following the manufacturer’s instructions. Briefly, cells
(1×103 cells/well) were seeded in 24-well plates and treated with free Dox, GM@Dox,
[(GM@Dox) LI], and [(GM@Dox) LI]-PF (having 50 g of Dox/mg of nano-assemblies)
at 37 °C for 3 h. Similarly, the cells were treated with 50 g/mL with GM carriers. The
cells were then treated with or without 808nm NIR laser (350 mW) for 15 min and were
allowed to continue incubating for another 3 h. The cells were washed with PBS, and GSHGlo reagent was added to each well for 30 min at room temperature, and the luminescent
signal was measured with a microplate reader.
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4.2.23 Assessment of mitochondrial membrane potential
A mitochondrial potential-sensitive probe, JC-1, was used in this study to evaluate
mitochondria in the cells after treatment with the laser-irradiated nano-assembly. For this
study, A549 cells (1×103 /well) were seeded in 24-well plates. After 24 h, the old medium
was replaced with a fresh medium containing free Dox, GM@Dox, and [(GM@Dox) LI]PF (having 50 g of Dox/mg of nano-assemblies) and incubated for 3 h. Then the cells
were treated with a GM carrier with 50 g/mL. The cells were then treated with or without
808nm NIR laser (350 mW) for 15 min and were incubated for another 3 h. After treatment,
the cells were washed twice with 1×PBS and incubated with 100 L of JC-1 dye (2 mg/ml)
for 20 min at 37 °C. Finally, images were taken in the green and red fluorescence channels
by fluorescence imaging. The images were obtained at 488 nm excitation and 530 nm
emission for green (JC-1 monomers) and 543 nm excitation and 590 nm emission for red
fluorescence (JC-1 aggregates).
4.2.24 Measurement of cellular ATP
A549 cells were seeded at a density of 1 × 103 cells/well and then incubated for 24
h before experiments. Cells were then treated with free Dox, GM@Dox, [(GM@Dox) LI],
and [(GM@Dox) LI]-PF (having 50 g of Dox/mg of nano-assemblies) and incubated for
3 h at 37 °C. Similarly, the cells were treated with a GM carrier with 50

g/mL.

Subsequently, the cells were treated with or without 808nm NIR laser (350 mW) for 15
min and were incubated for another 3 h. Then, the cells were washed with PBS and
harvested with trypsin for 1 min at 37 °C. Cold PBS was added to terminate the reaction,
and the cells were collected by centrifugation. The ATP level was assessed using the
adenosine 5’-triphosphate (ATP) bioluminescent assay kit (Sigma-Aldrich).
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4.2.25 Caspase 3 & 7 activity
To investigate the modulation of cell death by [(GM@Dox) LI]-PF-mediated PTT,
the expression of Caspase-3/7 within each NIR-treated sample was examined. Activation
of caspase-3 is an important event during apoptosis. Thus, caspase expression was analyzed
by fluorescence microscopy using the Cell Event Caspase-3/7 Green Detection Reagent
(ThermoFisher Scientific) to confirm cell death by apoptosis. This reagent is an amino acid
peptide (DEVD) conjugated to a nucleic acid-binding dye. Activated Caspase-3/7 cleaves
at the DEVD peptide sequence, which allows the conjugated dye to bind to DNA and
fluoresce green. For this experiment, A549 cells were seeded at a density of 1 × 10 3
cells/well and then incubated for 24 h. The cells were then treated with free Dox and
[(GM@Dox) LI]-PF ± Laser (having 50 g of Dox/mg of nano-assemblies) and incubated
for 3 h at 37 °C. A GM carrier (50 g/mL) was used to treat the cells. Next, the cells were
exposed to PTT treatment for [(GM@Dox) LI]-PF (NIR 808 nm laser, 350 mW, 15 min),
and incubation was continued for another 3 h at 37 °C. Before use, the CellEvent Caspase-

samples underwent PTT, the NP-3/7 Green Detection Reagent. Samples were allowed to
incubate for an additional 30 min before analysis and then imaged using a fluorescence
microscope. The fluorescent intensity was quantified at 525 nm, with excitation at 490 nm.
4.2.26 Morphological assessment of apoptotic cells
A549 cells were grown on sterile chamber glass slides overnight, and the cells were
then treated with [(GM@Dox) LI]-PF + Laser (having 50

g of Dox/mg of nano-

assemblies), incubated for 3 h at 37 °C. Then, the cells were exposed to PTT treatment for
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[(GM@Dox) LI]-PF (NIR 808 nm laser, 350 mW, 15 min), and incubation was continued
for another 3 h at 37 °C. At the end of the incubation, the cells were fixed with 4%
paraformaldehyde and then permeabilized with Triton X-100 (0.1% in PBS). The cells
were finally stained using DAPI in PBS (2.5 µg/mL) and allowed to stand for 20 min in
the dark. Finally, morphological changes were viewed using fluorescence microscopy.
4.2.27 Tubulin assay
Tubulin polymerization was determined using a biochemical detector following the
manufacturer’s protocol. Briefly, A549 cells (103 cells/well) were incubated with Dox and
[(GM@Dox) LI]-PF ± Laser (having 50 g of Dox/mg of nano-assemblies) for 3 h at 37
°C. Similarly, the cells were treated with a GM carrier with 50

g/mL. After that,

[(GM@Dox) LI]-PF-treated cells were exposed to an 808nm NIR laser for 15 min and
further incubated for 3 h. The culture medium was removed, and the cells were washed
twice with PBS and stained with diluted tubulin tracker green reagent for 30 min at 37 °C.
Cell nuclei were stained with DAPI for 15 min. Blue fluorescence and green fluorescence
were observed under an inverted fluorescence microscope.
4.3
4.3.1

Results and Discussion
Synthesis of [(GM@Dox) LI]-PF
The design and synthetic strategy of [(GM@Dox) LI]-PF is illustrated in Scheme

4.2. The photothermal agent, GNR, was synthesized via a seed method as described by ElSayed et. al., with some minor modifications.48 To achieve an effective Dox loading and
controlled drug release, a porous silica shell was grafted onto the surface of the GNR by a
modified protocol from Matsuura et al.74 CTAB was used as a soft template, which creates
the mesoporous silica shell structure during the polymerization of silane around the GNRs
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(to give GM).322 Afterwards, doxorubicin (Dox), a known broad-spectrum antitumor drug,
is loaded into the GNR-coated mesoporous silica shell, which is referred as GM@Dox.
Dox mainly inhibits topoisomerase II upon intercalation with DNA and induce cell death
via the production of reactive oxygen species (ROS), inducing oxidative DNA lesions and
lipid peroxidation.379-381

Scheme 4.2. Stepwise synthesis scheme for [(GM@Dox)LI-PF].

Furthermore, IR 780 dye was loaded in the liposome to enhance the photothermal
performance, which was referred to as Liposome-IR 780 (LI). IR 780 is a hydrophobic dye
widely used as a photosensitizing agent in PTT, and it has been extensively explored for
NIR fluorescence imaging and approved by the FDA for clinical applications. 382 This
synergistic combination of GNR and IR-780 dye in our nano-assembly would facilitate a
higher photothermal impact using low power laser intensity (350mW). The liposomes were
synthesized by the extrusion method using the DPPC, cholesterol, and DSPE-PEG(2000)
amine, along with IR 780. The as-prepared GM@Dox was encapsulated within the
liposome by reacting them in an ice bath, where the amphiphilic phospholipids self-
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Figure 4.1. Characterization of nano-assemblies by TEM and STEM. TEM images of (a)
GNR (Scale bar = 50 nm), (b) GM@Dox (Scale bar = 100 nm) and (c) [(GM@Dox) LI]
(Scale bar = 20 nm). (d) HAADF images of [(GM@Dox) LI] that indicate presence of (e)
gold, (f) silica, (g) oxygen, and (h) carbon.(i) Merged HAADF image (Scale bar = 30 nm).

assemble around the GM@Dox to create a lipid layer [(GM@Dox) LI]. The phospholipid
DPPC, which is used in an 85% molar ratio, makes this liposome thermo-sensitive due to
its melting point at 43 °C. Cholesterol in the lipid layer enhances membrane fluidity and
Dox retention.324 The large PEG group of DSPE-PEG(2000)amine is known to improve
drug delivery efficiency, increase systematic circulation time, reduce immunogenicity, and
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offer stealth properties, which facilitates the binding of the targeting ligands onto the
liposome.325, 326 The liposome layer acts as a gatekeeper that restricts the premature release
of Dox. The liposomal coating also helps to stabilize the GM@Dox and improves the
cellular uptake of nano-assemblies.
Next, to achieve target specificity and increase uptake efficiency into the cancer
cells, the cationic peptide, GE-11 (P), and folic acid (F) were conjugated to the surface of
the liposome through EDAC chemistry, and the final nano-assembly was abbreviated as
[(GM@Dox) LI]-PF. GE-11(YHWYGYTPQNVI) is known for its binding affinity for the
EGFR, which directs the nano-assemblies towards the cancerous cells. GE11 is a
dodecapeptide that binds specifically to EGFR, which is overexpressed in many tumors of
epithelial origin, including breast, lung, and ovarian cancers. 383 On the other hand, folic
acid has an affinity towards folate receptors, recognized biomarkers for tumor cells, due to
their overexpression on many tumors of epithelial origin, including breast, lung, and
ovarian cancers.384 Therefore, these folate receptors are an attractive candidate for drug
targets. The use of folic acid as a cancer cell-targeting ligand has become more
advantageous due to its non-immunogenicity, stability, tissue permeability, and ease of
conjugation into NPs.384, 385 We have successfully attached both targeting ligands to the
liposomal layer of the [(GM@Dox) LI]-PF nano-assemblies and showed the enhanced
cancer-targeting effects of these nano-assemblies compared to the drug-loaded particles
(GM@Dox).
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4.3.2

Morphology studies of nano-assemblies
The morphological analysis of nano-assemblies was carried out using TEM and

HAADF-STEM. As shown in Figure 4.1a, the average length and width of GNRs were
found to be 42 ± 3.8 nm and 11.2 ± 1.1 nm, respectively, and the calculated average aspect
ratio was 3.8:1. The GNRs displayed a uniform and well-dispersed rod-like morphology,
visible through Transmission Electron Microscopy (TEM) (Figure 4.1a). Dox was
encapsulated into the porous structure of the GM to create GM@Dox. TEM images (Figure
4.1b) show GNRs encapsulated in a mesoporous silica shell loaded with Dox (GM@Dox).
The silica shell has an average thickness of 15 ± 3 nm, and its porous structure can be
clearly seen by TEM. The photothermal effect of GNR has been enhanced using an
additional photosensitizer: IR 780 (I) and the dye loaded inside the liposome. Then,
GM@Dox was encapsulated inside the liposome, and the entire assembly was called
[(GM@Dox) LI]. The liposomal layer is visible through TEM, as shown with a red doubleheaded arrow (Figure 4.1c). The shape of GM@Dox dictates the oblong shape of the
liposomal layer. High-angle annular dark-field scanning transmission electron microscopy
(HAADF-STEM) images (Figure 4.1e-i) display the presence of gold (Au), silicon (Si),
oxygen (O), and carbon (C) elements in the layers of [(GM@Dox) LI]. The merged image
in Figure 4.1i depicts the individual layers overlaid on each other to confirm the structure
of the final construct of [(GM@Dox) LI]. HAADF images reveal the presence of carbons
from the long hydrocarbon chains of the lipids used to form the liposome. This proves the
presence of a liposomal layer surrounding GM@Dox, as indicated by a red double-headed
arrow in the merged image of Figure 4.1i. The combined TEM (Figure 4.1c) and HAADFSTEM (Figure 4.1i) images display the liposomal coating around the GM@Dox.
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4.3.3

Elemental analysis of nano-assemblies
I
a

b

Figure 4.2. EDS profile mapping of (a) GM@Dox and (b) [(GM@Dox) LI].

Energy-dispersive X-ray spectroscopy (EDS) is an analytical method for the
chemical characterization of materials. The chemical composition of GM@Dox and
[(GM@Dox) LI] was analyzed by energy-dispersive X-ray spectroscopy (EDS). The EDS
spectrum of GM@Dox (Figure 4.2a) clearly displayed the peaks of gold (Au), oxygen (O),
and silica (Si). A copper (Cu) peak was present in the EDS spectra due to using a Cu mesh
TEM grid as a substrate. The EDS spectrum of [(GM@Dox) LI] (Figure 4.2b) shows the
peaks for elements Au, Si, O, and C. The presence of C peaks was used to indicate the
existence of a liposomal layer. A liposome is composed of lipids with a long hydrocarbon
chain, for example, DPPC, which has a 40-carbon alkyl chain. The HAADF-STEM image
in Figure 4.2b shows the clear presence of C in the outermost liposomal layer.
4.3.4

Surface charge
The zeta potential was measured after the addition of each layer to monitor the

change in surface charge. The altered surface zeta potential is shown in Figure 4.3a. The
zeta potential of GNRs was 28 ± 0.59 mV, possibly due to the presence of positively
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Figure 4.3. (a) zeta potential (b) UV-vis absorbance spectra of nano-assemblies.

charged CTAB on the surface. After silica coating, the surface charge was reduced to -23.5
± 0.8 mV due to abundant Si-OH groups. The free cationic Dox has a surface charge of 18
± 1.8 mV in water; therefore, after loading Dox to GM, the zeta potential increased to 10.27 ± 0.76 mV. Liposomal coating increased the zeta potential to +7.25 ± 0.6 mV, owing
to the presence of amine groups from DSPE-PEG 2000 amine on the surface. The cationic
peptide GE-11 and folic acid were conjugated to the abundant -NH 2 groups present on the
surface of the liposome through EDC coupling chemistry. This is responsible for the final
increment of the zeta potential to +15.6 ± 0.88 mV.
4.3.5

Optical properties of nano-assemblies
The UV-vis spectra (Figure 4.3b) indicated two characteristic absorption peaks of

GNRs: the transverse surface plasmon resonance (TSPR) peak at 514 nm and the
longitudinal surface plasmon resonance (LSPR) peak at 790 nm. With the mesoporous
silica coating, the LSPR peak underwent a red shift towards 800 nm due to the change in
the local refractive index of the surrounding medium and changes in geometry. The laser
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was selected to match the new absorbance at 800 nm. After Dox loading, there was no
change in the observed LSPR peak. The absorption peaks of [(GM@Dox) LI] at 740 nm
belong to the characteristic absorption of IR 780 dye, and the peak at 800 nm belongs to
the GM@Dox. For [(GM@Dox) LI]-PF, the observed absorption peaks were similar to
[(GM@Dox) LI] (Figure 4.3b). The strong absorption of [(GM@Dox) LI]-PF in NIR
regions indicated PTT potential upon laser irradiation. Many studies have previously
reported that both GNR and IR 780 can act as outstanding PTT agents. 386, 387
4.3.6

Functional group characterization of nano-assemblies
The FT-IR spectra labeled with the characteristic peaks of the different components

of each fabrication step are presented in Figure 4.4. As shown in Figure 4.4a, GNRs show
-CH2 symmetric and asymmetric vibrations at 2847 cm-1 and 2870 cm-1, respectively. The
presence of a peak at 1473 cm-1 corresponds to the -CH2 scissoring mode of vibration. In
the fingerprint region, the bands at 960 and 817 cm-1 are consistent with C-O stretching
and in-plane C-H bending vibrations. The appearance of a peak at 1064 cm -1 (Si-O-Si
stretching) and the disappearance of symmetric (2847 cm-1) and asymmetric (2870 cm-1)
vibrations, which were seen in GNR, proves the mesoporous silica coating on the surface
of GNRs. The spectrum of free Dox showed characteristic peaks at 3311 cm -1 (OH and
NH, stretch), 2898 cm-1(CH stretch, aromatic), 1730 cm-1(C=O stretch, ketone), 1615 cm1

(C=O stretch), 1,282 cm-1 (C-O-C, stretch), 1115 cm-1(C-O stretch, tertiary alcohol), 1070

cm-1(C-O stretch, secondary alcohol), and 988 cm-1(C-O stretch, primary alcohol).388
Similar trends in characteristic peaks were seen after loading Dox into GM, which confirms
the successful loading of Dox.
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Figure 4.4. FTIR analysis of various nano-assemblies synthesized after each step. (a)
Comparison of between GNR, GM, GM@Dox, and free Dox. (b) FTIR spectra of
GM@Dox, [(GM@Dox) L], [(GM@Dox) LI], and free IR 780. Comparative FTIR
spectrum of free (c) GE-11 with [(GM@Dox) LI]-PF and (d) FA with [(GM@Dox) LI]PF.

Next, as shown in Figure 4.4b, the IR 780 loading inside the liposome and the
liposome wrapping on GM@Dox were analyzed by comparing FTIR spectra of GM@Dox,
[(GM@Dox) L], [(GM@Dox) LI], and IR 780. The symmetric and anti-symmetric -CH 2
stretching at 2850 cm-1 and 2920 cm-1 were the characteristic lines for the long carbon chain
of the lipids used. Also, the C=O stretching vibration around 1737 cm -1 and the PO2
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symmetric stretching vibration around 1111 cm-1 are from phospholipids, confirming the
successful liposome coating. IR 780 loading inside TSL was proved by comparing FTIR
spectra of IR 780 and [(GM@Dox) LI]. As shown in Figure 4.4b, the trend of characteristic
peaks of [(GM@Dox) LI] was similar to free IR 780, confirming the loading of IR 780 dye
inside the liposome.
Furthermore, the FTIR spectra of [(GM@Dox) LI]-PF and free GE-11 were
recorded to verify that the GE11 peptide had been conjugated to [(GM@Dox) LI]. The
intense broad band at 3289 cm-1 in Figure 4.4c represents N-H stretching vibrations,
indicating the presence of amino groups. We assign two sharp absorption bands at 1647
and 1515 cm-1 to the amide I and amide II groups of the GE-11 peptide, respectively. 389 By
contrast, the absorption bands for the amide I and amide II groups of the[(GM@Dox) LI]PF nano-assemblies appeared at 1637 and 1553 cm-1, respectively (Figure 4.4c). The shifts
of these two amide absorption bands to the higher wavenumber suggest that conformational
changes occurred to the GE-11 peptide upon binding to [(GM@Dox) LI]. The presence of
C=O groups in free GE-11 peptide at 1444 cm-1 corresponds to the symmetrical stretching
vibrations of carboxylate groups, while in [(GM@Dox) LI]-PF nano-assemblies, this shift
to a higher wavenumber 1517 cm-1 suggests that conformational change occurred to the
GE-11 peptide upon binding to [(GM@Dox) LI].
The conjugation of folic acid onto [(GM@Dox) LI] was investigated by comparing
free folic acid and [(GM@Dox) LI]-PF, as shown in Figure 4.4d. The characteristic IR
absorption peaks at 1690 and 1601 cm-1 are observed in the spectrum of free folic acid, due
to C=O amide stretching of

-carboxyl group and absorption of aromatic C=C group

respectively.390, 391 While the absorption bands of the [(GM@Dox) LI]-PF nano-assemblies
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Figure 4.5. (a) N2
analysis of nano-assemblies.

b) TGA

appeared at 1732 and 1636 cm-1, respectively. Again, the wavenumber shifting to a higher
range indicated that the folic acid's conformational changes upon conjugation with
[(GM@Dox) LI]. From all these FTIR spectra, we have successfully confirmed the
fabrication of the nano-assemblies after each step of the synthesis.
4.3.7

Porosity analysis of mesoporous silica shell
N2 adsorption-desorption isotherm and pore size distribution curves of GM and

GM@Dox are given in Figure 4.5a and as shown in Appendix Table C.1. These nanoassemblies exhibits a typical type IV isotherm with a narrow pore size distribution, having
a mean of 19.13 ± 1.1 Å and 12.19 ± 0.8 Å for GM and GM@Dox, respectively. This
verifies the porous character of the MS shell. Through BET, the total surface area and pore
volume of GM were quantified to be 53.852 ± 1.5 m 2g-1 and 0.23 ± 0.1 cc/g, respectively.
However, for GM@Dox, the total surface area and pore volume were quantified as 42.060
m2g-1 and 0.17 cc/g, respectively.
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4.3.8

TGA of various nano-assemblies
The quantitative analysis of the nano-assemblies after each synthesis step was done

through TGA. The results are shown in Figure 4.5b and Table 1. Percentage (%) weight
loss between the GM@Dox and GM was calculated to determine the amount of Dox loaded
onto GM. The Dox loading was found to be 32 ± 1.1% onto GM. Additionally, the
percentage weight loss between [(GM@Dox) LI] and GM@Dox showed that the lipid
layer and IR-780 together is 10 ± 1.6% of the weight of [(GM@Dox) LI]. The loading
content of IR 780 onto [(GM@Dox) LI] was found to be 45.2 ± 1.1 % using a plate reader,
based on calculations from the standard calibration curve of IR 780. The combined results
of TGA analysis and UV-vis spectroscopy indicated that 4.5% of IR 780 (TGA- total lipids
+ IR 780 was 10 ± 1.6% ~UV-vis 45% of IR-780 from plate reader) and 5.5% of lipids
were present on [(GM@Dox) LI]. Finally, peptide GE-11 and folic acid loading on
[(GM@Dox) LI] were quantified by TGA analysis between the [(GM@Dox) LI]-PF and
[(GM@Dox) LI]. The total ligand loading was found to be 12 ± 1.5 % on [(GM@Dox)
LI]-PF.
4.3.9

Quantification of targeting ligands on nano-assemblies
The total GE-11 peptide conjugated on [(GM@Dox) LI]-PF was 41.5 ± 1.0 % by a

Micro BCA assay. The amount of GE-11 was calculated using the standard calibration
curve of GE-11, using the Micro BCA assay as shown in

Figure C.4. Folic acid

conjugation on [(GM@Dox) LI]-PF was found to be 58 ± 0.8 % by measuring at 310 nm
with a plate reader. The amount of folic acid was calculated from the standard calibration
curve of folic acid, as shown in Figure C.3. These data correlated with the TGA data, which
gave the total amount of ligands on [(GM@Dox) LI] 12 ± 1.5 %. This means that 5% of
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GE-11 (TGA- total ligand 12 ± 1.5 % ~ UV-vis 42% GE-11 from Micro BSA assay) and
7% of FA (TGA-total ligand 12 ± 1.5 % of ~ 58% folic acid from plate reader) were present
on [(GM@Dox) LI]-PF.
4.3.10 Encapsulation efficiency and drug loading content
The encapsulation efficiency (EE) and loading content of Dox and IR 780 were
calculated using the standard calibration curve of Dox and IR 780 using a microplate
reader. (Table 4.3.1). The higher Dox loading in GM@Dox may be due to the porous
structure of the silica shell and the hydrophilic nature of Dox. The EE of Dox in
[(GM@Dox) LI] and [(GM@Dox) LI]-PF had negligible differences. The LC of Dox in
GM@Dox, [(GM@Dox) LI], and [(GM@Dox) LI]-PF were found to be 34.6 ± 0.5%, 32.8
± 0.9%, and 30.1 ± 0.9%, respectively. The high EE and LC of Dox in all the nanoassemblies was primarily due to the electrostatic interactions between the cationic
anticancer drug Dox and the negatively charged Si-OH porous walls of the mesoporous
silica shell. The high EE and LC of IR 780 in [(GM@Dox) LI] and [(GM@Dox) LI]-PF
may be due to the strong hydrophobic interaction between IR 780 and the lipophilic
phospholipids in the liposome composition.
Table 4.3.1. Encapsulation efficiency and loading content of Dox and IR 780 in
nano-assemblies
Nano-assemblies

EE (%)

LC (%)

GM@Dox

98.9 ± 0.8 (Dox)

34.6 ± 0.5 (Dox)

95.3 ± 0.7 (Dox)
[(GM@Dox) LI]
99.5 ± 0.5 (IR 780)
93.9 ± 0.9 (Dox)
[(GM@Dox) LI]-PF

97.9 ± 0.8 (IR 780)
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32.8 ± 0.9 (Dox)
45.2 ± 1.1 (IR 780)
30.11 ± 0.9 (Dox)
43.62 ± 0.5 (IR 780)

Calcein Cytoplasm

Dox

Merged of
Dox/Nucleus

Merged

[(GM@Dox) LI]-PF

GM@Dox

DAPI Nucleus

Figure 4.6. Evaluation of the targeting affinity of [(GM@Dox) LI]-PF compared to the
affinity of the non-targeted GM@Dox. The nano-assembly has Dox which has red,
fluorescence and the A549 cells and the nuclei were stained with Calcein AM and DAPI
respectively. (Scale bar, 10
).

4.3.11 Colloidal stability
The colloidal stability of the GM@Dox and [(GM@Dox) LI]-PF in the culture
medium was investigated, as shown in Appendix Figure C.5. The LSPR peak intensity,
aggregation index, and zeta potential of [(GM@Dox) LI]-PF were stable for 5 days in the
culture medium. This reflects the stability afforded by the liposomal layer in [(GM@Dox)
LI]-PF. GM@Dox, however, was comparatively unstable. The reducing LSPR peak
intensity, high aggregation index, and changing zeta potential of GM@Dox were evidence
of its instability. The final [(GM@Dox) LI]-PF nano-assembly is stable and suitable for
cancer applications.
4.3.12 Targeting efficiency of nano-assemblies
Moreover, to check the targeting efficiency of [(GM@Dox)LI]-PF, we have treated
A549 cells with GM@Dox and [(GM@Dox)LI]-PF and incubated them for 6 h. As shown
in Figure 4.6, cells treated with [(GM@Dox)LI]-PF show strong, intense red fluorescence
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(red fluorescence from Dox), while GM@Dox-treated cells have very little to no red
fluorescence, which confirms that the targeting capacity of [(GM@Dox)LI]-PF helped
more nano-assemblies to get inside the cells. These data suggest that [(GM@Dox)LI]-PF
could deliver the drug with enhanced efficiency due to the active targeting of GE-11 toward
EGFR and folic acid to folate receptors (FR) on cancer cell membranes. The EGFR and
FR have recognized biomarkers for cancer cells due to their overexpression on multiple
tumors, including liver cancer.290, 392, 393 Cancer cell-directed enhanced GE-11 and folic
acid synergistically facilitated drug delivery effects to increase therapeutic efficiency and
limit multidrug resistance.
4.3.13 Enhanced photothermal performance
The enhanced photothermal performance of GNR and the encapsulated IR 780
under laser irradiation was investigated. The temperature variations of GM@Dox, LI, and
[(GM@Dox) LI]-PF exposed to laser irradiation at 808 nm and 350 mW for 15 min were
tested and are displayed in Figure 4.7a. The temperature increases after laser irradiation of
the [(GM@Dox) LI]-PF was 60 ± 5.1 °C, which was higher than that of both GM@Dox
(45.2 ± 1.5°C) and LI (40 ± 1.1°C). The photothermal activity of the nano-assembly was
enhanced by 15 ± 4.5 °C even with the use of lower laser intensity, 350 mW. This was
done by co-encapsulating GNR and IR 780 inside a liposome layer. Furthermore, the
[(GM@Dox) LI]-PF exhibited concentration-dependent photothermal properties,
demonstrating a linear increase in temperature with the increasing concentration Figure
4.7b. Even at very low concentrations (10 g/mL), the temperature increased to 45 ± 1.3°C.
As shown in Figure 4.7c, two different weight ratios of liposome: IR 780 (LI) were
investigated to check the PT activity. With higher IR 780 weight ratios, higher PT activity
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Figure 4.7. Photothermal properties of nano-assemblies. (a) Enhanced PT effect of
GM@Dox, LI and [(GM@Dox) LI]-PF using 808 nm, 350 mW, laser for 15 min. (b) PT
effect of [(GM@Dox) LI]-PF at different concentrations. (c) The temperature profile of
different weight ratios of LI (100:5 and 100:1).
was observed. The greatly enhanced photothermal properties of the [(GM@Dox) LI]-PF
was attributed to the LSPR of the GNR, which increased the light absorption efficiency of
IR 780.
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Figure 4.8. NIR triggered drug release studies. (a) Dox release profiles of [(GM@Dox)
LI]-PF in PBS at pH 5.5 and 7.5 triggered by repeated NIR irradiation (808 nm, 350 mW,
15 min). The black arrows indicated the time point of laser irradiation on/off. (b)
Cumulative drug release profile of Dox from various nano-assemblies with and without
laser irradiation (808 nm, 350 mW, 15 min).

4.3.14 PTT-induced drug release studies
We examined the photothermally triggered Dox release from the nano-assemblies
in PBS at different pH values. As shown in Figure 4.8a, after 2 h of on-off NIR laser
irradiation, the accumulated release of Dox in [(GM@Dox) LI]-PF reached 35.2 ± 1.0%
and 12.1 ± 1.1 % in PBS at pH 5.5 and 7.5, respectively. In contrast, in pH 7.5 PBS buffer
solution, which mimics normal physiological conditions, the Dox release was (2.7 ± 1.0%)
in the absence of laser irradiation over a similar time frame (2 h). The higher release of
Dox at a lower pH was attributed to the protonation of silicates at a lower pH, resulting in
the dissociation of the electrostatic interaction between the negatively charged porous silica
shell and Dox consequently boosting the release of the drug. 394 In addition, when exposed
to NIR laser irradiation, the drug release can be controlled remotely through the melting of
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thermo-sensitive liposomes and the weakened interaction between the mesoporous silica
matrix and the drug.
PTT-induced drug release studies were carried out on various nano-assemblies in
the presence (+) or absence (-) of NIR laser. As shown in Figure 4.8b, cumulative Dox
released within 6 h was found to be 30.1 ± 1.2% and 46.3 ± 1.3% for GM@Dox - Laser
and GM@Dox + Laser, respectively. This indicates that the subsequent temperature
increases with laser irradiation increased the non-specific release of Dox. While
[(GM@Dox) LI] + Laser released 90.7 ± 1.0% of Dox, [(GM@Dox) LI] - Laser showed
only a 12.1 ± 0.8% Dox release in a similar time frame. This observation suggested that
the liposome acts as a protective layer that reduces the non-specific release of the
encapsulated Dox. Additionally, as shown in Appendix Figure C.6., comparing Dox
released by [(GM@Dox) L] + Laser (75.3 ± 1.2%) and [(GM@Dox) LI] + Laser (90.7 ±
1.0%) suggests that the enhanced photothermal performance of the nano-assemblies is
indicative of encapsulated IR 780 dye, which increased Dox release rate by 1.2-fold.
[(GM@Dox) LI]-PF + Laser demonstrated a similarly high Dox release of 95.3 ± 3.6%.
Only 15.1 ± 1.5% of Dox was released in the absence of Laser (Figure 4.8b). It is apparent
from the above results that the liposome plays a role in reducing premature Dox release.
With laser irradiation, the temperature of the [(GM@Dox) LI]-PF nano-assembly was
increased to 60 ± 5.1 °C. This was accompanied by the increase in the Dox release. At this
elevated temperature, the phospholipid membrane becomes permeable due to gel-to-liquid
phase transition.395 Due to the combined hyperthermia generated by GNR and IR-780
under the laser, the thermo-sensitive liposomal layer melts, allowing Dox release. 386, 396
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Figure 4.9. Intracellular trafficking of nano-assemblies and NIR triggered cellular drug
release. (a) Cellular uptake of the free Dox and [(GM@Dox) LI]-PF ± Laser. A549 cells
are stained with calcein dye (green), cell nucleus stained with Hoechst dye (blue), and
nano-assemblies were labelled with red fluorescent RITC dye (red). Scale bar: 10 m. (b)
Cumulative cellular Dox release of [(GM@Dox) LI]-PF + Laser at different time points in
response to the continuous 808 nm laser, 350 mW. Scale bar: 10 m. (c) Quantitative mean
fluorescence intensity of Dox red fluorescence in presence and absence of laser. Each
analysis was recorded on at least 25 cells using Fiji software. The data was presented as
the mean ± SD (n=3).
4.3.15 Cellular internalization of nano-assemblies
The cellular uptake and distribution of the nano-assemblies in A549 cells were
observed with an inverted fluorescence microscope. After 6 h of incubation in A549 cells,
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the subcellular localization of free Dox and [(GM@Dox) LI]-PF ± Laser irradiation were
imaged (Figure 4.9a). In the case of free Dox, the low fluorescence intensity indicated that
only a minimal amount of Dox was distributed in the cytoplasm. However, in the case of
[(GM@Dox) LI]-PF – Laser, moderate fluorescence indicated that slightly more Dox
entered the cells, owing to the targeting ability of the dual peptides, GE-11 and folic acid.
The lower amount of Dox fluorescence response around the nucleus also suggested that the
[(GM@Dox) LI]-PF prevented Dox from leaking out. Upon NIR laser irradiation, stronger
fluorescence was found with [(GM@Dox) LI]-PF + laser group, which can be ascribed to
the quick release of Dox. Dox distribution in the cytoplasm was seen mainly surrounding
the nucleus. This indicated that the GE11- and folic acid-modified liposome encapsulation
can enhance the cellular uptake efficiency of the nano-assemblies, and the NIR laser
irradiation could control the release of the drug. Additionally, we have also studied the
cellular uptake mechanism by which nano-assemblies are transported into the A549 cells,
which were described in detail in Appendix Section C.1 and Figure C.7. Briefly, nanoassembly-mediated drug delivery occurred preferably through clathrin-mediated
endocytosis, and nano-assembly internalization was enhanced due to the liposome and
targeting ligands.
4.3.16 NIR-triggered drug release in cells
The intracellular drug release under continuous laser irradiation was monitored by
fluorescence microscopy. Before laser irradiation, little or no Dox was seen distributed in
the cells (Figure 4.9b). After NIR laser radiation for 15 min, Dox was seen to be released
in the cells. Dox was seen dispersed homogeneously in the cytoplasm and surrounding the
nucleus (Figure 4.9b). The mean fluorescence intensity of released Dox from [(GM@Dox)
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LI]-PF + or - laser treatment was quantified, and the results were shown to correspond to
the fluorescence images (Figure 4.9c). Therefore, NIR laser irradiation plays an essential
role in controlling the release of Dox in A549 cells. The intracellular on-demand drug
release is critical to increasing therapeutic efficiency, reducing side effects, and reducing
drug resistance.
4.3.17 Cellular cyto-phototoxicity studies
The therapeutic potential of various nano-assemblies in presence or absence of laser
was evaluated. A549 cells were incubated with free Dox, GM, GM@Dox, [(GM@Dox)
LI], and [(GM@Dox) LI]-PF for 3 h and then irradiated with 808 nm NIR laser for 15
minutes. The obtained cell viability data are shown in Figure 4.10a. GM showed no obvious
cytotoxicity without the laser, but in the presence of laser irradiation, GM displayed slight

only GM@Dox (percentage viability 80 ± 3 % at 50 g/mL) showed a cytotoxic effect on
A549 cells. Lower cell viability in the presence of GM@Dox was possibly due to
continuous non-specific Dox release from mesoporous silica.
Compared to GM@Dox, both [(GM@Dox) LI] (90 ± 2.5 %) and [(GM@Dox) LI]PF (89 ± 3.1 %) had higher cell viabilities. However, in the presence of laser irradiation,
[(GM@Dox) LI] and [(GM@Dox) LI]-PF had much higher toxicity toward A549 cells.
[(GM@Dox) LI] + Laser had 25 ± 3.1 % cell viability, and [(GM@Dox) LI]-PF + Laser
had 8 ± 3 % cell viability. GM@Dox + Laser only had 61 ± 2.7 % cell viability, and Dox
alone had 89 ± 2.8 % cell viability. Therefore [(GM@Dox) LI]-PF + Laser was 20-fold
more effective when compared to Dox alone. This is due to the combined chemophotothermal effect and higher internalization afforded through GE-11 and folic acid.
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Figure 4.10. Cellular cyto-phototoxicity studies. (a) Quantitative determination of cell
viability A549 cells incubated with GM, Dox, GM@Dox, [(GM@Dox) LI] and
[(GM@Dox) LI]-PF with or without 808 nm laser irradiation at 350 mW for 15 min. (b)
Fluorescence microscopy images of the live/dead assay. Fluorescence microscopy images
showing the presence of live cells (green) stained with Calcein AM, and dead cells (red)
were stained with EthD-1 following treatment with GM, Dox, GM@Dox, [(GM@Dox)
LI], and [(GM@Dox) LI]-PF with or without 808 nm laser irradiation at 350 mW for 15

A live/dead assay was also conducted to visualize the chemo-phototherapeutic
effect of the nano-assemblies. The cells were stained with Calcein-AM to indicate
intracellular esterase activity in live cells and stained with ethidium homodimer-1(EthD-1)
to indicate the loss of plasma membrane integrity in dead cells.397 Live cells are indicated
with green fluorescence, and red fluorescence indicates dead or late apoptotic cells. Stained
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cells were observed using an inverted fluorescent microscope. As shown in Figure 4.10b,
the viability of cells treated with [(GM@Dox) LI] + Laser and [(GM@Dox) LI]-PF + Laser
was lower than that of cells treated with GM@Dox + Laser under the same conditions. The
fluorescence responses of the live/dead cells are shown in Figure 4.10b, which are
consistent with the results of the MTT assay (Figure 4.10a). In the absence of NIR laser
excitation, neither [(GM@Dox) LI] nor [(GM@Dox) LI]-PF exhibited apparent
cytotoxicity. The results reflect the combined chemo-photothermal effect of both
[(GM@Dox) LI] and [(GM@Dox) LI]-PF.
4.3.18 Intracellular ROS determination
Cellular ROS generation mainly occurs in the mitochondria, and mitochondrial
damage is closely correlated with high ROS levels.398, 399 Additionally, Dox has an affinity
to bind specifically to the abundant phospholipid cardiolipin located in the inner
mitochondrial membrane, which leads to mitochondrial accumulation of the drug. 400, 401
Hence, disrupting the electron transport chain (ETC) causes ROS production. 402 To
evaluate the photothermal effect of the nano-assemblies in vitro, ROS (typically 1O2) was
monitored in living cells using carboxy-H2DCFDA as a fluorescent indicator. This
nonfluorescent molecule is readily converted to a green, fluorescent carboxy-DCF. This
occurs when the acetate groups are removed by intracellular esterases and oxidation by
singlet oxygens (1O2). This enables living cells to exhibit bright green fluorescence,
indicating ROS production in cells. A549 cells were incubated with free Dox, GM,
GM@Dox, [(GM@Dox) LI], and [(GM@Dox) LI]-PF, followed by the addition of
carboxy-H2DCFDA. After being continuously irradiated for 15 min, the samples were
imaged through a fluorescence microscope (Figure 4.11a), and fluorescence intensity was
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Figure 4.11. Cancer cell death mechanism study. (a) Determination of mitochondrial ROS
generation after treatment various nano-assemblies with or without laser irradiation at
by fluorometric assay. (c) Intracellular GSH level measured by fluorometric assay. (d)
A549 cells were treated with various nano-assemblies with or without laser irradiation for
cellular ATP measurement. The data were presented as the mean ± SD (n=3). N.S stands
for non-significant. A ** indicates p < 0.01 and *** indicates p < 0.001, indicating that
the data was statistically significant by two-way ANOVA compared with free DOX.

quantitatively measured by a microplate reader (Figure 4.11b). The cells treated with GM
solution exhibited negligible fluorescence in the absence of laser irradiation. A slight green
fluorescence was displayed when cells were treated with GM@Dox + Laser, probably due
to premature Dox release. Higher green fluorescence intensity was seen in cells treated
with [(GM@Dox) LI]-PF + Laser. This can be attributed to the enhanced photothermal
effect due to the additional photosensitizer, IR 780. IR 780 has been used previously in
PTT and as a generator of ROS. ROS, such as 1O2, plays a vital role in PTT, damaging the
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cell structure or affecting cell function. Similarly, with [(GM@Dox) LI]-PF + Laser, the
fluorescence intensity of the treated cells was strong compared to cells treated with
GM@Dox + laser and [(GM@Dox) LI] + laser. We hypothesized that upon NIR exposure,
GNR and IR 780 would induce a hyperthermic condition that will melt the thermo-sensitive
liposome, thus delivering more Dox molecules into the mitochondria, thereby inducing
higher levels of ROS.
4.3.19 Intracellular GSH determination
It is well-known that ROS can cause a drop in GSH levels either by oxidation or by
reaction with the thiol group of GSH.403 GSH is a non-enzymatic antioxidant that functions
as the first line of the cellular defense mechanism against oxidative injury in all cell
compartments.404 Previous research has shown that ROS generation following GSH
depletion induces mitochondrial damage and up-regulation of pro-apoptosis mediators. 405407

Here, we wanted to evaluate further whether the laser-treated nano-assemblies could

down-regulate the intracellular GSH level. A fluorescent thiol probe was used to indicate
the intracellular GSH level with or without laser-treated nano-assemblies. As shown in
Figure 4.11c, without laser treatment, high GSH levels in the tumor cells were observed,
while with laser treatment, gradual GSH depletion was observed in GM@Dox (53.0 ± 4.2
%), [(GM@Dox) LI] (31.8 ± 3.5 %), and [(GM@Dox) LI]-PF (16.2 ± 3.3 %). The
intracellular GSH level for free Dox was found to be 93.8 ± 3.8 %, which is much higher
compared to [(GM@Dox) LI]-PF + Laser (16.2 ± 3.3 %).
4.3.20 Cellular ATP determination
After treatment with various nano-assemblies, the cellular ATP level was analyzed
to demonstrate the apoptotic pathway mediated via mitochondria. As shown in Figure
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Figure 4.12. Fluorescence micrograph of the JC-1 stained A549 cells that were cultured
with GM, DOX, GM@Dox ± laser and [(GM@Dox) LI]-PF ± laser at 808 nm for 15 min.
The fluorescence transition from red (J-aggregate) to green (J-monomer) indicated
significant mitochondrial damage. Scale bar: 10 m.
4.11d, the energy level in A549 cells remained higher, which was seen in the increased
ATP level in cells treated with nano-assemblies in the absence of laser irradiation compared
to laser. However, GM@Dox + laser, [(GM@Dox) LI] + Laser, and [(GM@Dox) LI]-PF
+ Laser caused a constant decrease in the intracellular ATP, which was related to the
decreased proliferation rates. After treatment with Dox only, the ATP level was 86.8 ± 3.1
%, while with [(GM@Dox) LI]-PF + Laser was 7.1 ± 3 %. The up-regulation of ROS,
downregulation of GSH, and decrease in the cellular ATP level are initiators to prompt
mitochondrial depolarization.408, 409
4.3.21 Mitochondrial function assessment
Next, mitochondrial function was checked qualitatively by fluorescence imaging
using JC-1 as a probe. Mitochondria are central organelles in which the intrinsic
mitochondrial pathway of apoptosis can be directly triggered by injury. 410,

411

Many

mitochondria-related critical events may result in cell apoptosis, such as mitochondrial
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membrane potential loss, electron transport chain destruction, caspase-activating protein
release, and disruption of the micro skeleton structure of tubulin 410-413
[(GM@Dox) LI]-PF + Laser-induced mitochondrial dysfunction was first
investigated by evaluating the mitochondrial membrane potential using JC-1 staining
(Figure 4.12). The JC-1 probe is capable of examining mitochondrial damage. The green
JC-1 monomer can enter the cytoplasm and aggregate in normal mitochondria, forming
numerous red J-aggregates. In contrast, the fluorescence transformation from red to green
indicates a loss of membrane potential in the mitochondria, suggesting significant
mitochondrial damage. Very little green fluorescence due to damaged mitochondria was
seen after treatment with GM, Dox, GM@Dox, and [(GM@Dox) LI]-PF, in the absence
of Laser. Red fluorescence indicative of healthy mitochondria was noticeable even after 6
h incubation of GM, Dox, GM@Dox, and [(GM@Dox) LI]-PF, in the absence of Laser.
An increase of green fluorescence could be observed after treatment with laser-irradiated
GM@Dox and[(GM@Dox) LI]-PF. The green fluorescence intensity of A549 cells treated
with [(GM@Dox) LI]-PF + Laser was much stronger than GM@Dox + Laser, indicating
significant mitochondrial dysfunction. Dox itself could also cause mild mitochondrial
dysfunction based on JC-1 staining, but extreme mitochondrial dysfunction could be
triggered by [(GM@Dox) LI]-PF + Laser, which was due to combinational therapy of
chemo-photothermal therapy and peptide targeting capability against A549 cells.
4.3.22 Apoptosis detection
Apoptosis of cancerous cells was first assessed by Caspase 3 &7 assay. The activity
of various caspases was used as an apoptosis-specific target for the direct visualization of
apoptosis since their activity changes correlate with the apoptosis stages. 414 Caspase-3 and
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caspase-7 are cysteine-aspartic acid proteases that can carry out apoptosis directly,
following sequential activation of caspase-8 or caspase-9 activation. 415 Hence, the caspase3/7-specific cleavable peptide substrate, Asp-Gly-Val-Asp (DEVD), has been commonly
used as a caspase-cleavable apoptosis imaging probe to track caspase activity in both invitro and in-vivo conditions of tumor cells.416, 417
As shown in Figure 4.13a, no green fluorescence was observed with the GM-treated
cells, while A549 cells treated with Dox alone showed slight green fluorescence. Upon
NIR laser irradiation, a higher level of strong green fluorescence was observed for
[(GM@Dox) LI]-PF + Laser compared to [(GM@Dox) LI]-PF – Laser. [(GM@Dox) LI]PF + Laser treatment caused morphological changes in cells. Shrinking and rounding of
cells were observed, as is typical of apoptosis and the activation of caspase3/7 (see merged
image Figure 4.13a). These results suggest that [(GM@Dox) LI]-PF + Laser induces
apoptosis through caspase-3/7 activation. The quantified data from the fluorescence images
show a 20-fold increase in green fluorescence intensity for [(GM@Dox) LI]-PF + laser
compared to GM alone (Figure 4.13b). Since caspase-3/7 activation indicates apoptotic
cell death activation, the data verify that the peak of apoptotic cell death occurs after laser
exposure to the nano-assemblies, which suggests that the combined approach of
chemotherapy nano-assembly-mediated PTT causes the apoptosis of A549 cells.
To further confirm apoptosis detection, DAPI staining was utilized to check the
morphology of the A549 cell nucleus with or without treatment with [(GM@Dox) LI]-PF
+ Laser (Figure 4.13c). A549 cells treated with [(GM@Dox) LI]-PF + Laser showed
apparent apoptotic features compared to the cells not given treatment. A549 cells treated
with [(GM@Dox) LI]-PF + Laser showed an increase in the number of cells with small,
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Figure 4.13. Apoptosis mechanism of A549 cells evaluated by Caspase-3/7 assay. (a) Cells
are shown in a bright field, and green fluorescent images correspond to the expression of
Caspase-3/7. Morphological changes such as shrunken cells and the aggregation of cell
nuclei in A549 cells were observed in laser-treated [(GM@Dox) LI]-PF compared to cells
treated with carrier GM. (b) Quantitative analysis of green fluorescence density, indicative
of Caspase-3/7 expression for cells treated with nanomaterials, was detected by a
fluorometric assay. The data are presented as the mean ± SD (n=3). N.S = non-significant.
A ** represents p < 0.01 and *** rep p < 0.001, indicating that data are statistically
significant by one-way ANOVA compared with free Dox. (c) DAPI fluorescence image of
apoptotic A549 cells treated with [(GM@Dox) LI]-PF + laser, white arrows indicate
nuclear disintegration (ND), red arrows indicate cell membrane blebbing (BL) and yellow
arrows indicate nucleus condensation (NC), Scale bar = 10 mm.
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condensed nuclei (nuclei condensation, NC), nuclei disintegration (ND), and membrane
blebbing (BL), which indicates cell structure loss (Figure 4.13c). These morphological
changes indicated that [(GM@Dox) LI]-PF + laser-treated A549 cells have undergone
apoptosis. Untreated control cells remained intact, and evenly shaped nucleus compared to
[(GM@Dox) LI]-PF + Laser treated A549 cells.
4.3.23 Tubulin assay
A tubulin assay was carried out, as microtubules are natural biopolymers that are
produced by the polymerization of

- and -tubulins, one of the components of the

cytoskeleton and they contribute to cellular transport, cell motility, and mitosis. 418
Previously, it has been reported that PTT inhibits cancer cell migration and invasion by
disturbing the cytoskeleton.419-421 To confirm the effect of PTT induced by [(GM@Dox)
LI]-PF in the presence and absence of laser irradiation on microtubule integrity, the
[(GM@Dox) LI]-PF nano-assemblies were incubated with A549 cells and was analyzed
by fluorescence microscopy.
As shown in Figure 4.14, the microtubules of the GM-treated A549 cells (control)
were outstretched and slender, exhibiting a well-organized cytoplasmic network.
Compared to the control, almost no noticeable morphological change in the microtubules
was observed when incubated with free Dox and [(GM@Dox) LI]-PF – Laser. However,
enhanced damage and disruption were seen in the microtubule skeleton structure when
cells were incubated with [(GM@Dox) LI]-PF + Laser. The peripheral microtubules were
shrunk, condensed, and rounded up into clusters. Damaged microtubules cause failed
replication and eventually lead to cell apoptosis. Based on the above results, we concluded
that the [(GM@Dox) LI]-PF + Laser (a) amplifies mitochondrial oxidative stress (mtROS)
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Figure 4.14. [(GM@Dox) LI]-PF + laser causes the damage of microtubules. Microtubules
and nucleus were stained by tubulin (green) and DAPI (blue), respectively. A substantial
disruption of the microtubule network was observed, which caused the cells to become
more round and undergo apoptosis when treated with [(GM@Dox) LI]-PF + laser,
compared to GM (carrier) treated A549 cells. A549 cells were treated by GM, Dox, and
[(GM@Dox) LI]-PF

(b) reduces GSH and ATP levels (c) disturbs the mitochondrial membrane potential (d)
upregulates caspase-3/7, and (e) disrupts the microtubule network which are all indications
of programmed cell death.
4.4

Conclusion
In summary, we have fabricated dual-targeted nano-assemblies that offer

combinational therapy: chemotherapy and PTT against NSCLC. The photothermal activity
of the nano-assembly was enhanced by 15 ± 4.5 °C even with the use of lower laser
intensity, 350 mW. This was done by co-encapsulating GNR and IR 780 inside a liposome
layer. Dox was loaded into the mesoporous silica coating surrounding the GNR. IR 780
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dye was encapsulated inside the liposome, and the entire nano-assembly was conjugated
with the tumor-targeting ligands GE-11 and folic acid. The nano-assemblies are efficiently
internalized inside the cancer cells through clathrin-mediated endocytosis via targeting
ligands. The burst of the TSL layer was driven by PT activity triggered by NIR laser
irradiation. Subsequently, Dox was released from the mesoporous pores due to a weakly
acidic condition-induced protonation in the tumor micro-environment. The encapsulated
Dox was 20-fold times more efficacious compared to free Dox. We have also investigated
the cancer cell death mechanism after treating the cells with the nano-assemblies. The
results indicate that the cancer cells undergo apoptosis via an intrinsic mitochondrial
pathway that can be directly triggered by the chemo-photothermal treatment given by nanoassemblies. Compared with monotherapy, the application of multiple treatments could
reduce the required dose of the drug to achieve the goal of overcoming drug resistance in
cancer. Due to the synergistic effect of chemo-photothermal therapy, this proposed
multifunctional targeted drug delivery system shows great promise in improving the
therapeutic effect, providing a powerful platform for optimal therapeutic effect at low
doses.
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CHAPTER 5. RAPID DIAGNOSTICS OF MYCOBACTERIA USING THE
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5.1

Introduction
Tuberculosis (TB) is an infectious disease generally caused by Mycobacterium

tuberculosis (Mtb) that exists as a latent and active condition. Latent TB occurs when
mycobacteria infect the body but remain silently in an inactive state, representing the silent
epidemic.422 According to the WHO Global Tuberculosis Report for 2020, approximately
almost 10 million new cases and 1.6 million deaths are caused by TB, making it one of the
most virulent diseases.285 Effective diagnosis of TB allows for early treatment and potential
prevention of disease spreading.423 Those diagnosed with latent TB infections may elect to
take medications to reduce the risk of TB becoming active. Diagnosis of active TB provides
opportunities to prevent the spread of tuberculosis, such as covering the mouth when
coughing, wearing a mask, and reducing contact with others while undergoing treatment,
which generally involves the administration of multi-drug regime antibiotics. 424 Common
detection methods include the tuberculin skin test, amplification tests, nucleic acid, culture
methods, and conventional microscopy.425

However, these methods are often time-

consuming, labor-intensive, and require expensive laboratory equipment. Hence, rapid
detection for Mtb is needed, which can be relatively inexpensive to manufacture, provide
accurate and reliable results, operate without requiring clinical personnel and instruments
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A variety of nanomaterials have been developed for the rapid capture and detection
of TB. Examples are silica nanoparticles, quantum dots, gold nanoparticles, and magnetic
nanoparticles.426 Qin et al. reported a study in which mesoporous silica nanoparticles
coupled with fluorescent dye for the detection of Mtb and the detection window has been
2 h.427 A study was reported by Liandris and his co-workers, who utilized quantum dots of
CdSeO3 coupled with streptavidin and species-specific probes, which detect surface
antigen of mycobacterium species in 2 h.428 The gold nanosphere (AuNPs) was firstly
reported in TB diagnosis by Baptista et al. and they have coupled DNA (oligonucleotide
derived from the gene sequence of the Mtb RNA polymerase subunit) onto AuNPs for the
colorimetric detection of Mtb with 15 minutes detection time.429 Magnetism-based
detection techniques in the past have employed magnetic nanoparticles to magnetically
separate analyte from the sample using an external magnet.
We have developed a simple and rapid diagnostic test for detecting mycobacteria
using magnetic nanoparticles.430 Mycobacterium smegmatis (Msmeg) is a mimic of
Mycobacterium tuberculosis (Mtb) that is often utilized in the study of tuberculosis due to
its faster doubling time and lower biosafety level facility requirements. In addition, Msmeg
shares many homologous genes and similar cell wall composition as Mtb. Therefore, the
diagnosis method could also diagnose a TB infection rapidly. The nanoparticles (NPs) have
a core-shell structure. The core consists of superparamagnetic nanoparticles (MNPs) and a
silica shell. Superparamagnetism is a phenomenon that occurs primarily in nanoscale,
single-domain MNPs. When exposed to an external magnetic field, this MNPs develops a
strong internal magnetization as a result of electron exchange coupling within the domain
and thus becomes superparamagnetic.431 Superparamagnetic properties of MNPs were used
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as an external cue to capture bacteria and silica coating offers stability and surface for
further modification. These multi-core shell nanoparticles (multiple MNPs core with single
silica shell – multi-core shell nanoparticles) are addressed as silica magnetic nanoparticles
(SMNPs). The ligand NHS-PEG-Silane coupled to a surface of silica shell (SMNP-PEGNHS). The reaction is between the hydroxyl group of silicates on the silica surface and
ethoxy silane of NHS-PEG-Silane.432 Following conjugation of NHS-PEG-Silane lectins
such as Concanavalin A (Con A) and Aleuria aurantia (AAL), Wisteria floribunda (WFL)
(AAL), and Bovine serum albumin (BSA) conjugated separately on SMNP-PEG-NHS.
NPs were abbreviated as SMNP-Con A, SMNP-AAL, SMNP-WFL, and SMNP-BSA.
The mycobacteria have a unique cell wall that distinguishes them from other
bacteria, as shown in Scheme 5.1. The cell wall of mycobacteria consists of five layers
such as outermost layers, mycomembrane, arabinogalactan, peptidoglycan, followed by the
plasma membrane (See Scheme 5.1).433 Mannose and arabinose are among the most
abundant carbohydrates present on the outermost layer, and an important virulence factor
of Mtb, which is found in lipoarabinomannan (LAM).433 The outermost layer also contains
arabinomannan, protein, and lipids. The outer layer is followed by the mycomembrane,
which consists of mycoloyal residue (mycolic acids), distributed as a thick layer, while the
internal layers of mycobacteria consist mostly of peptidoglycan covalently linked to the
arabinogalactan layer.433 We chose plant lectins Con A which has affinity toward mannose,
AAL has binding preference to arabinose, and WFL has binding affinities to GalNAc. The
reported binding affinity of Con A towards mannose carbohydrate epitope was 2.89 M.434
AAL, and WFL binds to arabinose and N
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Scheme 5.1. Schematic of cell wall of Mycobacteria. This scheme was produced
by Kavini Rathnayake and is used with her permission.

affinity 16 M and 92.3 M, respectively.435, 436 WFL and GalNac interaction used as a
positive control as GalNac residue was absent in cell wall of mycobacteria. 437 Similarly,
BSA protein act as a negative control. Lectins typically have multiple carbohydratebinding sites, and as a result, lectin binding to mycobacterial cell wall frequently results in
strong binding due to crosslinking with cell surface carbohydrate epitopes. 113 Multivalent
lectins with proper presentation and a lectin with two or more carbohydrate-binding sites
are required for multivalent interactions.113 Multivalent interaction between nanoparticles
conjugated lectins and carbohydrate epitopes present on the cell wall of mycobacteria is
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possible by taking advantage of the size and larger surface area of nanomaterials that can
be used as a scaffold.113 Hence, lectin such as Con A and AAL conjugated SMNP would
specifically bind to mannose/arabinose carbohydrates epitopes present on the LAM of
bacterial cell wall. This binding would then cause the bacteria to fall out of the solution
and present as a magnetic precipitate within 1 minute. This precipitate could therefore be
used to determine the presence of mycobacteria. We conducted a systemic study to prove
our developed rapid diagnostic test for TB can detect bacteria within 1 minute, with the
lowest detection limit being 10 CFU/mL.
5.2
5.2.1

Experimental
Materials and Instruments
Tetraethyl orthosilicate (TEOS, 98%), IGEPAL® CO-520, oleylamine (70%), oleic

acid (90%), iron (III) acetylacetonate (97%), benzyl ether (98%), ammonium hydroxide
(28-30%), cyclohexane (99.5%), concanavalin A lectin (ConA) from Canavalia
ensiformis, and N-(2-Hydroxyethyl) piperazine-N’-(2-ethanesulfonic acid) (HEPES
solution) (1M, pH 7.0-7.6) were purchased from Sigma-Aldrich (Missouri). Absolute
ethanol (200-proof), hexane (4.2%), and Hoechst dye were purchased from ThermoFisher
Scientific (Massachusetts). 1,2-Hexadecanediol was purchased from TCI America
(Oregon). NHS-PEG-silane (1000 Da) was purchased from Nanocs (Massachusetts).
Aleuria aurantia Lectin (AAL), Wisteria floribunda Lectin (WFL), and Bovine serum
albumin (BSA) were purchased from Vector Laboratories (California). Mycobacterium
smegmatis (ATCC® 700084TM) and Streptococcus mutans (ATCC® 25175TM) were
purchased from American Type Culture Collection (Virginia). Difco TM Middlebrook 7H9
broth, DifcoTM Middlebrook 7H10 agar, BBLTM Middlebrook ADC enrichment, BBLTM
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Middlebrook OADC enrichment, BBLTM Brain Heart Infusion (BHI), and DifcoTM BHI
agar were purchased from Becton Dickenson (New Jersey). Double distilled water was
used throughout these experiments unless otherwise specified.
Fluorescence microscopic images were obtained using an Olympus CKX53
inverted fluorescence microscope (Tokyo, Japan) equipped with a Lumenera Infinity 3
camera (Ottowa, Canada). Dynamic light scattering (DLS) measurements were taken
using a Malvern Zetasizer (Malvern Panalytical Inc., Massachusetts). Transmission
electron microscopy (TEM) images of the nanoparticles were obtained on an FEI Tecnai
G2 Osiris S/TEM (Oregon). Attenuated total reflectance Fourier-transform infrared (ATR
FTIR) spectroscopic analyses were done using Nicolet iS50 ATR FTIR (ThermoFisher
Scientific). Thermogravimetric analyses (TGA) were performed by a Discovery Q550 TA
Instrument (Delaware). Optical density measurements were taken from the Spectramax M2
plate reader (Molecular Devices, California). The Msmeg samples were incubated in a
Corning LSE shaking incubator (New York). The bacteria samples and the related
glassware were autoclaved in a BioClave autoclave (Ward’s Science, New York) All
aseptic bacterial techniques were conducted under a 1300 Series A2 biosafety cabinet
(ThermoFisher Scientific).
5.2.2

Fabrication of magnetic nanoparticles (MNPs)
The synthesis of MNPs followed the previously reported procedure of Sun et al.438

Iron (III) acetylacetonate (0.706 g, 2.0 mmol), 1,2-hexadecanediol (2.584 g,10.0 mmol),
oleic

acid

(2.239

mL,

6.0

mmol),

and oleylamine (2.820

mL,

6 mmol)

in

dibenzyl ether (20 mL) were stirred under a blanket of nitrogen. The mixture was then
heated to 200 °C for 2 h, followed by heating at 280 °C for 1 h, and finally stirred overnight
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at 400 rpm. The resulting MNP solution was purified by adding ethanol (200-proof, 40
mL), and the mixture was centrifuged at 7000 rpm for 10 min. The black precipitate was
re-dispersed in hexane (30 mL) containing oleic acid (0.05 mL) and oleylamine
(0.05 mL), and the mixture was centrifuged at 6000 rpm for 10 min. The precipitate was
discarded, the supernatant was collected, and ethanol was added. After centrifugation, the
precipitate was re-dispersed in hexane.
5.2.3

Synthesis of multi-core shell silica-coated magnetic nanoparticles (SMNPs)
A modified Stöber process was employed to introduce a silica coating to the

MNPs.439 IGEPAL (0.225 g) was dissolved in cyclohexane (11 mL) and sonicated for 10
min. MNPs (0.5 mg) was then dispersed in the IGEPAL and cyclohexane mixture and
4

added dropwise to the solution, and the mixture was stirred overnight. The product was
purified by centrifugation at 15000 rpm for 10 min and re-dispersion in ethanol for 3 times
to give SMNPs. To prepare the fluorescent magnetic nanoparticles, RITC-APTMS
precursor was first prepared. Briefly, rhodamine isothiocyanate (RITC) (8.0 mg, 0.015 mM
in ethanol) was stirred overnight with (3-aminopropyl)trimethoxysilane (APTMS) (5.2 uL,
0.03mM) in anhydrous ethanol (15.0 mL) at 42 °C to obtain the RITC-APTMS precursor.
As-prepared RITC-APTMS precursor was then grafted to the magnetic nanoparticles
through the reaction between APTES and hydroxyl groups on the SMNPs. The rest of the
procedures were similar as described above for SMNP preparation. Similarly, FITC-SMNP
was prepared.
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5.2.4

Functionalization of SMNPs with NHS-PEG-Silane
To determine the mass of NHS-PEG-silane required to completely encapsulate the

SMNPs, the surface area of the nanoparticles was calculated from the hydrodynamic radius
and concentration of SMNPs and multiplied by the footprint of NHS-PEG-silane. This
value was then multiplied by the volume of SMNPs to give the amount of NHS-PEG-silane
required to functionalize the SMNPs. SMNPs were mixed with the calculated amount of
NHS-PEG-silane, and the mixture was stirred overnight. The solution was purified by
centrifugation at 15,000 rpm for 10 min and redispersion in ethanol. The purified NPs
abbreviated as SMNP-PEG-NHS.
5.2.5

Conjugation of proteins with SMNP-PEG-NHS
The carbonyl groups present on the surface of functionalized SMNPs were used for

conjugation with the amine groups of the various proteins. The proteins Con A, AAL WFL,
BSA, and mycobacterial polyclonal antibody (pAb) were mixed with functionalized
SMNPs and stirred overnight. The amount of each protein needed to conjugate 1mg/mL of
functionalized SMNPs was calculated based on the hydrodynamic size and concentration
of functionalized SMNPs. This value was multiplied by the volume of functionalized
SMNPs to give the total protein required for conjugation of the entire batch of
functionalized SMNPs. Finally, the solution mixtures were purified by centrifugation at
15,000 rpm for 10 min and redispersion in water. The purified final NPs abbreviated as
SMNP-PEG-NHS- Con A or SMNP-Con A, SMNP-PEG-NHS- AAL or SMNP-AAL,
SMNP-PEG-NHS- WFL or SMNP-WFL, and SMNP-PEG-NHS- BSA or SMNP-BSA,
respectively.
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5.2.6

Morphology and size analysis by dynamic light scattering and electron
microscopy
The size and zeta potential of the nanoparticles (MNPs, SMNPs, SMNP-PEG-NHS,

and protein conjugated SMNPs) were determined by DLS. TEM images of the
nanoparticles were obtained at an accelerating voltage of 200 kV. To prepare samples for
TEM, 200 mesh carbon thin film-coated Cu grids were drop-casted with a dilute solution
of the nanoparticle and vacuum dried overnight.
5.2.7

Fourier-transform infrared spectroscopy (FT-IR)
Nanoparticle samples were prepared for ATR FT-IR by centrifugation and drying

to remove the solvent. The successful synthesis of SMNPs, SMNP-PEG-NHS, and proteins
conjugated SMNPs was then verified using ATR FT-IR.
5.2.8

Thermogravimetric analysis
TGA of the nanoparticles MNPs, SMNPs, SMNP-PEG-NHS, and SMNP-Con A

was performed under argon (99.999%). Approximately 1 mg dried nanoparticles were
heated at a rate of 5°C/min to 100°C and then held isothermal for 15 min, followed by
heating at a rate of 5°C/min to 700°C. The MNPs loaded in silica shell was calculated by
analyzing the weight loss difference between MNPs and SMNPs. Similarly, the ligand
(NHS-PEG-Silane) content was analyzed by measuring the weight loss difference between
SMNPs and SMNP-PEG-NHS. Finally, the amount of Con A was calculated by measuring
the weight loss difference between SMNP-PEG-NHS, and SMNP-PEG-NHS-Con A.
5.2.9

Bacterial culture
Mycobacterium smegmatis (Msmeg) was grown in sterilized Middlebrook 7H9

medium supplemented with 10% Middlebrook ADC enrichment and 0.05% glycerol at
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37°C while shaking at 150 rpm. Once an optical density (OD650) of 2.0 was reached, the
bacterial concentrations were determined by serial dilution and plating on Middlebrook
7H10 agar plates with Middlebrook OADC enrichment. Streptococcus mutans (S. mutans)
was grown in BHI and plated on BHI agar following a similar protocol to Msmeg.
5.2.10 Hoechst staining
Once OD650 of 2.0 was reached, Msmeg bacteria cells (2 mL, ~109 bacteria cells)
were harvested, centrifuged at 5,000 rpm, and re-dispersed in 1 mL of HEPES buffer with
Ca+2 (0.1mM) and Mn+2 (0.1mM). T
incubated at 37°C for 1 h. To remove the excess dye, Hoechst-dyed bacteria were
centrifuged at 5,000 rpm for 10 min and the supernatant was discarded. The pellet was redispersed in fresh HEPES buffer (5 mL) containing Ca+2

+2

(100

5.2.11 Magnetic precipitation assay
SMNPs conjugated with proteins (Con A, AAL, WFL, BSA or polyclonal
-dyed Msmeg

9

CFU/mL) in a microcentrifuge tube and rubbed in between palms for a minute. The
formation of a brown precipitate within less than a minute was observed. The magnetic
precipitation was confirmed using a neodymium iron boron magnet (max. pull 69 lb). The
same process was followed with the S. mutans bacteria. The precipitate from the magnetic
precipitation assay was separated and smeared on a glass slide and observed using a
-SMNPs-Con A was
-dyed Msmeg (~109 bacteria cells/mL) in HEPES with Ca+2
(0.1mM) and Mn+2 (0.1mM) and incubated at 37°C for 1 h while shaking at 180 rpm. Wet
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and dried samples of the mixture of fluorescence-labeled bacteria and nanoparticles were
observed under fluorescence microscopy to see the interactions between bacteria and
nanoparticles.
5.2.12 Colony counting to determine the CFU/mL
After OD650

Msmeg suspension was taken

and serially diluted 108-fold in OADC-enriched Middlebrook 7H9 broth. From the diluted
-enriched Middlebrook 7H10 agar plates. Colonies
were counted after 48 h of incubation at 37°C. After multiplying the number of colonies
by dilution factor it was reported as log colony-forming units (CFUs)/mL. A similar
protocol was followed to count the colonies of S. mutans grown in BHI and plated on BHI
agar.
5.2.13 Bacterial capture efficiency of SMNP-Con A
We have tested the bacterial capture efficiency of nano-assemblies at various
concentration series. Hoechst-dyed Msmeg

3

CFU/mL) bacterial suspension

was incubated with different amounts (5, 10, 15, 25, 50, 75, and 100 mg/mL) of SMNPCon A in a microcentrifuge tube and rubbed in between palms for a minute. The formation
of a brown precipitate within less than a minute was observed. The magnetic precipitation
was confirmed using a neodymium iron boron magnet. After magnetic separation by the
nanoparticles, the supernatant was discarded. 100 L of HEPES buffer was added to the
microcentrifuge tube to dissolve the magnetic pellets stuck on the wall of the
microcentrifuge tube, then sampled and analyzed for bacterial concentration via a plate
counting method. The bacterial-capture efficiency of the NPs was tested by counting the
number of CFU on the agar plates.
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5.2.14 Ability of SMNP-Con A to detect lowest concentration of bacteria
SMNPat very low concentrations (10 and 102 CFU/mL). After magnetic separation by the
nanoparticles, the supernatant was discarded. 100 L of HEPES buffer was added to the
microcentrifuge tube to dissolve the magnetic pellets stuck on the wall of the
microcentrifuge tube, then sampled and analyzed for bacterial concentration via a plate
counting method. The bacterial-capture efficiency of the NPs was tested by counting the
number of CFU on the agar plates. To check bacteria-NPs interaction at the lowest
concentration of bacteria 10 CFU/mL), precipitate from magnetic precipitation assay was
separated and smeared on a glass slide and observed using a fluorescence microscope.
-SMNPs-

-dyed

Msmeg (~109 bacteria cells/mL) in HEPES with Ca+2 (0.1mM) and Mn+2 (0.1mM) and
incubated at 37°C for 1 h while shaking at 180 rpm. Wet and dried samples of the mixture
of fluorescence-labeled bacteria and nanoparticles were observed under fluorescence
microscopy to see the interactions between bacteria and nanoparticles.

Scheme 5.2. Stepwise synthesis of protein (Con A) conjugated SMNP.
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Figure 5.1. Morphology study of nanomaterials. TEM image of (a) MNPs (scale bar: 20
nm), (b) TEM image showing crystal lattice structure of MNP, with a single plane
marked by the white arrows (scale bar: 5 nm) and (c) TEM image of SMNPs (scale bar:
50 nm).
5.3
5.3.1

Results and Discussion
Synthesis and characterization of nano-assemblies
The stepwise synthesis of lectin conjugated SMNPs was illustrated in Scheme 5.2.

Firstly, MNPs were synthesized by the thermal decomposition method as reported by Sun
et al.438 High-temperature reaction of iron(III) acetylacetonate (Fe(acac)3), with 1,2hexadecanediol in the presence of oleic acid and oleylamine leads to monodisperse
magnetite (Fe3O4) nanoparticles (MNPs). Fe(acac)3 act as an ideal precursor due to high
yields and low cost. 1,2- hexadecanediol, reacted well with Fe(acac)3 to yield MNPs. Oleic
acid and oleylamine are necessary for the formation of particles. The MNPs synthesis by
thermal decomposition method controls the NPs size to get monodisperse MNPs with 5 to
10 nm in diameter. The uniform shape and size distribution of MNPs was analyzed by
transmission electron microscopy (TEM) and showed an iron oxide core of about 10.2 ±
0.7 nm in diameter on average (Figure 5.1a and Table 5.3.1). The crystal lattice structure
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of the MNPs could clearly be seen (Figure 5.1b), with the distance between planes being
3.5 Å. The size of the nanoparticles was further analyzed by DLS which was found to be
11.7 ± 2.3 nm (Table 5.3.1). The multi-core shell structure of the SMNPs was confirmed
by high-angle annular dark-field scanning transmission electron microscopy (HAADFSTEM) and energy-dispersive X-ray spectroscopy (EDS) (Appendix Figure D.1.). SEM
analysis of SMNPs was also shown in Appendix Figure D.2.
Table 5.3.1. Characterization of nanomaterials by TEM and DLS
Nanomaterials

TEM (nm)

MNP
SMNP
SMNP-PEG-NHS
SMNP-PEG- NHS-Con A

10.2 ± 0.7
35.4 ± 3.2
-

Hydrodynamic
diameter (nm)
11.7 ± 2.3
166.5 ± 7.2
238.6 ± 13
462.5 ± 12

Zeta potential
(mV)
NA
-35.1 ± 0.7
-28.9 ± 1.4
-17.5 ± 0.7

Next magnetic nanoparticles were coated with silica by the reverse micelle method. 440
Magnetic nanoparticles were previously coated with hydrophobic ligands and then
dispersed in an organic media. The dispersion is then contacted with aqueous alkaline
ammonium hydroxide solution containing the surfactant, IGEPAL with constant stirring,
determining the microemulsion formation. In the final stage, a silica precursor, generally
TEOS is added and allowed to react during a determinant period of time. The growth of
the silica coating on the magnetic surface is regulated by experimental parameters such as
TEOS concentration, amount of NH4OH, IGEPAL concentration and MNPs
concentration.441 The volume of TEOS precursor is an important factor that affected the
thickness of the silica shell of superparamagnetic MNPs. When TEOS is added to the
mixture, it converts to hydrolyzed TEOS adsorbed onto the superparamagnetic MNPs
surface, followed by condensation reaction to form the silica shell. 442 As shown in
Appendix Table D.1., as the amount of TEOS increases (100 to 200 mL) the size of the
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silica shell increases and hence increases in size. The NH4OH content also affects the size
of the silica shell. As shown in Appendix Table D.1 and Table D.2., the increase in the
content of both TEOS and NH4OH can increase the shell thickness of SMNPs, but a good
match between these two components is essential to avoid the formation of core-free silica
particles. It has been previously reported, IGEPAL self assembles into micelles in
cyclohexane due to its hydrophilic groups.441, 443 The oleic acid that adsorbed on the surface
of superparamagnetic MNPs was exchanged to IGEPAL in the cyclohexane. At volume
that concentration is higher than the surfactant CMC (0.22 to 0.45 g), superparamagnetic
SMNPs was well obtained with diameters of 182.8 ± 6 nm with 0.22 g of surfactant
(Appendix Table D.3.). However, IGEPAL micelles could fuse at high concentrations,
resulting in aggregated SMNPs. MNPs concentration also affects the formation of SMNPs.
As shown in Appendix Figure D.3., as the amount of MNPs increases, the size of SMNP
increases as more than one MNPs are covered with one silica shell and form multi-core
silica nanoparticles. We have conducted a systematic study to understand the impact of
each reagent on silica coating surrounding MNPs and from all of the above observations,
we have selected, 0.02 mg of MNPs, 0.22 g of IGEPAL, 100 L of NH4OH, and TEOS
were used for further study. As shown in the TEM image, SMNPs have a diameter of 35.4
± 3.2 nm and indicated that multiple MNPs cores were encapsulated in the silica shells
(Figure 5.1c). The multi-core shell structure of the SMNPs was confirmed by high-angle
annular dark-field scanning transmission electron microscopy (HAADF-STEM) and
energy-dispersive X-ray spectroscopy (EDS) (Appendix Figure D.1). Furthermore, the size
of the SMNP was analyzed by DLS (Table 5.3.1). The hydrodynamic diameter of SMNPs
was determined to be 166.5 ± 7.2 nm.
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NHS-PEG-Silane is a surface reactive PEG derivative that is used to modify, silica
shell surface via the reaction between hydroxyl group and ethoxy silane.444

In addition

to that, pegylation can greatly suppress the non-specific binding of charged molecules to
the modified surfaces, provide stability and surface to further conjugation with
biomolecules such as proteins, aptamers, and antibodies.445, 446 Finally, SMNP-NHS-PEG
Silane was used for crosslinking between primary amines (NH2) in lectin. The Nhydroxysuccinimide ester (NHS) groups at SMNP-NHS-PEG Silane end react specifically
and efficiently with N-terminal amino groups of lectins and form stable amide bonds. 447
After functionalization with NHS-PEG-silane to form PEG-SMNP, the hydrodynamic
diameter increased to 238.6 ± 13 nm. The conjugation of the protein Con A further
increased the hydrodynamic diameter of the final nano-assembly to 462.5 ± 12 nm.
The zeta potential of the nanoparticles was also measured after the addition of each
layer to monitor changes in surface charge. The zeta potential of MNPs could not be
obtained due to their hydrophobicity, but the zeta potential of SMNPs was determined to
be -35.1 ± 0.7 mV due to the presence of Si-OH groups. The surface electrical charge of
nanomaterials also represents the stability of colloidal system. 119 As shown in Appendix
Table D.1, Table D.2, and Table D.3, the impact of varying concentrations of TEOS,
IGEPAL, and NH4OH on silica shell formation as well as the stability of SMNP. After
functionalization with NHS-PEG-silane, the nanoparticles showed a more positive zeta
potential of -28.9 ± 1.4 mV, due to the addition of amine groups on the surface of PEGSMNPs. Finally, the conjugation of proteins to the amine groups through NHS ester
coupling chemistry further increased the zeta potential to -17.5 ± 0.7 mV.
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To further confirm the successful synthesis of the nanoparticles, FTIR analysis was
carried out after the addition of each layer. Characteristic peaks for the nanoparticles were
identified after each step in the synthesis (Figure 5.2a). SMNPs showed characteristic
peaks at 1045 cm-1 and 880 cm-1 due to the asymmetric stretching vibration of Si-O-Si
bending and the asymmetric bending vibration of Si-OH bending respectively. After
functionalization with NHS-PEG-Silane, the spectrum of SMNP-PEG-NHS continued to
show the characteristic peaks for SMNPs and displayed additional peaks that are
characteristic of PEG-NHS. Characteristic peaks of SMNP-PEG-NHS due to the
functionalization with NHS-PEG-silane were observed at 1179 cm -1 and 1640 cm-1
corresponding to C-N and C=O stretching vibrations, respectively. The success of protein
conjugation was confirmed with FTIR. Characteristic peaks of Con A were due to the
presence of amides, which showed peaks between 1391 cm -1 and 1555 cm-1 due to N-H
bending vibrations and between 1563 cm-1 and 1633 cm-1 due to C=O stretching vibrations.
Similar spectra were observed for control proteins, which are displayed in Appendix
Figure D.4. These peaks confirmed the presence of the protein on the surface of the
nanoparticles.
Analysis of the ligand content of the nanoparticles was completed after each step
of synthesis using TGA, as shown in Figure 5.2b. Percentage weight loss was calculated at
each step to determine the amount of ligand conjugated to the nanoparticle. The percentage
of weight loss between MNPs and SMNPs was found to be 2.55 ± 0.6%. Additionally, the
percentage of weight loss between SMNPs and SMNP-PEG-NHS showed NHS-PEGSilane ligand was determined to be 22.81 ± 1.5%. Similarly, the percentage weight loss
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a

b

Figure 5.2. (a) FTIR spectra for SMNP, SMNP-PEG-NHS, SMNP-PEG-NHS-Con A, and
pure Con A. (F) TGA curves of various nano-assemblies.
between the protein-conjugated nano-assemblies and SMNP-PEG-NHS was found to be
9.83 ± 0.8%.
5.3.2

Rapid bacterial detection by magnetic precipitation assay
The rapid detection of Msmeg bacteria was carried out by our developed magnetic

precipitation assay as shown in Scheme 5.3. Briefly, SMNPs conjugated with proteins (Con

9

mixed with an aliquot of Msmeg

CFU/mL) and incubated at

room temperature for 1 min. Subsequently, a magnet was used to capture the “magnetized”
bacteria (magnetic nanoparticles bounded to the cell surface of Msmeg) onto the wall of
the tube. As shown in Figure 5.3a and Figure 5.3b, the brown precipitates were observed
in less than 1 minute after rubbing the eppendorf between the palm when SMNP-Con A or
SMNP-AAL was used. The lectins, Con A and AAL recognize the mannose and arabinose
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Scheme 5.3. Illustration of the procedures of bacteria capture. Msmeg in suspension are
mixed with SMNP-Con A followed by 1 min incubation. The “magnetized” bacteria were
attracted onto the wall of the vial by a magnet. After the removal of the remaining
solution, bacteria were captured by NPs, washed using HEPES buffer, then plated and
counted from the number of the bacterial colonies.
carbohydrate epitopes, found in the cell wall of the Mycobacteria.
Multivalent SMNP-Con A/AAL bind to the mycobacteria bacterial cell wall and
crosslink the bacteria within minutes to form a visible precipitate without the need for any
instrumentation. The ability of SMNP-Con A or SMNP-AAL to form a precipitate with
mycobacteria was compared with SMNP conjugated with mycobacterial polyclonal
antibody (SMNP-pAb). The brown precipitate observed with SMNP-pAb was similar to
the precipitate observed with SMNP-ConA/AAL. Therefore the ability of Con A and AAL
to detect mycobacteria is similar to polyclonal antibody (pAb). However, when Msmeg
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Msmeg/SMNP-Con A

a

Msmeg/SMNP-WFL

d

Msmeg/SMNP-AAL

Msmeg/SMNP-pAb

c

b

Control Study with
S. mutans- SMNPCon A

Msmeg/SMNP-BSA

e

f

Figure 5.3.Photographs of magnetic precipitation assay.

was incubated with SMNP-WFL and SMNP- BSA, no precipitate was seen. (Figure 5.3d
and Figure 5.3e). WFL was used as a positive control which has binding affinity towards
GalNac carbohydrate residue which are absent on mycobacterial cell wall. BSA is used as
a negative control. We have also conducted control experiment by incubating
Streptococcus mutans bacteria with SMNP-Con A, as S. mutans species are abundantly
found in oral mucosa. As shown in Figure 5.3f, no precipitate was observed when sputum
was spiked with S. mutans. To observe the bacterial precipitate under fluorescence
microscope, Msmeg was stained with Hoechst dye (blue) and SMNPs-ConA/AAL/pAb
was fluorescently tagged to green fluorescent FITC dye. As shown in Figure 5.4, SMNP-
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FITC stained NPs

Merged

SMNP-pAb

SMNP-AAL

SMNP-Con A

Hoechst stained
Msmeg

Figure 5.4. Fluorescent image of Msmeg bacteria binding to FITC- SMNP-Con A, where
NPs stained with FITC and Msmeg bacteria stained with Hoechst dye. Scale bar is 10 m.

Con A/AAL/pAb, crosslinked to the Msemg to form large fluorescent agglomerates.
5.3.3

Detection of low concentration of Msmeg bacteria
To further study the bacteria and SMNP-Con A interactions at various

concentration series of SMNP-Con A, we incubated Msmeg at a constant concentration of
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a

b

Figure 5.5. Detection of the lowest concentration of bacteria. (a) Capture efficiencies of
Msmeg by SMNP-Con A at various concentrations indicated. (b) Photograph of agar plates
of display the quantity of Msmeg captured in the precipitate when incubated with 5 – 100
mg/mL of SMNP-Con A. Msmeg was kept at a constant concertation of 103 CFU/mL. The
control agar plate is of 103 CFU/mL Msmeg without incubation with SMNP-Con A.

103 CFU/mL with various concentrations of SMNP-Con A ranging from 5 to 100 mg/mL.
The SMNP-bound Msmeg were then magnetically captured, separated, and plated on agar
plates. The magnetic capture efficiencies of bacteria by NPs are plotted as shown

%

=

.

× 100%

.

(5.1)

in Figure 5.5. The capture efficiency was calculated as shown in equation 5.1. At 5 mg/mL
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b

100

10

Figure 5.6. (a) Limit of detection for capturing Msmeg (100 and 10 CFU/mL) at 15 mg/mL
concentration of SMNP-Con A. (b) Photograph of agar plates with Msmeg (100 and 10
CFU/mL) captured by SMNP-Con A.

of SMNP-ConA the capture efficiency was 11 ± 1 %. The capture efficiency increased in
a concentration-dependent manner as shown in Figure 5.5a. However, at SMNP-Con A of
5 and 10 mg/mL the magnetic precipitate was slight and was not discernible by eye.
However after a threshold value of 15 mg/mL concentration of SMNP-Con A, the magnetic
precipitates were sufficiently large enough for visual detection. At 15 mg/mL concentration
the capture efficiency of bacteria was found to be 25 ± 1 %. Additionally, as seen from the
agar plates assays a dose-dependent increase of bacterial colonies with SMNP-Con A was
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RITC stained
NPs

Merged

SMNP

SMNP-Con A

Hoechst
stained Msmeg

Figure 5.7. Fluorescent image of Msmeg bacteria binding to RITC- SMNP-Con A, at
lowest concentration of bacteria (10 CFU/mL), where NPs stained with RITC and Msmeg
bacteria stained with Hoechst dye. Scale bar is 10 mm.

demonstrated in Figure 5.5b. The control was Msmeg (103 CFU/mL) without incubation
with SMNP-Con A. To obtain the lowest detection limit of Msmeg that can be detected by
SMNP-Con A, we incubated SMNPsuspension at very low concentrations 100 and 10 CFU/mL of Msmeg. Then the captured
Msmeg were plated on agar. As shown in Figure 5.6a, SMNP-Con A treated with 100 and
10 CFU/mL of Msmeg had capture efficiency 45 ± 3% and 11 ± 2%, respectively. Using
SMNP-Con A at 15 mg/mL we could capture Msmeg even at 10 CFU/mL.
To further confirm the capturing ability of Con A, we incubated Msmeg (10
CFU/mL) with the control SMNP and SMNP-Con A (15 mg/mL). The Msmeg was stained
with Hoechst dye (blue). SMNP-Con A and SMNP were tagged with red fluorescent RITC.
As shown in Figure 5.7, SMNP-Con A, crosslinked the Msmeg and form large
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agglomerates that were visualized using a fluorescence microscope. However, when
Msmeg was incubated with SMNP no agglomerates were seen.

5.4

Conclusion
In summary, we have developed a simple and rapid diagnostic, magnetic precipitation

assay for TB. Con A conjugated SMNP bind to mannose carbohydrates which are prevalent
in the bacterial cell wall of Msmeg. This binding would then cause the bacteria to crosslink
followed by forming large agglomerates that appeared as a magnetic precipitate within 1
minute. This precipitate could therefore be used to determine the presence of mycobacteria
sputum. SMNP-Con A can effectively detect as low as 10 CFU/mL of mycobacteria
Msmeg even in presence of other bacterial species in the sputum matrix.
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CHAPTER 6. CONCLUSION

The aim of this thesis is to engineer drug delivery nanomaterial-based platforms to
target and eradicate intracellular bacterial infections. Nanotechnology has the capability to
offer novel therapeutic approaches that can be used in conjunction with small-molecule
therapies to reduce drug resistance in infectious diseases. In the thesis, we looked into two
disease types; bacteria-based infectious diseases such as tuberculosis (TB) and lung
carcinomas. Treating intracellular bacterial infections like TB is extremely difficult
because mycobacteria develop strategies to evade the immune system and thus remain
silent in the host.
Our multifaceted platform offers (1) small molecule drug therapy combined with
photothermal therapy (PTT), (2) targeted drug delivery to the site of infection (3) drug
release through external near-infrared laser light stimulation. This platform consists of gold
nanorods (GNRs) as a core that acts as a photothermal agent. GNRs coated with
mesoporous silica shell that offers drug loading surface. This is followed by thermosensitive liposome (TSL) encapsulation of drug-loaded nano-assembly, which prevents
premature drug release and provides stability. Finally, mycobacteria targeting peptide NZX
conjugated on liposome. Upon irradiation with NIR laser light, GNRs convert light into
heat, causing melting of TSL, which induces the release of antibiotics. Mycobacteria
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targeting peptide NZX guides the nano-assemblies to approach the bacterial cell surface.
The drug encapsulated in nano-assemblies was 20-fold more efficacious than free drug
equivalent.
Using another engineered nano-assembly: host-targeted nano-assemblies (HTNs),
we were able to target intracellular mycobacteria (Msmeg) residing within the macrophage.
Intracellular mycobacteria are intelligent enough to alter the function of immune cells,
making treatment of intracellular bacterial infection very challenging. Our engineered
HTNs can increase the response of macrophages against intracellular mycobacteria by
inducing the production of ROS/RNS and reactivating macrophages’ own host defense
mechanisms. These events finally lead to the apoptosis of Msmeg infected macrophages.
HTN’s were capable of killing 99 % of intracellular Msmeg residing within macrophages.
Carrying forth therapeutics, we have also engineered similar nano-assembly to
deliver chemotherapeutics to lung carcinomas. A dual-targeted nano-assemblies combined
therapeutic features: chemotherapy and PTT were designed to target non-small cell lung
carcinoma (NSCLC). IR 780 photosensitizer was used additionally with GNR to enhance
PTT using lower-powered laser irradiation. IR 780 dye was encapsulated inside a TSL, and
the entire nano-assembly was conjugated with the dual tumor-targeting ligands GE-11 and
folic acid. The encapsulated drug doxorubicin (Dox) was 20-fold times more efficacious
than free Dox.
We have also developed a simple and rapid diagnostic magnetic precipitation assay
to detect mycobacteria in sputum. Mycobacteria tuberculosis (Mtb) is the major causative
pathogen in tuberculosis (TB). The rapid detection of Mtb is crucial for TB treatment. We
have utilized lectin-carbohydrate interaction to recognize specific carbohydrate epitopes
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found abundantly in the cell wall of mycobacteria to design a detection technique. The
lectin conjugated magnetic nanoparticles (SMNPs) were synthesized and conjugated plant
lectins Con A and AAL, which bind to mannose and arabinose. Lectin conjugated SMNPs
would bind to mycobacteria in sputum and crosslink to form large agglomerates. These
agglomerates are magnetic and would be precipitated within minutes. Therefore, it could
be used to determine mycobacteria presence in sputum, which can be taken as an indicator
for TB detection. Even in the presence of other bacterial species in sputum, the lectin
conjugated SMNP can detect mycobacteria Msmeg at a detection level as low as 10
CFU/mL.
As discussed above, our engineered nano-assemblies have improved drug efficacy
by offering on-site delivery and combination therapy. Our rapid diagnostic platform also
offers quick verification of pathogens in sputum. Nanotechnology has a lot to offer in
theranostics, and we will look to continue to improve existing processes with
nanotechnology.
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APPENDICES

A. APPENDIX A

Figure A.1. Calibration curve of bedaquiline (BDQ) by HPLC.
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o

o

GNR@MSNP at 37 C
in media
Day 1

GNR@MSNP@TSL at 37 C
in media
Day 1

Day 5

Day 5

o

Figure A.2. Photographs of stability studies for GNR@MSNP and GNR@MSNP@TSL 37 C
in mammalian cell culture media.
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A.1

Laser triggered TSL melting

To support the laser triggered photothermal (PT) activity-based melting of
TSL, a fluorescent dye (green, fluorescent calcein) release assay was designed to
demonstrate the PT triggered melting of TSL. TSL-calcein was prepared by
encapsulating calcein in TSL by thin-film method followed by extrusion.448
Similarly, GNR@MSNP@BDQ@TSL-calcein was prepared. The release of calcein
was measured in proportion to the fluorescence intensity of the solution. TSLcalcein and GNR@MSNP@BDQ@TSL-calcein were exposed to NIR laser for 15
min, and the fluorescence intensity was quantified at 5 min intervals, and the
temperature change was recorded. The percentage of calcein released from
GNR@MSNP@BDQ@TSL-calcein with laser trigger was calculated using the
following equation 1. Before laser irradiation, blank fluorescence (Ipre) was
measured at an excitation wavelength of 490 nm, emission wavelength 515 nm.
Fluorescence intensity (Ipost) was measured after laser irradiation (808 nm, 15 min).
The fluorescence intensity (I100), due to a 100% release of calcein from TSL-calcein,
was recorded by solubilizing TSL in detergent Triton-X100.
%

=

100%

× 100%

(1)

The melting of TSL was evaluated by calcein dye leakage assay, as shown in
Appendix Figure A.3. The fluorescent intensity from GNR@MSNP@BDQ@TSLcalcein increased continuously after laser irradiation compared with TSL-calcein
(Figure A.3.a). The PT effect of GNRs caused a rise in temperature up to 60 ± 3 oC
for 15 min., which helps permeate the TSL and increase the release of calcein
280

(Figure A.3.a and Figure A.3.b). Figure A.3.a shows the increase in calcein release
upon an increase in laser irradiation time, and Figure A.3.b displays calcein intensity
with the temperature change. When the temperature reaches and surpasses the
melting point (48 ± 3 oC) of TSL, the maximum release of calcein occurs (Figure
A.3.c). It is noteworthy that fluorescence intensity increased rapidly from a
temperature range of 40 – 55 oC, where the range includes the melting point of TSL.
The observed melting point of TSL was quantified to be 48 ± 3 oC. The percentage
release of calcein was quantified, as shown in Figure A.3.c. Calcein release from
TSL-calcein was low (2.5 ± 1.1%) when compared to GNR@MSNP@BDQ@TSLcalcein (70.11 ± 1.3%) after 15 min of laser irradiation. This release profile ( Figure
A.3.c) shows that 35% of calcein from 70% total release was between the
temperature range of 40 – 55 oC. Since the measured melting point of TSL was 48
± 3 oC, the higher calcein release can be positively correlated to the melting of the
TSL. In addition, the continuous temperature increase in the system can be seen only
in the presence of GNRs in GNR@MSNP@BDQ@TSL-calcein ( Figure A.3.b),
which confirms the PT effect of GNRs. From these observations, it is apparent that
calcein release increased in the range of the melting point of TSL, which confirms
the correlation of PT activity of GNRs with the subsequent melting of TSL.

281

a

b

c

Figure A.3. Change in calcein release from TSL-calcein and GNR@MSNP@BDQ@TSLcalcein. (a) Change in fluorescent intensity with laser irradiation times for TSL-calcein and
GNR@MSNP@BDQ@TSL-calcein. (b) Change in fluorescence intensity with
temperature in TSL-calcein and GNR@MSNP@BDQ@TSL-calcein. (c) Percentage
release of calcein from TSL-calcein and GNR@MSNP@BDQ@TSL-calcein after
irradiating with laser for 15min.
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A.2

Morphological changes of Msmeg through TEM

The morphological changes of Msmeg after treatment with various nanoassemblies were observed through TEM. Msmeg (108 CFU/mL) was treated with
GNR@MSNP@BDQ and GNR@MSNP@BDQ@TSL@NZX and exposed to NIR
laser for 15 min, followed by incubation (37 oC, 4 h). Bacteria were pelleted and
washed by centrifugation at 5000 rpm for 10 min and fixed with 2.5%
glutaraldehyde for 4 h at 4 °C. After washing 3x with HEPES, the bacteria were

through TEM operating at 200 kV.Figure A.4.a-a shows that laser irradiated
GNR@MSNP@BDQ has minimal damage to the cell membrane of bacteria. In
contrast, when laser irradiated GNR@MSNP@BDQ@TSL@NZX is treated with
Msmeg, increased surface aggregation of GNR@MSNP@BDQ@TSL@NZX is
seen on Msmeg. The surface aggregation compromises the outer cell membrane
integrity and eventually complete degradation of Msmeg (Figure A.4.a-b, red arrows
indicate degraded cells). The loss of outer membrane integrity is due to the physical
aberrations caused by nano-assemblies pressing hard against the surface. NZX
mediated adhesion is the probable cause for the high interaction between Msmeg and
the GNR@MSNP@BDQ@TSL@NZX. These TEM studies show possible NZX
peptide-mediated adhesion of GNR@MSNP@BDQ@TSL@NZX and high
antibacterial activity upon NIR laser exposure (Figure A.4.a-b). The schematic
illustration

in

Figure

A.4.b

shows

NZX

mediated

adhesion

of

GNR@MSNP@BDQ@TSL@NZX on Msmeg surface (pink block), PT activity,
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and disintegration of TSL upon NIR irradiation (red block) and BDQ release and
lysis of Msmeg (grey block).

GNR@MSNP@BDQ
@TSL@NZX

GNR@MSNP@BDQ

a
a

+ Laser

b

1 m

1 m

b

Figure A.4. Morphological study of bacteria after treatment with various nanoassemblies upon laser exposure. (a) Morphological changes observed under
TEM, The scale bars are 1 m. (b) Schematic illustrated the mechanism of action
of final nano-assembly GNR@MSNP@BDQ@TSL@NZX upon interacting
with Msmeg.
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A.3

Cell cytotoxicity assay conducted on host A549 cells.
The live-dead assay was conducted on lung cells treated with GNR@MSNP,

GNR@MSNP@BDQ, and GNR@MSNP@BDQ@TSL@NZX after laser irradiation.
A549 cells were seeded onto 24 well plates at 1 × 10 3 cells/well (1 mL per well). After
reaching 90% confluence, cells were treated with (0.5 mg/mL) of GNR@MSNP@BDQ
and final nano-assembly GNR@MSNP@BDQ@TSL@NZX for 18 h at 37 o C. Treated
cells were exposed to NIR laser 808 nm, 500 mW for 15 min. A549 cells treated with nanoassemblies were stained with SYTO 9 and propidium iodide (PI) for 30 min at 37°C.
Finally, the live and dead cells were examined under an inverted fluorescence microscope.
The live-dead assay consists of two fluorescent dyes (propidium iodide and SYTO
9) that differentially label live (green) and dead (red) cells. 449 Due to the compromised
plasma membrane of the dead cell, propidium iodide (PI) intake increases, which
subsequently binds to the nucleic acids, resulting in red fluorescence. SYTO 9 dye labels
intact plasma membrane; hence viable cells appear in green fluorescence. As shown in
Figure

A.5,

lung

cells

incubated

with

GNR@MSNP@BDQ

and

GNR@MSNP@BDQ@TSL@NZX even after laser irradiation appears to be live (green
fluorescent). A live-dead assay makes it apparent that laser irradiation has minimal
cytotoxic effects on the lung cells.
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Dead

Merge

GNR@MSNP@BDQ
@TSL@NZX + Laser

GNR@MSNP@BDQ
+ Laser

Live

Figure A.5. Fluorescence microscopy images of the live/dead assay. Live/dead assay
performed on A549 cells treated with different nano-assemblies for 18 h with laser
exposure. Scale bar: 50 m.

286

B. APPENDIX B
B.1

-Glucan concentration determination
-Glucan was carried out, the various concentration of
-Glucan (5-50 nM ~ 1-10 ug/mL) interacted with Congo red 5 g/mL (Congo red
-Glucan) for 30 minutes at room temperature with constant stirring. The

absorbance comes from Congo red itself at 536 nm which is subtracted from the test
-Glucan tagged with Congo red). Then absorbance was recorded at 546 nm as
the Congo red-

-Glucan had abs at 546 nm (verified it from Congo red assay), Free

-Glucan) concentration vs absorbance was plotted as shown in Figure B.1.a.
Similarly, a calibration curve for folic acid (FA) was carried out, the various concentration
of free FA 5-50 mM ~ 2-20 mg/mL was prepared. The calibration curve was prepared by
recording the absorbance value at 310 nm using UV-Vis spectroscopy, as shown in Figure
B.1.b.
a

Figure B.1

b

-Glucan and (b) FA.
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B.2

Determination of dectin-1 receptor concentration
Jiang et al.

-Glucan toward dectin-1 receptor

and explored their binding sites.321

-Glucan ligand and

dectin-1 receptors is ratiometrically 1:1 and a calculated K D of 0.003 M.321 The binding
is therefore monovalent. The concentration of receptor [R] was also calculated from the
standard calibration curve, as shown in Figure B.2. The standard calibration curve was
prepared by varying the concentration of targeting ligands and recording the absorbance at
546 nm. Free ligand concentration was displayed on the x-axis, while ligand-receptor
absorbance was plotted on the y-axis. As observed in Figure B.2.a. binding saturation was
-Glucan. Since binding is monovalent, the
receptors' concertation is approximated to be 25 nM. The amo

-Glucan moles was

calculated as follows and was found to be 3 × 10-11

-

Glucan 2 x 105 gmol-1. The amount of receptors was calculated as following and was
calculated to be 1.8 × 1011 molecules of decitin-1 receptors.
25 nM = 6
-Glucan
= 6 g/2 × 1011 gmol-1
= 3 × 10-11 moles
= 3 × 10-11 moles × 6.022 × 1023
= 1.8 × 1011
-Glucan; hence dectin-1 receptors
Each well was seeded with 104cells. Therefore in 1 cell, 1.8 × 107 molecules of dectin-1
receptors can be approximated. Similarly, we calculated the number of folate receptors on
the macrophage, and it was found to be 2.3 × 1015 molecules of folate receptors.
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a

Figure B.2

b

-Glucan and (b) FA.

Figure B.3. Calibration curve for BQ by RP-HPLC.
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Scheme B.1

-Glucan conjugation by EDAC chemistry.
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Scheme B.2. Folic acid conjugation on liposome by EDAC chemistry.
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B.3

Calculation of ligand density by TGA.
2

) of nano-

assemblies.
(1)

=

Where nP is the amount of ligand on one (GM)L (gold nanorod coated mesoporous silica
shell encapsulated inside liposome) and A is the surface area of one (GM)L. Since (GM)L
were ellipsoid in shapes due to the oblong shape of gold nanorods. The mean length (a),
width(b), and depth(c) of (GM)L ellipsoid shaped nano-assembly was found to be 46, 31,
and 30 nm, respectively, and were calculated from analyzing TEM images using ImageJ
software. Hence, surface area (A) of ellipsoid shape (GM)L was found to be 15803 nm 2
calculated using equation 2.
( )=4

). (

(

). (
3

)

.

.

(2)

The volume of ellipsoid shape450 (GM)L was 1.79 × 105 nm3 and was calculated using
equation 3.
( )=

4
3

(3)

The number of (GM)L nano-assemblies (N) in 1 mg of (GM)L was calculated using
equation 4.
=

1
×

(4)
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As reported in literature, the density of gold nanoparticles is 19.7 g/cm 3.451 Hence, the
3

and N was calculated by using volume (V) from

equation 3.
-Glucan) concentration CL (mol per mg) of (GM)L-Glu or
(GM)L-FA can be determined from the following equation 5.
=

(

(5)

)
×

The P is the percent weight (%) of the (GM)L before (P b) and after (Pa) ligand coupling at
700 °C. The Mw is the molecular weight of the organic residue (HEPES buffer) of the
particles ~ 283.3 g/mol.
-Glucan ) (mol) on one (GM)L (nP) is found to be 0.0848 ×
10-16 by combining equations 4 and 5.
(6)

=

(7)

=

-Glucan on (GM)L was found to be 53.7 nmol/nm2. Similarly, we
have calculated ligand density of FA on (GM)L was found to be 12.9 nmol/nm 2.
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Figure B.4.

B.4

-Glucan by phenol sulphuric acid assay.

-Glucan ligand density by phenol sulphuric acid assay.
-Glucan where various concentrations (10-Glucan in 1 mL of DMSO were placed in boiling tubes. Add 1 mL of 2.5 N

HCL and hydrolyzed glucan by keeping it in a boiling water bath for 1 h. The mixture was
cooled at room temperature and neutralized with sodium carbonate until effervescence
ceased. Then centrifuged it at 15000 rpm for 10 min and collected the supernatant. 1 mL
of supernatant was added in 24 well plates, following that 100 L of 5% phenol solution
and 500 L of 96% H2SO4 were added. Then incubate this at room temperature for 30 min.
Finally, UV-Vis spectra of the resulting solutions were recorded at 490 nm, and the data
-Glucan concentration.
Durin

-Glucan ligand 200 nM ~ 64 g was added with

(GM)L (0.5 mg). After purification and performing assay, we got 96.6 nM ~ 31

-

Glucan ligand was obtained from the calibration curve of the assay ( Figure B.5.). This
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indicating that 0.5 mg of (GM)L have 96.6 nM ~ 31

-Glucan ligand. The molar

concentration of ligand was calculated using equation 1.
=

×

1

(1)

Where C is the molar concentration (96.6 nM), V is the total volume 1.6 mL, Mw is the
molecular weigh

-Glucan 2 x 105 gmol-1

-Glucan 31 g.

Calculation of the mass of one (GM)L-Glu
(

=

Mass of (GM)L

(2)

)
(

Glu = 19 gcm

)
× 1.79 × 10 nm

g

= 35.54 × 10

The density of (GM)L-Glu was approximated to be close to the density of GNR. From the
literature, the value is 19.3 gcm-3.451 The volume of ellipsoid shape450 (GM)L was 1.79 ×
105 nm3. Therefore, the mass of one (GM)L-Glu was 34.54 × 10-16 g.
Total number of (GM)L-Glu
(

)

=

(
(

=

0.5 x 10 g
34.54 × 10
g

)
)

(3)

= 1447 × 10

Therefore, 1.4 x 1011 (GM)L-Glu are present in 0.5 mg mass of (GM)L-Glu.
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-glucan
(4)
(

=

(
=

)

×

)

31 × 10
2 × 10

× 6.022 × 10

mol

= 9334.1 × 10

Therefore, 9.3 × 1013

-glucan are present

-glucan per (GM)L-Glu
(

)

=

=

9334.1 × 10
1447 × 10

= 645

-glucan per (GM)L-Glu.
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(5)
(

)

Figure B.5. Typical nitrite standard calibration curve.
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a

b

c

Figure B.6. Characterization of various nano-assemblies (a) zeta potential, (b) UV-Vis, (c)
FT-IR analysis.
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Figure B.7. Concentration dependent photothermal activity of (GM@BQ)LGlu using 808 nm NIR laser, 500 mW, 15 min.
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C. APPENDIX C

Figure C.1. Standard calibration curve of Doxorubicin.

Figure C.2. Standard calibration curve of IR 780.
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Figure C.3. Standard calibration curve of Folic acid.

Figure C.4. Standard calibration curve of GE-11.
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Table C.1. BET analysis of nano-assemblies
GM

GM@Dox

Surface area (Multipoint BET)

53.852 m²/g

42.060 m²/g

Pore volume (BJH method)

0.23 cc/g

0.171 cc/g

Pore size (BJH method)

19.13 Å

12.19 Å
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a

b

c

d

Figure C.5. Colloidal stability analysis of GM@Dox and[(GM@Dox) LI]-PF. UV-vis
spectra of (A) GM@Dox (B) [(GM@Dox) LI]Aggregation index (AI) of GM@Dox and[(GM@Dox) LI]-PF. (D) Zeta potential of
GM@Dox and[(GM@Dox) LI]-

303

Figure C.6. Cumulative drug release profile of Dox for [(GM@Dox)
L] and [(GM@Dox) LI] nano-assemblies with laser irradiation (808
nm, 350 mW, 15 min).
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Cell uptake mechanism.
The primary mechanism by which nanoparticles are transported into cells is endocytosis.
At least four fundamental pathways are involved in endocytosis: caveolae-mediated
endocytosis, clathrin-mediated endocytosis, macropinocytosis, and clathrin- and caveolaeindependent endocytosis.452 Clathrin-mediated endocytosis is well-known for its function
in the selective ingestion of molecules via unique receptors by all eukaryotic cells to
internalize nutrients and degrade or recycle substances.453,

454

Specific endocytosis

inhibitors: chlorpromazine (an inhibitor of clathrin-mediated endocytosis), nystatin (an
inhibitor for caveolin-dependent endocytosis), and wortmannin (a macropinocytosis
inhibitor) were investigated to study the mechanism of cellular uptake. 304 The mechanism
for the internalization of the nano-assemblies into the lung cells was monitored by
fluorescence microscopy ( Figure C.7.a). The cellular uptake mechanism of RITC GM@Dox and RITC – [(GM@Dox) LI]-PF in A549 cells was determined under different
endocytosis-inhibited conditions. We have also quantified the cellular uptake of nanoassemblies using fluorescent assays. The fluorescence microscopy images reveal little or
no visible red fluorescent RITC – [(GM@Dox) LI]-PF in chlorpromazine treated A549
cells ( Figure C.7.b), which indicates chlorpromazine treated lung cells shows inhibited
uptake of RITC – [(GM@Dox) LI]-PF. However, uptake of RITC – [(GM@Dox) LI]-PF
into lung cells was not hindered when treated with wortmannin and nystatin ( Figure C.7.b).
These observations suggested that the trafficking of the nano-assemblies occurred
preferably through a clathrin-mediated endocytosis.
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To investigate the role of the liposome in cellular uptake, we quantified the cellular
uptake of RITC-labelled nano-assemblies GM@Dox and [(GM@Dox) LI]-PF by
measuring the intracellular fluorescence intensity using a fluorescence microplate reader.
Liposome coating enhances the cellular uptake of nano-assemblies due to interaction with
the lipophilic cell membrane that allows cellular entry of nanoparticles by various
endocytosis pathways.304 In addition, the liposome was modified with the cationic peptide
GE-11, so due to electrostatic interactions with the negatively charged cell membrane, the
cellular uptake was higher for [(GM@Dox) LI]-PF as compared to GM@Dox. As shown
in Figure C.7.b, chlorpromazine, an inhibitor of clathrin-mediated endocytosis,
significantly inhibited both GM@Dox and [(GM@Dox) LI]-PF delivery into A549 cells.
The quantified intracellular uptake of GM@Dox and [(GM@Dox) LI]-PF was 8.1 ± 1.2 %
and 27.01 ± 1.5 %, respectively. Even in the presence of the inhibitor, a higher amount of
[(GM@Dox) LI]- PF uptake was found in A549 cells, which indicates the inclusion of the
liposome and the cationic peptide (GE-11) increases the ability of the cells to internalize
the nano-assembly. GM@Dox has consistently shown a lesser amount of uptake ( Figure
C.7.b).

These studies collectively suggested that the nano-assembly-mediated drug

delivery occurred preferably through clathrin-mediated endocytosis, and nano-assembly
internalization was enhanced due to the presence of the liposome and GE-11 cationic
peptide.
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a

b
Calcein
Cytoplasm

RITC[(GM@Dox) LI]-PF

Merged

Nystatin

Wortmannin Chlorpromazine

DAPI
Nucleus

Figure C.7. Mechanism of cellular uptake of nano-assemblies. (a) Evaluation of
cell uptake mechanism of nano-assemblies by A549 cells under different
endocytosis inhibitory conditions - fluorescence microscopy – A549 cells are
stained with calcein dye (green), cell nucleus stained with DAPI (blue),
[(GM@Dox) LI]-PF were labelled with red fluorescent RITC dye (red). Scale bar:
10 m. (b) Shows quantitative intracellular uptake of GNR@MSNP@BDQ and
GNR@MSNP@BDQ@TSL@NZX by A549 cells after inhibitor treatment.
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D. APPENDIX D

Figure D.1. HAADF-STEM images and EDS spectra of SMNPs.

308

Figure D.2. SEM image of SMNP.
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Table D.1. Parameters for fabricating SMNPs with different TEOS amounts
MNPs
(mg)
0.02

IGEPAL
(g)
0.225

Ammonia
( L)
100

TEOS
( L)
100

0.02

0.225

100

0.02

0.225

100

SIZE (nm)

Zeta (mV)

166.5 ± 7

-35.1 ± 2

150

263.2 ± 10

-20.1 ± 1

200

582.8± 13

-9.2 ± 2

Table D.2. Parameters for fabricating SMNPs with different ammonia amounts
MNP
(mg)
0.02

IGEPAL
(g)
0.225

Ammonia
( L)
100

TEOS
( L)
100

0.02

0.225

150

0.02

0.225

200

SIZE (nm)

Zeta (mV)

175.3 ± 9

-30.2 ± 2

100

489.2 ± 12

-5.1± 2

100

678.3 ± 15

2.78± 2

Table D.3. Parameters for fabricating SMNPs with different IGEPAL amounts
MNP
(mg)

IGEPAL
(g)

Ammonia
( L)

TEOS
( L)

SIZE (nm)

Zeta (mV)

0.02

0.225

100

100

182.8 ± 6

-29.1 ± 1

0.02

0.337

150

100

565.1 ± 16

2.8 ± 1

0.02

0.450

200

100

786.8 ± 12

4.7 ± 3
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Figure D.3. Fabricating SMNPs with varying concentrations of MNPs

311

Figure D.4. FTIR spectra of nanoparticles conjugated with control proteins.

312

